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ABSTRACT 
 
The thesis spans the spectrum of causative and therapeutic aspects of chronic kidney 
disease (CKD), which is a significant and growing health burden. An adverse in utero 
environment is increasingly recognised to predispose to chronic diseases in adulthood. 
Maternal smoking remains the most common modifiable adverse in-utero exposure 
leading to low birth weight, which is strongly associated with CKD in later life. In 
order to investigate underlying mechanisms for such susceptibility, a mouse model of 
maternal smoke exposure was used and the offspring examined at different 
developmental milestones. Maternal smoke exposure led to lower birth weight and 
increased proteinuria at adulthood compared to control. From birth throughout 
adulthood smoke exposed offspring had increased levels of mitochondria-derived 
oxidative stress and increased mitochondrial DNA copy numbers. In addition, the 
kidneys of smoke exposed offspring demonstrated mitochondrial structural 
abnormalities at birth and adulthood along with a reduction in oxidative 
phosphorylation (OXPHOS) proteins, lysosome density and mitochondrial 
antioxidants. The development of mitochondrial alterations preceding the proteinuria 
may point towards its mechanistic role in fetal programming of CKD in response to 
maternal smoking. While it is desirable that these findings will translate into effective 
strategies of CKD prevention, the disease is frequently diagnosed when renal fibrosis 
has already developed. Thus, the second part of this thesis focused on therapy and 
explored whether lysyl oxidase-like 2 (LOXL2), an enzyme central to extracellular 
matrix modification (ECM), would be suitable as a novel treatment target. LOXL2 
was increased in early renal fibrosis after unilateral ureteral obstruction and in a 
diabetic mouse model that mimics the development of chronic renal fibrosis. 
Inhibition of LOXL2 with a highly selective, small molecule inhibitor reduced 
	   	   	   	  vi	  
markers of ECM deposition in the diabetic mouse model. Importantly, LOXL2 
inhibition resulted in amelioration of proteinuria and glomerulosclerosis in the 
diabetic mice. It thus had a beneficial effect on preserving glomerular structure and 
function. We conclude that it may be a suitable therapeutic target in diabetic 
nephropathy and renal fibrosis of other aetiologies. 
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1.1 Chronic kidney disease (CKD) - Definition, epidemiology, risk    
factors 
 
Chronic kidney disease (CKD) is a significant and growing health burden affecting an 
estimated 11% of the population of high-income countries including Australia (257).  
CKD is defined as the presence of kidney damage and/or decreased kidney function 
for three or more months, irrespective of the underlying cause. Kidney damage is 
indicated by the presence of albuminuria or haematuria after exclusion of lower 
urinary tract causes. Decreased kidney function is defined by a measured or estimated 
glomerular filtration rate (eGFR) of < 60ml/min/1.73m2. CKD is not associated with 
significant symptoms until advanced stage and is thus unrecognised in 80-90% of 
cases (54, 128). In Australia and New Zealand an estimated 2,600 individuals 
progress to end-stage kidney disease (ESKD) and start dialysis or undergo kidney 
transplantation each year (8). The number of patients receiving these renal 
replacement therapies in Australia are projected to increase by 60% in the 9 years to 
2020, by which stage cumulative treatment costs are projected to reach $12 billion 
(11). This will create an enormous financial burden for society, not to mention the 
implications for affected individuals from increased morbidity and premature 
mortality. However, the burden of CKD not only comes from the percentage of 
patients that have progressed to ESKD. CKD is considered an independent risk factor 
for cardiovascular disease (215), one of the leading causes of mortality in the general 
population.  
 
The aetiology of CKD is diverse.  Renal injury may start in the tubulointerstitial 
compartment, the glomeruli or in the renal vessels as a consequence of systemic 
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diseases, such as diabetes, hypertension or autoimmune reactions. In addition, the 
effect of drugs, toxins, infections, mechanical damage, ischemia, urinary tract 
obstruction or genetic disorders such as polycystic diseases may lead to CKD. The 
progression of renal injury can vary substantially, even among individuals with 
similar comorbidities. This has prompted a search for mediators and processes that 
predict the increased risk of CKD progression and which are amenable to modifying 
interventions. Known risk factors include hypertension, poor glycemic control, 
dyslipidemia and smoking. Additionally, evidence is mounting for environmental 
factors that influence CKD susceptibility, including epigenetic modifications, which 
may occur early in life.  
 
1.2  Fetal programming: A new concept of CKD risk 
 
A growing body of evidence supports the theory that adverse conditions in utero 
affect the developing fetus, resulting in an increased susceptibility to diseases in adult 
life. The hypothesis involves the concept of fetal programming, which proposes that 
insults during sensitive stages of development can alter the structure and function of 
various organ systems permanently. Following a period of clinical silence in younger 
years, diseases may occur at adulthood. This concept, nowadays also referred to as 
fetal origins of adult disease (FOAD) or developmental origins of health and disease 
(DOHaD), was originally described by Barker et al. after observing an association of 
cardiovascular disease and mortality with poor maternal nutrition and low birth 
weights (18, 19). Subsequently the hypothesis has been expanded to cover a range of 
chronic conditions including hypertension (148), type 2 diabetes mellitus (20), obesity 
(147) and hypercholesterolemia (21). In recent years the development of chronic 
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kidney disease has been linked to low birth weight (143, 159, 252). As low birth 
weight (weight < 2,500g) is considered a surrogate for a poor intrauterine 
environment (48), it is conceivable that fetal programming plays a role in CKD 
susceptibility in this cohort. However, the mechanisms behind this association remain 
poorly understood. 
 
1.2.1 The Barker hypothesis 	  
Barker and colleagues were the first to describe in the late 1980’s the association of 
cardiovascular disease with low birth weight and prenatal environment (23). In 
studying a large cohort of people born in Hertfordshire, UK between 1911-1930, they 
discovered that the mortality due to coronary heart disease was inversely correlated 
with birth weight and other low anthropometric measurements at birth. Major 
cardiovascular risk factors were subsequently studied as mediators for this link. In 
1989 Barker et al. reported an inverse relationship between birth weight and blood 
pressure (22) and in a secondary analysis it was suggested that this relationship 
becomes amplified in later life (148). Similarly, the association between 
hypercholesterolemia (21) as well as type 2 diabetes with low birth weight was 
published (20). Barker’s hypothesis not only involves the association of 
anthropometric characteristics particularly low birth weight with chronic conditions in 
adult life but also the explanation that the poor fetal growth can be accounted for by 
unspecified nutritional deficiencies experienced in utero (19). Hales and Barker called 
it the “thrifty phenotype hypothesis” arguing that fetal malnutrition results in down-
regulation of some developmental processes to ensure the selective protection of brain 
growth (101). Thus, the growing fetus is being programmed to thrive in a poor 
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nutritional environment. However, the adaptions made prenatally may place the 
individual at risk of developing diseases in later life if the subsequent postnatal 
environment is not matched to the adverse conditions in utero. Although some of the 
studies have been criticised for selection bias (261) and lack of adjustment for 
potential confounders (225), a number of subsequent epidemiological and 
experimental studies have confirmed the link with chronic diseases (64, 154, 228, 
250). Since the original publications from Barker’s group, it has become apparent that 
not only nutrition affects the fetal growth and development but also environmental 
pollutants and toxins such as those derived from maternal smoking during pregnancy. 
 
1.2.2 Low birth weight and kidney disease 	  
White et al. indicated in a systematic review that individuals born with LBW have a 
70% relative risk increase of developing CKD in later life (259).  Impaired 
nephrogenesis resulting in reduced nephron number is a postulated mechanism 
linking LBW with subsequent hypertension and risk of CKD (41). Autopsy studies 
have supported the notion that hypertension is associated with low nephron 
endowment (118, 134).  Nephron deficiency in animal models is frequently associated 
with renal disease in later life evidenced by lower glomerular filtration rate, 
proteinuria and glomerulosclerosis (91, 93, 229). Studies on children with 
oligomeganephronia (67, 177) and in the Aboriginal population who have high rates 
of CKD confirm the link between reduced nephron number and progressive renal 
injury (115). Brenner and colleagues hypothesised that reduced nephron number 
causes glomerular hyperfiltration and compensatory hypertrophy (41, 42), possibly at 
the expense of increased intraglomerular pressures and subsequent 
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glomerulosclerosis. The underlying molecular mechanism of a reduced nephron 
endowment remains unknown. Moreover, as some experimental models of 
congenitally reduced nephron endowment have failed to demonstrate hypertension 
and glomerular sclerosis (35, 113), it suggests that low nephron number is unlikely 
the sole risk factor for CKD susceptibility in later life and additional factors are 
involved in programming of hypertension and renal disease.  	  
1.3 Mechanisms of fetal programming 	  
1.3.1 Maternal smoking and fetal programming 	  
Maternal smoking during pregnancy remains the most common modifiable risk factor 
for fetal growth restriction and other adverse perinatal outcomes (7, 122). Despite an 
encouraging decrease in population wide smoking rates over the last decade, smoking 
in pregnancy is still prevalent. 12% of Australian women smoked during their 
pregnancy in 2013 with higher numbers in lower socioeconomic groups, including 
47% of indigenous mothers (10). Cigarette smoke contains more than 4000 toxins 
(132), many of which, are able to cross the placenta. Nicotine levels are higher in the 
amniotic fluid, fetal serum and placenta than in the corresponding maternal serum 
(168). These toxins can exert a direct toxic effect on fetal cells or indirectly affect the 
fetus through morphological and functional changes of the placenta, which include 
but are not limited to thickening of the trophoblastic membrane, changes in placental 
enzymatic functions and placental vasoconstriction (124). Studies have shown that 
smoking in pregnancy is associated with increased BMI in adult offspring even after 
adjustment for postnatal confounders (171, 205). An association of maternal smoking 
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during pregnancy and development of hypertension in the offspring has been 
demonstrated in several studies and this effect was independent of birth weight 
suggesting that fetal cigarette smoke exposure results in long term cardiovascular 
consequences (32, 193). A recent review by Duskova et al. nicely discusses the 
evidence for smoking induced endocrine changes affecting pituitary hormones, 
cortisol, estrogens and androgens in the offspring, which may influence reproductive 
ability in later life (72).  Smoke exposure during gestation and lactation in mice 
resulted in altered renal protein expression in the offspring. Markers of inflammation 
and components of cell to cell signaling, lipid metabolism, cell cycle, nucleic acid and 
carbohydrate metabolism were involved (123). The detrimental effect of maternal 
smoking on kidney development was investigated in a retrospective cohort study 
among 1072 children. Taal et al. demonstrated that smoking more than ten cigarettes 
per day was associated with smaller kidney volume in fetal and postnatal life (236).  
These results were recently corroborated by MRI imaging in pregnant women that 
smoked a mean of 9 cigarettes a day showing reduced kidney volume (6). As there 
has been a documented association of neonatal kidney volume and nephron number 
(280), it is necessary to investigate whether maternal smoking leads to a susceptibility 
to CKD in adult offspring. However, studies investigating this link are scarce. Ibrahim 
et al. detected in male offspring mice renal developmental retardation, fewer nephron 
numbers and albuminuria at adult age in response to continuous maternal smoke 
exposure during gestation (2). In another study, Chen et al. demonstrated renal 
fibrotic changes in rat offspring whose mothers were exposed to subcutaneous 
nicotine injection during gestation (57). The underlying cellular mechanisms remain 
to be elucidated and constitute one of the aims of this thesis. 
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1.3.2 Maternal smoking and oxidative stress in the offspring 	  
Several lines of evidence support the association of smoking with increased oxidative 
stress in the entire organism (132, 172, 206). Oxidative stress results from the 
imbalance of increased reactive oxygen species (ROS) and reduced detoxification of 
these products by antioxidants. The gas phase and tar particles of cigarette smoke are 
a rich source of radicals. Peroxyl radicals and reactive nitrogen species cause cellular 
damage by lipid peroxidation as well as oxidative damage to proteins and DNA. The 
formation of aldehydes can result in the depletion of antioxidants such as glutathione 
and modify –SH and –NH2 groups in proteins, while products from the tar phase 
diffuse across cell membranes forming semiquinone, superoxide and hydrogen 
peroxide radicals (132). The net result is a wide variety of biologically destructive 
effects. 
 
Pregnancy in itself is a state of increased oxidative stress. However, problems arise 
when there is overproduction of ROS, which can cause placental remodeling and 
affect fetal development and growth. In fact, emerging evidence has linked oxidative 
stress to pregnancy related disorders such as preeclampsia and fetal growth restriction 
(83). High oxidative stress levels in the mother correlate with high oxidative stress 
markers in the fetus, which can even exceed the mother’s levels. This was 
demonstrated by measuring oxidative stress markers including protein carbonyl 
groups, lipid peroxides and total antioxidant capacity in the placenta and umbilical 
cord blood (9). The same study demonstrated that the concentration of the measured 
oxidative stress markers was higher in smoking mothers, with newborns from these 
women having significantly lower birth weight. This is one of few studies 
investigating oxidative stress in the offspring of smoking mothers and it surprises that 
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despite the still high smoking rates during pregnancy there is a relative paucity of data 
on this topic.  
 
1.3.3 The effect of maternal smoking on mitochondria 	  
Mitochondria serve a crucial role in development by providing energy for rapid fetal 
growth and playing key roles in cell signaling. Mitochondria are the major source, but 
also a primary target of ROS, which are generated as by-products of adenosine 
triphosphate (ATP) synthesis through the oxidative phosphorylation system 
(OXPHOS) in the electron transport chain (ETC).  The mitochondrial toxicity of 
cigarette smoke has previously been demonstrated (180). Carbon monoxide for 
example, being one of the 4000 toxic compounds of cigarette smoke, binds with great 
affinity to cytochrome c oxidase (COX) of the mitochondrial respiratory chain 
complex IV, thereby inhibiting its enzymatic activity (87). It is likely that some of the 
other toxic compounds of cigarette smoke cross the placenta contributing to increased 
ROS and potentially lead to mitochondrial perturbations in the fetus. Garrabou et al. 
found both a trend towards reduced mitochondrial COX activity and increased lipid 
peroxidation in newborn cord blood mononuclear cells of smoking mothers. The 
newborns had significantly lower birth weight and high cotinine levels, an indicator 
that toxic compounds such as nicotine have crossed the placenta. The mitochondrial 
content in the placentas was significantly increased, which could indicate a 
compensatory response (86) Although the sample size was small and may have 
limited statistical significance, the study strongly suggested smoking associated 
mitochondrial perturbations in the offspring of smoking mothers.  It also highlights a 
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need for further studies including longitudinal assessments that may indicate a 
“programming” effect. 
 
1.4 Potential for mitochondrial perturbations in fetal programming 
 
1.4.1 Mitochondrial structure and function 	  
The mitochondrion is a double-membrane organelle that exists in most eukaryotic 
cells and plays a pivotal role in energy metabolism. The double membranes create 
two mitochondrial compartments: the intermembrane space between the inner and 
outer mitochondrial membrane, and the matrix, located inside the inner membrane. 
The outer membrane contains pores for passive diffusion of molecules smaller than 
5,000 Daltons while the transport of larger molecules through the membrane is 
mediated via translocases. The inner membrane is much less permeable to ions or 
small molecules and is extensively folded with numerous invaginations called cristae. 
These extend into the matrix, thus increasing the inner membrane surface area. The 
inner membrane is embedded with proteins that form the four complexes of the 
electron transport chain, the ATP synthase complex and transport proteins. The 
mitochondrial matrix contains the mitochondrial DNA and proteins required in 
mitochondrial replication and transcription as well as enzymes for the citric acid 
cycle. Mitochondria continuously change shape through the highly regulated action of 
fission and fusion giving rise to a highly dynamic network. 
 
Mitochondria are often referred to as “powerhouse of the cell” due to their role as 
energy producers through oxidative phosphorylation. They also have other functions 
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in regulation of cellular metabolism, hormonal signaling, calcium homeostasis, 
growth and apoptosis by generating oxidants utilised in these processes. Oxidative 
phosphorylation is the process in cell metabolism by which enzymes in the 
mitochondria synthesise ATP from ADP and inorganic phosphate during the 
oxidation of nicotinamide adenine dinucleotide hydrate (NADH) by molecular 
oxygen.  
 
1.4.2 The Oxidative Phosphorylation System 	  
During oxidative phosphorylation electrons are carried from electron donors to 
electron acceptors via multiple redox reactions (Figure 1.1). These redox reactions 
release energy, which is needed to form ATP. A chain of large protein complexes 
located in the inner mitochondrial membrane carries out theses reactions. This so 
called respiratory chain or electron transport chain (ETC) consists of four complexes, 
three of which act as protein pumps and one provides a physical link to the citric acid 
cycle (Krebs cycle).  
 
Complex I (NADH-Q oxidoreductase), a large enzyme consisting of 34 polypeptide 
chains receives electrons from the Krebs Cycle electron carrier NADH and transfers 
them to coenzyme Q (ubiquinone). Coenzyme Q also receives electrons from 
complex II (succinate dehydrogenase or succinate-Q reductase) and passes these to 
complex III (cytochrome reductase or Q-cytochrome c oxidoreductase). Cytochrome 
c is the next electron acceptor donating the electrons to complex IV (cytochrome c 
oxidase). The energy released during the transfer of electrons within complex I, III 
and IV is coupled with the transport of protons across the inner mitochondrial 
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membrane creating an electrochemical proton gradient. Complex V, the ATP 
synthase, utilises the electrochemical gradient for ATP synthesis. Protons flowing 
back across the membrane through the ATP synthase drive the phosphorylation of 
ADP to ATP. During the electron transfer a small percentage of electrons may leak 
from the respiratory chain and partially reduce oxygen to form superoxide anion (O2-), 
which is a precursor of most reactive oxygen species. 
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Figure 1.1   Electron transport chain and ATP synthase 
 
(A) Electrons are shuttled from NADH and FADH2 to oxygen via OXPHOS 
complexes that are embedded in the inner mitochondrial membrane. In the process, 
protons are pumped across the mitochondrial membrane and oxygen is reduced to 
form water. (B) Protons flowing back across the membrane drive ATP synthesis. 
Images from “Oxidative Phosphorylation”, by Open Stax College Biology 
A 
B 
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1.4.3 Mitochondrial DNA 	  
Mitochondria are unique among the cytoplasmic organelles in that they contain their 
own DNA. Mitochondria are thought to have originated from bacteria that developed 
a symbiotic relationship with cells in which they lived (endosymbiosis). The 
mitochondrial genome is a ring-shaped structure of double-stranded DNA containing 
37 genes that encode 13 proteins as well as transfer and ribosomal RNA involved in 
the mitochondrial protein synthesis. The 13 mitochondrial DNA (mtDNA) encoded 
proteins are designated as components of the OXPHOS system (subunits of 
complexes I, III, IV and V). The remainder of the approximately 1100 mitochondrial 
proteins are encoded by nuclear genes and imported into the mitochondria. Unlike 
nuclear DNA there are no non-coding nucleotides in the mitochondrial genome with 
the exception of the 1.1kb displacement loop (D-loop), which contains transcriptional 
promotors. Each mitochondrion is estimated to contain 2-10 mtDNA copies. As each 
cell contains many hundreds to thousands of mitochondria, there are multiple copies 
of mtDNA per cell and the number varies greatly according to the bioenergetics needs 
of each particular tissue (179). Mitochondrial genetics differ considerably from 
Mendelian genetics as mitochondrial DNA is exclusively maternally inherited. In 
addition, if mtDNA mutations occur, there is often heteroplasmy, which means that 
cells harbor a mixture of normal and mutated mtDNA. In general high mutation loads 
are required before a clinical phenotype becomes apparent (threshold effect) 
(reviewed in (220)). 
 
An increase in mtDNA content has been shown in response to oxidative stress in 
vitro, which was suggested to occur to compensate for defects in mitochondria 
harboring mutated mtDNA (151). Variation in mtDNA copy number has been 
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demonstrated as a direct effect of cigarette smoke exposure. Masayesva et al. detected 
an increase in mtDNA in saliva cells of smokers in a dose-dependent fashion. This is 
known to persist for decades after smoking cessation (175). In utero or neonatal 
second hand smoke exposure in mice has also lead to an increase in mtDNA copy 
number in aortic tissue (80). Whether a similar effect will be seen in kidney tissues 
from offspring of smoke exposed mothers will be investigated as part of this thesis. 
 
1.4.4 Mitochondrial biogenesis regulation 
Mitochondrial biogenesis is defined as the process by which cells increase their 
mitochondrial mass through growth and organelle division. Mitochondrial biogenesis 
is a tightly coordinated process in response to energy and growth demands, including 
exercise and caloric restriction as well as oxidative stress. Mitochondrial biogenesis 
requires the complex coordination of mtDNA replication and the synchronised 
synthesis of both mitochondrial and nuclear-encoded proteins as well as the 
coordinated import of the latter. This appears to be through the concerted action of a 
group of transcription factors such as nuclear respiratory factors 1 and 2 (NRF-1 and 
NRF-2) or mitochondrial transcription factor A (Tfam), all of which stand directly or 
indirectly under the command of the master transcription activator: Peroxisome 
proliferator-activated receptor γ coactivator 1α (PGC-1 α). 
1.4.4.1 Peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) 	  
In addition to its role as the primary regulator of mitochondrial biogenesis, PGC-1α is 
able to induce many ROS-detoxifying proteins including glutathione peroxidase, 
catalase, uncoupling protein 2 and manganese superoxide dismutase (MnSOD) (227). 
Thus, it appears to be essential for protection from oxidative stress.   
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PGC-1α appears to play also a role in fetal programming of adult β-cell dysfunction. 
Mice that had β-cell-overexpression of PGC-1α only during their fetal life but normal 
PGC-1α from birth had adult onset impaired glucose tolerance and decreased glucose-
stimulated insulin secretion without alterations in β-cell mass (248). Interestingly, 
overexpression of PGC-1α at adult age did not alter these outcomes.  The authors also 
demonstrated that glucocorticoids stimulate an increase in PGC-1α expression. The 
caloric restriction in rodent models of maternal undernutrition results in increased 
glucocorticoid expression (247), thus underpinning a potential mechanism of Barker’s 
fetal programming concept. Whether other environmental stimuli, such as maternal 
smoking can alter fetal PGC-1α expression and whether this may affect fetal 
programming of other chronic diseases such as CKD remains to be shown.  	  
1.4.5 Mitochondrial perturbations in kidney disease 
The kidney is a highly metabolic organ. Numerous transport processes in the renal 
tubular system rely on adequate biogenesis of mitochondria and their proper 
functionality. Alterations in mitochondrial gene or protein expression are likely 
determinants in renal disease susceptibility. Indeed, increasing evidence has 
implicated mitochondrial perturbations in both acute kidney injury (AKI) and 
development of CKD. Some forms of AKI are characterised by sub-cellular pathology 
rather than gross histopathological damage. In experimental models of ischemia-
reperfusion injury mitochondrial swelling within tubular cells have been reported as 
the only detectable structural change (194, 204). Several studies have shown a 
reduction of the mitochondrial OXPHOS enzymes and their activity in experimental 
models of AKI (84, 197, 245). A reduction in gene transcripts for OXPHOS enzymes 
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in AKI was accompanied by diminished expression of PGC-1α (245). Both in vitro 
and in vivo experiments revealed the importance of mitochondrial biogenesis and 
intact PGC-1α for recovery of AKI (208, 245). PGC-1α knockout mice had sustained 
loss of glomerular filtration rate (GFR) following sepsis (245).  
 
Recent findings have also linked mitochondrial perturbations to development and 
progression of CKD. High throughput genome-based microarray technology of blood 
samples in a large dialysis cohort revealed differential expression of numerous genes 
encoding for OXPHOS along with reduced OXPHOS complex IV activity (96). In 
addition, mitochondrial dysfunction has been implicated in podocyte injury (230, 274, 
281) and epithelial to mesenchymal transition (EMT) (273, 278). Evidence is 
mounting for a putative role of impaired mitochondrial homeostasis in development 
of diabetic nephropathy. Urine metabolomics in diabetics with CKD versus those 
without CKD revealed differential expression of various metabolites, the majority of 
which were linked to mitochondrial metabolism. Diabetic nephropathy biopsy 
samples in this study also had lower OXPHOS complex IV and PGC-1α along with 
reduced mitochondrial DNA content in urine exosomes (222). While these 
mitochondrial changes could have developed in response to an insult in AKI or 
secondary to the uremic milieu in CKD, it is tempting to speculate that in some 
individuals they may have been present from birth as a result of unfavorable in utero 
conditions setting the stage for disease at later life if additional insults were to occur. 
 	    
	   18	  
1.4.6 Mitochondrial perturbations and fetal programming 	  
There is evidence that mitochondrial perturbations occur in the developing fetus in 
response to a suboptimal environment and that these alterations contribute to the 
development of chronic diseases in later life. Protein malnutrition in rats during 
gestation lead to reduced mitochondrial DNA content in the offspring’s liver and 
skeletal muscle, which remained present in later life even when optimal nutrition, was 
supplied (195). Similarly, Taylor et al. demonstrated a reduced mitochondrial DNA 
copy number in the adult kidneys of offspring fed a high fat diet during gestation. In 
addition, the adult offspring had reduced aortic mitochondrial gene expression and 
reduced pancreatic insulin secretion raising the hypothesis that mitochondrial 
alterations link environmental programming in utero to disease manifestations in 
various organs at adulthood (240). Surprisingly, little consideration has been given to 
the potential mitochondrial-mediated fetal programming of disease susceptibility in 
the kidney. Pereira et al. appear to date the only group investigating renal tissue in a 
baboon model of gestational nutrient reduction. They demonstrated differential 
expression of genes encoding mitochondrial homeostasis and a reduced OXPHOS 
protein IV in the offspring kidneys at birth (200). Whether these changes persist into 
adulthood and lead to disease was not reported. 
 
Programming of mitochondrial status and potential disease susceptibility in later life 
has also been detected in models of maternal nicotine/smoke exposure. Reduced 
mitochondrial oxidative capacity was evident in adult lung tissue of rat offspring 
exposed to perinatal nicotine exposure (49).  In another rat model, subcutaneous 
nicotine during gestation resulted in increased oxidative stress, mitochondrial 
structural abnormalities and reduced OXPHOS complex IV activity in the offspring, 
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preceding pancreatic beta cell dysfunction (46). It seems conceivable that the kidneys, 
which are rich in mitochondria, may be affected in a similar way in response to in 
utero smoke exposure. An animal model of maternal smoking and longitudinal 
assessment of the offspring from birth to adulthood will form part of this thesis. 	  
1.5 Epigenetic regulation and fetal programming 	  
Epigenetic modifications are regarded as a mechanistic link between environment and 
phenotype. Particular interest is mounting into the role of epigenetic processes in fetal 
programming and the potential for disease susceptibility in later life.  
 
1.5.1 Epigenetics in general  
Epigenetics refers to stable and heritable changes in gene expression that are not 
mediated by alterations in the underlying DNA sequence (30). The epigenetic 
information is stored in the form of chromatin, which consists of DNA wrapped 
around histone protein complexes determining its higher order structure. Densely 
packed chromatin, called heterochromatin makes DNA less accessible to the 
transcriptional machinery and generally represents transcriptionally silent regions. 
Euchromatin is a lightly packed form of chromatin with an unfolded structure, thus 
facilitating the accessibility of transcription regulators and active transcription (156). 
Epigenetic mechanisms such as DNA methylation and histone modifications, which 
include methylation, acetylation, phosphorylation and ubiquitination participate in the 
remodeling of the chromatin structure.  
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1.5.2 DNA methylation 
DNA methylation is the most studied epigenetic modification. It describes the 
covalent addition of a methyl group to the 5th carbon of a cytosine residue that is 
located adjacent to a guanine nucleotide (CpG dinucleotide). In human somatic cells 
cytosine methylation accounts for approximately 1% of total DNA bases (30). Of the 
approximately 28 million CpG sites in the human genome 60-80% are methylated.  
Less than 10% of CpG dinucleotides can occur in clusters, known as CpG islands, 
which are predominantly located in promotor regions of genes (226). 
Hypermethylation of CpG sites can prevent transcription factor binding and results in 
changes to chromatin structure. Thus, it is commonly associated with transcriptional 
silencing, whereas hypomethylation activates gene expression. DNA methylation is 
catalysed by DNA methyltransferases (DNMT) that transfer a methyl group from S-
adenyl methionine (SAM) to the cytosine residue. DNMT1 is responsible for 
maintaining the methylation status of DNA during DNA replication of cells 
undergoing mitosis. DNMT3a and DNMT3b can establish de novo methylation to 
unmodified DNA. The growing fetus relies on the proper establishment of the 
epigenetic program during development. DNA methylation is erased during 
preimplanatation with subsequent resetting of the genome-wide methylation pattern in 
a cell-type specific manner in order to dictate somatic development (53). Once re-
established, DNA methylation marks can be maintained through many cell divisions 
providing long-term stability. Evidence suggests, that the methylation patterns can 
also be influenced by environmental cues during embryogenesis. Inbred mouse 
strains, where genetic variations are minimal have provided an opportunity to study 
epigenetic modification. Offspring of agouti mice exposed to alcohol exposure or fed 
a methyl-rich diet during pregnancy had long-lasting phenotypic alterations with the 
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characteristic coat-color change caused by transcriptional silencing from 
hypermethylation of the corresponding gene locus (62, 133). Another example of 
environmentally induced epigenetic changes is the insulin-like growth factor 2 (IGF-
2) gene, which was differentially methylated in individuals exposed to in utero 
malnutrition during the Dutch famine (243). Thus, it appears that the embryonic 
development period is a sensitive window for environment induced DNA methylation 
profile changes that may persist until later life, although research into this area is still 
in its infancy stages. 
 
1.5.3 Aberrant DNA methylation in association with maternal smoking 	  
Evidence is mounting for an effect of maternal smoking on DNA methylation in the 
offspring. Studies have investigated changes in DNA methylation profiles in placenta, 
cord blood, buccal cells or granulocytes.  Both an aberrant global genomic 
methylation pattern involving the total 5-methyl cytosine content of a given DNA 
sample (43, 100, 173, 234) as well as gene-specific DNA methylation changes in 
smoke exposed offspring (43, 233) have been observed in these tissues. Large-scale 
epigenome-wide association studies (EWAS) have been conducted more recently 
using a high-density DNA methylation array (the Illumina Human Methylation 450k 
Bead Chip) that interrogates 450,000 CpG sites and 96% of CpG islands (130, 173, 
234). Using EWAS on cord blood, Joubert et al. reported an association of maternal 
smoking during pregnancy and differentially methylated CpG sites including from 
genes involved in embryogenesis and developmental processes (131). Moreover, 
Richmond et al. performed longitudinal studies at age 7 and age 17 demonstrating that 
at least some of the CpG changes in smoke exposed offspring persisted over time 
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(210). Hence, it appears that an epigenetic memory of in utero smoke exposure can 
still be determined in childhood and adulthood. It remains to be elucidated whether 
this ‘epigenetic memory’ is clinically relevant and whether these epigenetic marks 
become mediators of disease susceptibility in later life.  
 
1.5.4 Aberrant DNA methylation associated with disease 	  
Type 2 diabetes is one of the diseases where altered DNA methylation profiles have 
been implicated in pathogenesis (55, 188). Genome-wide promotor analyses of DNA 
methylation to screen for differentially methylated genes in type 2 diabetes revealed 
hypermethylation of a significant number of genes involved in mitochondrial function 
(25). Gene expression of the mitochondrial biogenesis regulator PGC-1α is reduced in 
muscle and pancreatic islands of diabetic subjects (160, 182) and this is associated 
with an increase in DNA methylation in CpG sites of the PGC-1α promotor (25, 160). 
In addition, the differential methylation of CpG sites in the PGC-1α promotor was 
associated with adiposity and the methylation profiles remained stable in examined 
children between the age of 5 and 14 (59). In addition, maternal BMI was associated 
with differential PGC-1α promotor methylation in newborn cord blood (88). These 
findings suggest that, methylation patterns for some sites are established very early in 
life, even in utero. They remain stable over time and are associated with risk factors 
for disease or disease itself. It remains to be elucidated whether maternal smoking as 
the commonest adverse in utero exposure can influence the offspring’s methylation of 
genes like PGC1-α and whether this will have a clinical impact on highly metabolic 
organs like the kidney. 
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DNA methylation has recently been implicated in kidney diseases (265). Bechtel et al. 
identified a key role for DNA methylation in fibroblast activation in the kidney. The 
hypermethylation of RASAL-1, an inhibitor of the Ras oncoprotein was associated 
with renal fibrogenesis and kidney fibrosis was ameliorated in DNMT1+/- 
heterozygous mice (28). In addition, DNA methylation status appears to play a role in 
glomerular pathology. The expression of nephrin, an essential component of the 
glomerular filtration barrier, is linked to the methylation status of its promotor, which 
seems to stand under the influence of Kruppel-like factor 4 (106). It remains to be 
shown whether the differential DNA methylation in the diseased kidney has occurred 
over time or has been present since the fetal period that is undoubtedly highly 
sensitive to altered programming in response to environmental factors.  
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1.6 Renal fibrosis – the final common pathological manifestation of 
CKD 	  
Renal fibrosis is the principal process underlying the progression of CKD. In addition, 
it is a predictor of prognosis and major determinant of kidney function. The 
histopathology of advanced renal fibrosis is characterised by progressive 
glomerulosclerosis, tubulointerstitial atrophy and fibrosis as well as loss of glomerular 
and peritubular microvasculature.  	  
1.6.1 Pathogenesis of renal fibrosis  	  
Irrespective of the underlying aetiology, the pathological process of progressive renal 
fibrosis leads to a loss of normal glomerular and tubular epithelial architecture and 
replacement with an excessive amount of extra-cellular matrix (ECM), including 
collagens, elastin and fibronectin. Often described as a failed wound healing process 
after chronic sustained injury, the underlying cellular and molecular pathways of 
fibrogenesis are complex and incompletely understood. The pathogenesis follows 
several stages and involves the concerted action of numerous cellular events and 
molecular signaling cascades. Cell injury as one of the initiating events results in the 
release of proinflammatory cytokines and infiltration with inflammatory cells (e.g. 
macrophages and T-cells). The non-resolving inflammation is intrinsically linked to 
the fibrotic process (186). This triggers the activation and expansion of matrix 
producing fibroblasts from various sources. The presence of activated fibroblasts, the 
so-called myofibroblasts, which are characterised by their de-novo synthesis of α-
smooth muscle actin (αSMA), is strongly associated with disease progression (109). 
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The synthesis of ECM proteins by these cells stands under the transcriptional control 
of a host of fibrogenic signals by growth factors and cytokines. Among these, 
transforming growth factor-β1 (TGF-β1) is generally regarded as one of the key 
players (31) but others like platelet-derived growth factor (PDGF), fibroblast growth 
factor 2, (FGF2), connective tissue growth factor (CTGF) and angiotensin II have 
additional important roles. The final fibrogenic phase relies on the fibrogenic 
machinery of integrins and associated proteins that orchestrate the exaggerated 
deposition and assembly of the ECM (108). Integrins, a family of cellular 
transmembrane receptors, bind both to the ECM and the cytoskeleton, thereby 
facilitating communication between the extracellular milieu and the intracellular 
signaling cascade. The deposited matrix proteins undergo further biochemical 
modifications, such as collagen cross-linking, which renders the ECM stiff and 
resistant to proteolysis. The enhanced stiffness can perpetuate fibrogenesis (196) via 
the integrin mediated cross talk resulting in a vicious cycle (68). Additional factors 
contributing to the fibrogenesis are oxidative stress and chronic hypoxia, secondary to 
microvascular rarefaction as a result of the fibrotic restructuring and the increased 
metabolic demand of tubular cells (81). This activates hypoxia-inducible factor 1 
(HIF1) pathways which can evoke the expression of fibrogenic genes and epithelial to 
mesenchymal transition (EMT) (110). As the cellular and molecular 
pathomechanisms of renal fibrosis are diverse and intertwined with many in-built 
redundancies, treatment strategies targeted towards inhibiting the final fibrogenic 
phase are worthy of exploration.	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1.6.2 The extracellular matrix in renal fibrosis 	  
Excessive extracellular matrix (ECM) deposition is the most striking feature of 
tubulointerstitial fibrosis and glomerulosclerosis. The ECM is a highly dynamic 
network of collagens, glycoproteins and proteoglycans. In normal tissue the ECM acts 
as a support structure for cells and is essential for cell signaling, cell growth, 
differentiation, migration, wound healing and maintenance of tissue integrity. It 
senses various environmental cues and acts as reservoir for local	  growth factors (184). 
ECM is found in different compartments of the kidney fulfilling different functions 
depending on its molecular components. It is a key component of glomerular, tubular 
and peritubular capillary basement membrane and is present in the Bowman’s 
capsule, the mesangium and the tubulointerstitium. The overall amount of matrix 
proteins deposited in normal renal tissue is a regulated balance between synthesis and 
degradation. Proteases such as matrix metaloproteinases (MMPs) and their inhibitors 
are essential to maintain this balance (89). However, in tissue fibrosis this equilibrium 
shifts towards synthesis of matrix proteins exceeding the rate of degradation (266). 
 
1.6.2.1 Fibronectin  	  
Fibronectin (FN) is deposited as one of the first ECM proteins in renal fibrosis, thus 
preceding the synthesis of fibrillar collagens (74). It is an adhesive glycoprotein that 
activates integrins, serves as a fibroblast chemoattractant (90) and forms a scaffold for 
the deposition of fibrillar collagens (242).  Fibronectin is covalently cross-linked into 
high molecular weight polymers by cell surface tissue transglutaminase (tTG), an 
integrin-binding adhesion co-receptor that binds with high affinity to fibronectin (29). 
This process provides the ECM with additional rigidity and resistance against 
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proteolytic degradation. In addition to quantitative changes in matrix proteins, 
qualitative changes in their molecular composition may also play a role in the 
fibrogenic process.  Fibronectin generates diversity through alternative splicing of a 
single pre-mRNA, creating at least 20 different protein isoforms in human, so called 
splice variants, with some being found to modulate fibrogenic potential (76, 258).  
 
1.6.2.2 Collagen 	  	  
Collagen I, III and IV are the main collagenous components found in the kidney with 
type IV being the most abundant (3). Collagen I and III are fibrillar collagens while 
type IV collagen is a network-forming collagen and major constituent of renal 
basement membranes (BM) in glomeruli and tubules. Collagen I and III are found to a 
small degree in the tubulointerstitial space of healthy kidneys but are absent in the 
glomerular mesangium, while traces of collagen type III are found in the Bowman’s 
capsule of healthy glomeruli. However, in renal fibrosis collagen I and III deposition 
is enhanced and found in both glomeruli and interstitium (92, 272).  
 
All collagen molecules form a triple-helical structure consisting of three coiled 
polypeptide chains (Figure 1.2). The triple helical region of fibrillar collagen I, II and 
III is flanked by short non-helical domains called telopeptides (Figure 1.3). The tight 
packing of the triple helix dictates an order with every third amino acid being glycine 
as this is the only residue that can fit into the sterically restricted space. Among the 
remaining amino acids there is an abundance of proline and hydroxyproline, which 
provide rigidity to the triple helix due to their ring structure. Fibrillar collagens are 
synthesised as large, more soluble precursor polypeptides called procollagens with 
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large flanking propeptide domains at the N- and C-terminus. Post-translational 
modifications take place in the endoplasmic reticulum with hydroxylation of proline 
and lysine residues and glycosylation (267). Next, the procollagen is secreted into the 
extracellular space and propeptides cleaved at the N-and C-terminal ends resulting in 
tropocollagen. Multiple tropocollagen molecules form collagen fibrils that are 
stabilised by the formation of covalent cross-links.  The cross-linking is initiated 
enzymatically by lysyl oxidases (78) and significantly decreases the collagen’s 
solubility. Thus, the assembly of multiple tropocollagen molecules follows a complex, 
hierarchy that eventually leads to macroscopic fibers and networks with considerable 
tensile strength (209) (Figure 1.2). 
 
Collagen IV, in contrast to fibrillar collagens has no precursor and the N- and C-
terminal regions are called 7S and NC1 domains respectively. Collagen IV is 
stabilised by disulphide bonds in the 7S domain in addition to lysyl oxidase mediated 
cross-links. 
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Figure 1.2   Synthesis of fibrillar collagen and cross-link formation 
Image from Bhattarcharjee A et al., International Union of Biochemistry and 
Molecular Biology Life 2005 
 
 
1.6.2.3 Collagen cross-linking 	  
Collagen cross-linking is the final post-translational modification in the synthesis of 
collagen fibrils. In the absence of these cross-links, collagen has no tensile strength 
and remains fragile. Enzymatic cross-linking of collagen results from the oxidative 
deamination of the ε-amino groups of lysine and hydroxylysine residues to form 
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aldehydes (called respectively allysine and hydroxyallysine). This enzymatic reaction 
is carried out by a group of enzymes of the lysyl oxidase family. The highly reactive 
aldehydes then react with corresponding aldehydes on adjacent polypeptide chains to 
form aldol condensation products. Alternatively, aldehydes react with unmodified 
lysine or hydroxylysine residues to form divalent cross-links. The divalent 
condensation products can further react to form tri-, tetra- or even pentavalent cross-
links, thus further increasing the mechanical strength of the fiber (mature cross-links).  
For example, dihydroxylysinonorleucine (DHLNL) is an immature divalent cross-link 
while pyridinoline (PYD) represents a mature cross-link (Figure 1.4). Once fibrillar 
collagens are cross-linked they become increasingly resistant against proteolytic 
enzymes, thereby rendering the ECM stiff and insoluble (249).   
 
 
 
 
 
Figure 1.2   Intra- and intermolecular cross-links 
Cross-links are formed between aldehydes in the N-or C-terminal telopeptides (open 
circles) and between telopeptidyl aldehydes and helical lysine or hydroxylysine 
residues (closed circles). Image modified from Yamauchi et. Sricholpech. Essays 
Biochem 52: 113-133, 2012 
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Figure 1.3   Pathway of collagen cross-linking mediated by lysyl oxidases 
Lysine hydroxylases catalyse tissue-specific the intracellular hydroxylation of some 
lysine residues in the telopeptides. Both unmodified lysine (Lys) and hydroxylysine 
(Hyl) are substrates for extracellular lysyl oxidase (LOX) to form allysine and 
hydroxyallysine, respectively. These aldehydes, which are located in the N-terminal 
or C-terminal telopeptides then react with Lys or Hyl residues in the triple helical 
region of an adjacent collagen molecule to form divalent immature cross-links such 
as deH-dihydroxylysinonorleucine (DHLNL, deH-hydroxylysinonorleucine (HLNL) 
and deH-lysinonorleucine (LNL). The divalent cross-links spontaneously react with 
other allysine or hydroxyl allysine to form trivalent mature cross-links. Image from 
Saito M et al. Front. Endocrinol 4 (72): 1-7, 2013 
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1.6.2.4 Myofibroblasts 
 
Myofibroblasts are considered the dominant ECM-producing cells in fibrosis. In 
contrast to fibroblasts, the activated myofibroblastic phenotype is characterised by an 
increased contractile response due to the de-novo expression of α-smooth muscle 
actin (αSMA) and increased synthesis of extracellular matrix proteins. While in 
physiological wound healing myofibroblasts disappear upon resolution of the wound, 
their persistence at sites of tissue injury is a hallmark of fibrotic diseases, leading to 
the continued accumulation of ECM and ultimately replacing the functional 
parenchyma of the organ. The origin of myofibrobasts in kidney fibrosis has long 
been a subject of debate. According to the traditional view, resident fibroblasts are 
regarded as myofibroblast precursors (149, 211) while others favor the idea that 
myofibroblasts in renal fibrosis are derived from perivascular smooth muscle cells 
(pericytes) (98). On the other hand the recruitment and differentiation of bone marrow 
derived cells as a contributor to the myofibroblast pool has been highlighted in some 
studies (44, 157). Finally, the contribution of epithelial to mesenchymal transition 
(EMT) in the emergence of myofibroblasts (121) and more recently endothelial to 
mesenchymal transition (EndMT) has been proposed (158, 276). Genetic fate 
mapping studies have tried to shed light on the origin of these central effector cells in 
renal fibrosis, however, have yielded discrepant results (120, 121, 149). Equally 
important to the origin of myofibroblasts is the determination of mechanisms that 
differentiate, activate and cause the persistence of these cells at the site of injury. 
Targeting pathways that regulate myofibroblast activation may be promising to halt 
disease progression in renal fibrosis.   
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1.6.3 Epithelial to mesenchymal transition (EMT) 	  
Compelling evidence from numerous in vitro and in vivo experiments as well as 
biopsy studies support a role for EMT in the diseased kidney (164). Epithelial to 
mesenchymal transition (EMT) describes a process whereby epithelial cells loose 
their defined cell-cell contacts and structural polarity to acquire a spindle-shaped, 
motile, mesenchymal phenotype. This transition follows a strictly regulated program 
that involves four key events: loss of epithelial adhesion, actin reorganisation, 
disruption of the tubular basement membrane and enhanced migration and invasion 
(164). Normal tubular epithelial cells are interconnected via several cell adhesion 
proteins (tight junctions, gap junctions, adherens junctions).  E-Cadherin, an adhesion 
receptor found in adherens-type junctions is required to maintain the structural 
integrity of epithelial cells.  The suppression of E-Cadherin is one of the earliest 
events during EMT (268, 277) and is followed by the reorganisation of the actin 
cytoskeleton with de novo expression of αSMA. This process is accompanied by the 
exchange of cytokeratin, an epithelial cytoplasmic filament type, for vimentin a 
mesenchymal type (192, 268).  The disruption of the tubular basement membrane is 
another important event in the highly regulated EMT process. This step is supported 
by the increased expression of matrix metalloproteinases MMP-2 and MMP-9 that 
can degrade the basement membrane through which transformed cells invade the 
interstitium (268). The newly developed mesenchymal phenotype has the capacity for 
increased deposition of ECM setting the stage for renal fibrosis to develop. 
 
Of the many factors identified, the profibrotic cytokine TGF-β appears to be the most 
potent inducer of EMT, either on its own or in conjunction with other mediators (166, 
268).  Active TGF-β1 induces EMT via various Smad dependent (201, 217) and 
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Smad independent signaling pathways, including but not limited to p38 mitogen-
activated protein kinase (MAPK) (107), phosphatidylinositol 3-OH kinase (PI3K/Akt) 
(15), β-catenin (137) and Snail (50). The zinc finger transcription factor Snail is 
considered a common downstream target of various signaling pathways regulating 
EMT (52). Snail expression is increased in biopsies of fibrotic human kidneys. 
Activation of Snail in transgenic mice downregulates E-Cadherin and (37) is 
sufficient to induce EMT and renal fibrosis (37, 271). Additionally, evidence is 
increasing that hypoxia regulates EMT and Snail via hypoxia inducible factor 1α 
(HIF1α), independent of TGF-β (232).  	  
1.7 The lysyl oxidase (LOX) family 	  
Originally identified by Pinnell and Martin in 1968 (202) the copper dependent  
enzyme lysyl oxidase (LOX)  is foremost known for its ability to promote covalent 
cross-linking of collagen and elastin in the ECM. Later four other isoenzymes, known 
as lysyl oxidase-like proteins (LOXL1, LOXL2, LOXL3, LOXL4) have been 
described that share structural homology and have similar function (117, 139, 170, 
214). All members of the LOX family have a C-terminal region in which a copper 
binding site, a lysine tyrosylquinone (LTQ) cofactor and a cytokine receptor-like 
domain are situated. This region is highly conserved among the different LOX 
isoforms and contains the catalytic domain that is required for the oxidative 
deamination of the ε-amino group in lysine residues of collagens and elastin in the 
extracellular space. The N-terminal end of lysyl oxidases is less conserved and 
contains different sequence motifs that may determine individual yet not entirely 
identified roles. LOX is characterised by the presence of an N-terminal propeptide, 
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which is proteolytically cleaved by bone morphogenetic protein-1 (BMP-1) following 
secretion into the extracellular space.  The resulting product is the catalytically active 
LOX (99). LOXL1 contains a proline-rich domain at the N-terminus of unknown 
function. LOXL2, 3 and 4 on the other hand share higher structural homology with 
four scavenger receptor cysteine-rich (SRCR) domains. The SRCR domains are 
thought to be involved in protein-protein interactions to mediate cell signaling in the 
extracellular matrix (170, 174).  
 
      
Figure 1.4   Structural homology between the lysyl oxidase isoforms 
 
The in vivo expression patterns of each of the LOX isoforms differ from tissue to 
tissue. For example LOX is most abundant in heart, lung and kidney whereas lower 
levels of LOXL2 are detected in these tissues that abundantly express LOX and 
LOXL1 (181). Traditionally, lysyl oxidases have been regarded as extracellular 
enzymes. However, there is increasing evidence for an intracellular role for some of 
the LOX enzymes in transcriptional regulation and modulation of cell signaling 
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pathways (183, 198). LOX and LOXL2 in particular have been implicated in the 
regulation of EMT (199), the downregulation of tight junction and cell polarity 
complexes (183) and histone modification (178). Dysregulation of LOX and LOXL2 
is strongly associated with cancer progression, where they are thought to play a role in 
adhesion, motility and metastatic dissemination of cancer cells (183, 198). In addition, 
high LOX and LOXL2 levels have been linked to the development of tissue fibrosis 
in liver, lung, heart and kidney (58, 224, 246). 
 
1.7.1 Lysyl oxidases in renal fibrosis 	  
The induction of renal lysyl oxidases, in particular LOX and LOXL2 has been 
demonstrated in experimental models of renal fibrosis (66, 95, 110).  In Sprague 
Dawley rats with adriamycin nephropathy, a model involving both glomerulosclerosis 
and tubulointerstitial fibrosis, LOX mRNA was upregulated in glomeruli, medulla 
and whole kidneys and this preceded the development of diffuse fibrotic lesions (66).  
Fibrotic mouse kidneys in experimental nephrotic syndrome with fibrosis had higher 
LOX mRNA expression and LOX activity with de novo expression in tubular cells 
compared to controls (95). In rodent models of unilateral ureteral obstruction (UUO) 
both LOX and LOXL2 mRNA were increased by day 8 after ureteral ligation and this 
was associated with marked tubulointerstitial fibrosis (110, 152). When treated with 
β-aminoproprionitrile (BAPN), an irreversible inhibitor of all the LOX family 
members, there was a reduction in collagen immunostaining in the UUO kidneys 
(110).   Upregulation of LOXL2 has not only been observed in experimental models 
but also in renal biopsies of patients with chronic kidney disease of various 
aetiologies. Higgins et al. found increased LOXL2 expression in the tubulointerstitial 
	   37	  
compartment of kidneys from patients with diabetic nephropathy, IgA nephropathy 
and hypertensive nephrosclerosis providing additional evidence that LOXL2 may play 
a role in the development and progression of chronic kidney disease (110).   
 
To date little is known about the regulation of LOX and LOX-like protein expression, 
which may be driven in a tissue and cell-specific manner.  TGF-β was found to induce 
the expression of lysyl oxidases in ocular cells (221), oocytes (79), hepatocellular 
carcinoma (264) and renal proximal tubule epithelial cells (95). Hypoxia also appears 
to be an important stimulus for the upregulation of LOX and LOXL2 (219). 
Rarefaction of peritubular capillaries, commonly observed in renal fibrosis, decreases 
the oxygen supply and induces hypoxia in the tubulointerstitium. Hypoxia was found 
to induce LOXL2 mRNA expression in a renal proximal tubular cell line (232). 
LOXL2 is known to have a Hypoxia inducible factor 1 (HIF 1) binding domain (219) 
and was shown to be a downstream target of HIF-1α, the master transcription factor 
that controls cellular adaptation to hypoxia (219, 232).  
 
1.7.2 Fibrogenic role of lysyl oxidases via ECM stabilization 	  
Lysyl oxidase-mediated collagen cross-linking confers resistance to proteolytic 
degradation by matrix metalloproteinases (MMP) (249).  This is important for the 
maintenance of tensile strength and structural integrity in healthy tissues but may lead 
to the development of tissue fibrosis if lysyl oxidases are overexpressed. The 
upregulation of LOX in experimental adriamycin-induced renal fibrosis was an early 
and transient event preceding the increase of collagen cross-links and appearance of 
fibrotic lesions (66). The inhibition of lysyl oxidase by β-aminoproprionitrile (BAPN) 
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in a liver fibrosis model was shown to suppress collagen cross-links and render 
fibrosis more readily reversible after cessation of the fibrogenic stimulus (163). Lysyl 
oxidases also appear to have profibrotic effects on non-cross-linked ECM proteins 
such as fibronectin. In vitro stimulation of fibroblasts with recombinant LOXL2 
significantly increases the expression of fibronectin (24). Silencing of LOX in tubular 
epithelial cells exposed to uric acid, a stimulator or fibronectin synthesis, significantly 
attenuated fibronectin protein expression by 80-90% (270).  
 
1.7.3 Fibrogenic role of LOXL2 via EMT and myofibroblast activation 	  
Recent findings emphasise an additional intracellular role of LOX enzymes.  LOXL2 
in particular has become the focus of attention as it was found to be involved in the 
regulation of EMT via its interaction with the transcription factor Snail (199). LOXL2 
is proposed to oxidise two lysine residues (Lys98 and Lys 137) of Snail leading to the 
generation of an intramolecular link.  The resulting conformational change is thought 
to protect Snail from glycogen synthase kinase 3β (GSK3β)-catalysed 
phosphorylation and subsequent ubiquitination and proteosomal degradation (199). 
Blockade of the GSK3β phosphorylation site will thus lead to a more stable Snail 
protein, favouring the acquisition of a mesenchymal cell phenotype.  
 
Regulation of EMT is not exclusively how lysyl oxidases contribute to the 
myofibroblast pool in renal fibrosis. Mechanical tension such as created by collagen 
cross-linking is considered to be crucial for myofibroblast activation (111). 
Fibroblasts sense external mechanical cues through integrins. These cell surface 
receptors form focal adhesion complexes with intracellular molecules that activate the 
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cytoplasmic focal adhesion kinase (FAK) (103). Barker et al. demonstrated that 
recombinant LOXL2 induced phenotypic changes and the de-novo expression of 
αSMA in fibroblasts in vitro. When further adding an FAK inhibitor these changes 
were abrogated, thus providing evidence for a mechanistic link between LOXL2 and 
myofibroblast activation through integrin mediated FAK activation (24). 
 
1.8 Treatment options in renal fibrosis 	  
In theory, renal fibrosis provides an excellent treatment target as it is considered the 
final common outcome of a wide spectrum of pathophysiologically distinct diseases. 
However, in practice, effective therapies are lacking due to the complexity of this 
process involving many mediators, different cells and a plethora of signaling 
pathways with enormous redundancy. In addition, many potentially promising targets 
in the pathogenesis of renal fibrosis have also physiological function in cellular 
homeostasis or immunity. For example, targeting systemically the profibrotic key 
mediator TGF-β might lead to severe adverse effects since TGF-β is involved in 
numerous roles in control of immunity, regulation of cell proliferation, cell 
differentiation or wound healing. Indeed, a TGF-β1 neutralising antibody showed no 
evidence of efficacy and resulted in serious adverse events in patients with systemic 
sclerosis (65). A phase-II trial with varying doses of a monoclonal TGF-β1 antibody 
in diabetic nephropathy was also discontinued due to a lack of efficacy 
(NCT01113801). 
Thus, current treatment options of renal fibrosis remain limited to a small number of 
antagonists of the renin-angiotensin-aldosterone system (RAAS). RAAS inhibitors 
abrogate the pro-fibrotic effects of angiotensin-II, which include the upregulation of 
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TGF-β and renal TGF-β2 receptor levels (262, 263), induction of CTGF expression 
(161) and pro-inflammatory effects via NFκB stimulation (212). However, RAAS 
blockade is at best only partially effective in slowing disease progression (253), 
highlighting the importance of an ongoing search for treatment targets that have good 
chances of translation into clinical practice. 
 
1.8.1 LOXL2 as a potential treatment target 	  
Targeting the extracellular matrix in fibrogenesis may prove to be a rational strategy 
since a great variety of distinct signaling pathways converge into this final step. Lysyl 
oxidases appear to be promising targets due to their multifaceted mechanisms of 
action on ECM modification. While LOX is believed to be constitutively expressed in 
many healthy tissues, LOXL2 appears to be strongly induced in inflammation making 
it perhaps the superior target (163). In vitro experiments using a monoclonal LOXL2 
antibody (AB0024) in murine models of liver and lung fibrosis have resulted in a 
reduction of histological fibrosis scores, activated myofibroblasts, fibrillar collagen 
and inflammatory cytokines, including TGF-β1 (27). It remains to be shown whether 
targeting LOXL2 in renal fibrosis has a similar effect. 
 
1.9 Aim of the thesis 	  
The thesis focuses on factors involved in the development, prevention and treatment 
of renal fibrosis. The development aspect of this study explores the role of early life 
determinants on future CKD risk and renal fibrosis. Maternal smoking remains the 
most common modifiable adverse exposure for a growing fetus and is a major cause 
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of low birth weight and other detrimental pregnancy outcomes. Whether maternal 
smoking “programs” the offspring to susceptibility of CKD in adult life and the 
underlying mechanisms remain to be investigated. 
Hypothesis 1:  Maternal cigarette smoke exposure prior to, during gestation and 
lactation leads to fetal programming of CKD in adulthood. 
Aim 1: To examine in a mouse model the impact of maternal smoke exposure on the 
development of proteinuria, abnormal renal function and histological evidence of 
renal fibrosis in the offspring at three different time points: at birth, weaning and 
adulthood. 
Aim 2: To examine the impact of maternal smoke exposure on the offspring’s risk of 
renal oxidative stress and mitochondrial perturbations at the different renal 
developmental milestones. 
Aim 3: To examine the effect of maternal smoke exposure on epigenetic 
modifications in the offspring. 
 
While prevention of CKD forms one important aspect of the fight against a disease 
that is reaching epidemic proportions, investigating therapeutic strategies remains 
another. The second part of this thesis focused on ECM modifications as a potential 
treatment target in renal fibrosis. 
Hypothesis 2: Inhibition of LOXL2 provides a suitable treatment target in renal 
fibrosis.  
Aim 4: To examine the effect of a novel, small molecule LOXL2 inhibitor in both an 
early and chronic animal model of renal fibrosis. 
Aim 5:  To delineate the role of LOXL2 inhibition in a pro-fibrotic environment using 
genetic and pharmacological knockdown in vitro.  
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Chapter 2  
 
Materials and methods 
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2.1 Animal models 	  
Three individual animal models were used to investigate the different aims of the 
thesis. The smoking mouse model was used to determine the effect of maternal 
smoking on susceptibility of renal disease in the offspring. Unilateral ureteral 
obstruction (UUO) in mice served as a model of early renal fibrosis with 
predominantly tubulointerstitial injury to investigate the potential renoprotective role 
of LOXL2 inhibition. A diabetic mouse model, characterised by both 
glomerulosclerosis and tubulointerstitial damage, was used to determine whether 
LOXL2 inhibition has a beneficial effect in preventing chronic renal fibrosis from 
slowly sustained injury. All animal work complied with the Australian Code of 
Practice for the Care and Use of Animals for Scientific Purposes. The studies were 
approved by the Animal Care and Ethics Committee (ACEC) of the University of 
Technology (ACEC# 2011-313A) or the Royal North Shore Hospital Animal Care 
and Ethics Committee (ACEC# 1210-017A and 1309-003A). Mice were housed in 
filter top cages in a pathogen free facility at 20±2°C, maintained on a 12:12h 
light/dark cycle and had free access to standard chow and drinking water. Animals 
were anaesthetised using short inhalational anaesthesia with 2% isoflurane for minor 
procedures and were euthanised at the end of the experiment under 2% isoflurane 
anaesthesia using cardiac puncture terminally. The individual mouse models were 
conducted according to the following experimental designs. 
 
2.1.1 Smoking mouse model 	  
Female Balb/c mice (Animal Resources Centre, Perth, Australia) underwent smoke 
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exposure (SE) twice daily (5 days/week) in a Perspex chamber containing smoke 
generated from 2 cigarettes (nicotine<1.2mg, CO<15mg) for 6 weeks before mating, 
throughout gestation and lactation.  The control sham exposed mice were put in an 
identical chamber filled with air for the same period. During lactation the offspring 
remained in the home cage without SE. Pups were weighed every 5 days and weaned 
at postnatal day 20. Male offspring were sacrificed at day 1, day 20 (weaning) and 
week 13 (mature age). Blood was collected via cardiac puncture after mice were 
anaesthetised with sodium thiopental (0.1ml/g i.p., Abbott Australasia Pty Ltd, NSW, 
Australia), then mice were sacrificed by decapitation. Urine was collected from the 
bladder when available. Plasma was separated immediately and stored at -20°C for 
creatinine measurements. Hemisected kidneys were harvested and either snap-frozen 
in liquid nitrogen, placed in O.C.T embedding medium (Sakura Finetek, Torrance, 
CA, USA) for frozen tissue specimen and stored at -80°C for further processing or 
fixed for 24 hours in 10% buffered formalin (Sigma-Aldrich, St Louis, MO, USA), 
then moved into 70% ethanol until paraffin embedding. Only male offspring were 
used for this study as previous studies have shown male gender to be more susceptible 
to renal damage (223).  
 
2.1.2 Unilateral ureteral obstruction (UUO) model 	  
In-house-bred C57BL/6 mice were anaesthetised by 2% isoflurane gas and underwent 
UUO surgery at 6-8 weeks of age. Through a flank incision the left ureter was 
exposed and completely ligated at two points using fine suture material (4-0) silk. 
Sham animals underwent the same procedure with manipulation of the kidney except 
for ureteral ligation. PXS-S2B, a highly selective small molecule LOXL2 inhibitor 
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(LOXL2i) which was kindly provided by Pharmaxis Ltd, Frenchs Forest, Australia 
was given at a dose of 10mg/kg by daily intraperitoneal injection using sterile water 
as vehicle. Treatment started on the day of UUO surgery and continued until harvest 
for 7 days. Telmisartan (Telmi) (Santa Cruz, Dallas, TX USA, 2mg/kg/day) as 
comparative limb of current best practice was mixed in drinking water 5 days before 
the operation and continued until the end of the experiment. Animals were divided 
into the following treatment groups: 1) Sham, 2) UUO, 3) UUO+LOXL2i, 4) 
UUO+Telmi, 5) UUO+LOXL2i+Telmi and housed in single cages after the 
procedure. Each group consisted of 5-7 animals. Mice were sacrificed by decapitation 
after anaesthesia with 2% isoflurane. Kidneys were perfused in ice-cold phosphate 
buffered saline prior to harvest.  	  
2.1.3 Diabetic nephropathy mouse model 	  
Male endothelial nitric oxide synthase knockout (eNOS-/-) mice on C57BL/6 
background were purchased from Jackson laboratory, ME, USA and housed in single 
cages.  Diabetes mellitus was induced by a low dose streptozotocin (STZ) protocol 
(55mg/kg diluted in sterile 10mM citrate buffer, pH4.5 given intraperitoneally daily 
for 5 consecutive days, Sigma, MO, USA) at 6-9 weeks of age. A group of mice 
receiving citrate buffer alone served as the non-diabetic controls. Blood glucose levels 
(BGL) were determined by tail vein blood collection using an Accu-chek glucometer 
(Roche Diagnostics, North Ryde, NSW, Australia) after a 6-hour daytime fast. Mice 
with BGL > 16mmol/L two weeks post STZ injection were considered diabetic. 
Fasting BGL were tested at least fortnightly. Long lasting insulin was administered as 
required (Insulin Glargine, Sanofi Aventis, Macquarie Park, Australia) if blood 
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glucose levels exceeded 28mmol. PXS-S2B, a small-molecule selective LOXL2 
inhibitor with high oral bioavailability (courtesy of Pharmaxis Ltd, NSW, Australia) 
was administered by daily oral gavage (10mg/kg) through a flexible plastic gavage 
tube (Instech laboratories, PA, USA) once diabetes was established. Telmisartan 
(Santa Cruz, Dallas, TX, USA) was mixed in drinking water (2mg/kg/d, pH7.4). 
Animals were divided into the following groups: 1) Control (Ctrl), 2) Diabetes 
mellitus (DM), 3) Diabetes+PXS-S2B (DM+LOXL2i), 4) Diabetes+Telmisartan 
(DM+Telmi) 5) Diabetes+PXS-S2B+Telmisartan (DM+LOXL2i+Telmi). Mice were 
sacrificed after 24 weeks of treatment using the same protocol as in the UUO model. 
In the diabetic groups only mice with HbA1c≥ 7.5% at the time of sacrifice were 
included into the analysis. 	  
2.2 Renal and metabolic parameters  	  
Body weight in the diabetic model was obtained monthly. 24-hour urine was collected 
in metabolic cages prior to sacrifice. Urinary creatinine was measured using a picric 
acid method (Creatinine Companion, Exocell Inc, Philadelphia, PA, USA). Albumin 
was determined by ELISA (Albuwell, Exocell, Inc) and the urine albumin to 
creatinine ratio calculated.  HbA1c was measured from a preterminal blood collection 
using a DCA Vantage analyser (Siemens Healthcare, Bayswater, VIC, Australia). 
Serum creatinine was measured with an automated analyser (ARCHITECT, Abbott 
Australasia PTY. LTD, Macquarie Park, NSW, Australia) 
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2.3  Histology 	  
Paraffin embedded kidneys sections (2µm) were stained with Masson’s Trichrome 
and Periodic acid-Schiff (PAS). Assessment of glomerulosclerosis and 
tubulointerstitial fibrosis was done by an independent examiner. Twenty non-
overlapping fields were captured under an Olympus photo light microscope linked to 
a Leica DFC 480 digital camera. A semi-quantitative glomerulosclerosis index (GSI) 
score was graded on a scale of zero to four (0_normal; 1_involvement of <25% of the 
glomerulus, 2_ involvement of 25-50% of the glomerulus; 3_involvement of 50-75% 
of the glomerulus and 4_totally sclerosed glomeruli) (169) The whole kidney average 
GSI score was obtained by averaging scores from all counted glomeruli in one 
section. For tubulointerstitial scoring ten non-overlapping fields were assessed. A 
semi-quantitative tubulointerstitial fibrosis index (TFI) score of cortical areas was 
graded on a scale of zero to four (0_normal; 1_involvement of <25% of the field of 
view, 2_ involvement of 25-50%, 3_involvement of 50-75% and 4_>75%). The 
features of tubulointerstitial fibrosis included tubular atrophy or dilatation, widening 
of interstitial spaces with deposition of extracellular matrix and interstitial cell 
proliferation. The whole kidney average TFI score was obtained by averaging scores 
from all counted sections (279). Paraffin sections of liver, lung and heart from control 
and control animals treated for 24 weeks with the LOXL2 inhibitor were stained with 
haematoxylin and eosin (HE) and evaluated for structural damage by an independent 
pathologist.  
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2.4 Cell culture 	  
2.4.1 Human kidney 2 cell line (HK-2) 	  
HK-2, a proximal tubular cell line derived from normal kidney and immortalised by 
transduction with human papilloma virus 16 (HPV-16) E6/E7 genes (213) were 
purchased from American Type Culture Collection (ATCC, VA, USA). HK-2 cells 
were grown in keratinocyte serum-free medium (Life technologies, Carlsbad, CA, 
USA) supplemented with 25mg bovine pituitary extract and 2.5µg recombinant 
epidermal growth factor (Life technologies, Carlsbad, CA, USA) on 10cm Petri 
dishes (Corning Inc., Corning, NY, USA). Cells were incubated at 37°C, 21% O2, 5% 
CO2 in a humidified incubator (Thermo Fisher Scientific, North Ryde, NSW, 
Australia).  Fresh growth medium was exchanged every other day. Cells were 
subcultured at 50-80% confluence. Pre-warmed TrypLE Express solution (Life 
technologies, Carlsbad, CA, USA) was used to detach cells from the Petri dish. Cells 
were centrifuged at 1000rpm for 3 minutes. The pellet was resuspended in 
keratinocyte serum-free medium and plated onto 6-well plates (Corning Inc., Corning, 
NY, USA). Experiments were performed at cell passage 10-16. 	  
2.4.2 MTS assay (non radioactive cell proliferation assay) 	  
Cytotoxicity of the LOXL2 inhibitor PXS-S2A was determined using the HK-2 cells 
proliferation rate in the colorimetric MTS assay. The assay is based on the reduction 
of the MTS tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] by 
viable cells to generate a colored formazan product that is soluble in cell culture 
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media. Cells were grown in 96-well dishes until reaching approximately 80% 
confluence, at which time growth medium containing PXS-S2A in increasing 
concentrations between 0.3nM and 1000nM was applied to the cells. The cells 
remained in these defined conditions for 48hrs hours in both normoxia and hypoxia 
before the MTS assay was performed using the CellTiter96®Aqueous One Solution 
Cell Proliferation Assay (Promega, Madison, WI, USA). The medium was removed at 
the end of the 48hour incubation period and replaced with 100µl growth medium and 
20µl CellTiter96®Aqueous One Solution Reagent into each well. The plate was then 
incubated at 37°C for 1-4 hours in a humidified 5% CO2 atmosphere, until a change in 
colour was observed. Absorbance was read at 490nm using the LP400 Diagnostic 
Pasteur plate reader (Anthos Labtec Instruments, Austria). 
 
2.4.3 Stimulation of HK-2 cells with transforming growth factor-β1 (TGF-β1) 
in normoxic and hypoxic conditions 	  
Cells were grown to 80% confluence in 6-well plates (Corning Inc., Corning, NY, 
USA) and exposed to 1ng/ml TGF-β1 (R&D Systems, Minneapolis, MN, USA) while 
cells from the same passage remaining in keratinocyte medium served as control. 
Cells were cultured under ‘normoxic conditions’ (21% O2, 5% CO2, 95% humidity) 
at 37°C prior to culture under hypoxic conditions for 48hrs. Hypoxic conditions were 
created using a CoyLabs hypoxia chamber (Edwards Instruments, Narellan, NSW, 
Australia: 37°C, 1% O2, 5% CO2, 94% Nitrogen, 95% humidity). In experiments 
where hypoxia was required, cells from the same passage were concurrently 
incubated under normoxic conditions and served as a control. Cells were collected in 
the same manner irrespective of the experimental conditions. 
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2.4.4 In vitro LOXL2 silencing  	  
HK-2 cells at passage 13-16 were seeded onto 6 well-plates  (Corning Inc, Corning, 
NY, USA). Silencing experiments were performed the following day when they 
reached approximately 60% confluence. Prior to transfection the keratinocyte cell 
culture medium was changed to OPTI-MEM (Life technologies, Carlsbad, CA, USA). 
The cells were transfected with either small interfering RNA (siRNA) targeting 
human LOXL2 (Gene Pharma, Shanghai, China) at a final concentration of 80nM or 
non-targeting control siRNA (Gene Pharma) using RiboJuice siRNA transfection 
reagent (Novagen, San Diego, CA, USA) according to the manufacturer’s 
instructions. 5 hours after transfection the siRNA containing medium was replaced 
with fresh keratinocyte serum-free medium (Life technologies, Carlsbad, USA) and 
1ng/ml TGF-β1 (R&D Systems, Minneapolis, MN, USA) added. Keratinocyte serum-
free medium without TGF-β1 served as control. The cells were incubated for 48 hours 
under normoxic or hypoxic conditions. Cell lysates were then collected for further 
analyses. 
 
2.5 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 	  
2.5.1 mRNA extraction and cDNA synthesis 	  
Total RNA was extracted from cells using the ISOLATE II RNA Mini kit (Bioline, 
Alexandria, NSW, Australia) or from kidney tissue using the RNeasy Plus mini kit 
(Qiagen, Hilden, Germany). RNA concentration and purity were assessed using a 
NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, 
USA). Absorbance at 260nm (A260) and 280nm (A280) were measured and an A260/280 
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ratio of 1.9-2.1 indicated RNA purity. cDNA was generated using the Transcriptor 
First Strand cDNA synthesis kit (Roche Diagnostics, Mannheim, Germany) according 
to the manufacturer’s instruction. Briefly, the reaction mixture containing the primer 
and 1µg RNA template was incubated for 10 minutes at 65°C followed by cooling to 
4°C to denature RNA secondary structures. A prepared mastermix containing buffer, 
RNase inhihibitor, deoxynucleotide mix and the Reverse Transciptase were added and 
samples incubated at 25°C for 10 minutes, 55°C for 30 minutes and 85°C for 5 
minutes in a MJ Research PTC-200 Thermal Cycler (Bio-Rad, Hercules, CA, USA). 
The reaction was stopped by cooling to 4°C and samples stored at -20°C until real-
time PCR. 
 
2.5.2 Real-time PCR 	  
Real-time PCR was performed using an ABI Prism 7900 HT Fast Real-Time PCR 
System (Applied Biosystems, Foster City, CA, USA).  All primer sequences are listed 
in the method sections of the individual chapters of this thesis. SensiFAST SYBR Hi-
ROX (Bioline, Eveleigh, NSW, Australia) was used for the in vitro experiments. To 
each 3µL cDNA template a mastermix was added containing per reaction 0.4µL of 
10µM forward primer, 0.4µL of 10µM reverse primer, 5µL SensiFAST SYBR Hi-
ROX and nuclease free water to make a final reaction volume of 10µL. Amplification 
was performed using the following profile: 
 
1. Polymerase activation Hold at 95°C     2 minutes 
2. Two-step cycling at 40 cycles: 
• Denaturation 
 
95°C     5 seconds 
	   52	  
• Annealing/Extension 60°C   15 seconds 
3. Creation of melting curve 95°C   15 seconds 
60°C     1 minute 
95°C   15 seconds 
      
For the animal experiments SensiMix SYBR Hi-ROX was used. To each 3µL cDNA 
template a mastermix was added containing 0.25µL of 10µM forward primer, 0.25µL 
of 10µM reverse primer and 5µL SYBR Hi-ROX per reaction as well as 
DNA/nuclease-free water to make a final reaction volume of 10µL. Amplification was 
performed using the following profile: 
 
1. Polymerase activation Hold at 95°C     2 minutes 
2. Three-step cycling at 40 cycles: 
• Denaturation 
• Annealing 
• Extension 
 
95°C     15 seconds 
60°C     15 seconds 
72°C     15 seconds 
3. Melting curve creation 95°C   15 seconds 
60°C     1 minute 
95°C   15 seconds 
 
 
The cycle threshold (Ct) value, defined as the number of cycles required for the 
fluorescent signal to cross the threshold above background level was analysed using 
the comparative Ct method. Results are presented as fold-change compared to the Ct 
value of the housekeeping gene in each reaction.  β-actin was used as housekeeping 
	   53	  
gene for the in vivo experiments. For the in vitro studies γ-tubulin was used as 
housekeeping gene as the gene expression of β-actin did not remain constant under 
hypoxic conditions. 
 
2.6 Protein studies 	  
2.6.1 Protein extraction from mouse kidney tissue 	  
Prior to protein extraction, frozen mouse kidney tissue was rinsed with phosphate 
buffered saline (PBS), pH7.4, containing 0.16mg/ml heparin (Sigma) to remove any 
red blood cells and clots. The kidney tissue was homogenised with a Qiagen 
TissueRuptor (Qiagen, Hilden, Germany) in 1.5ml of cold homogenisation buffer 
containing 20mM HEPES buffer, pH 7.2 (Sigma), 1mM EGTA (Sigma), 210mM 
mannitol (ICN Biomedicals, Aurora, OH, USA), 70mM sucrose and one tablet 
protease inhibitor cOmplete™ Mini per 50ml buffer (Roche Diagnostics, Mannheim, 
Germany). The homogenate was centrifuged at 1.500 x g for 5 min at 4°C. The pellet 
was resuspended in the cold protein extraction buffer. The supernatant was further 
used for mitochondrial protein extraction if required (Chapter 2.7.1).  Protein 
quantification (Bio-Rad, Hercules, CA, USA) was carried out in a colorimetric assay 
according to the Bradford dye-binding method (38) to determine the protein 
concentration. 
 
2.6.2 Western blot 	  
20µg of protein were mixed with 4X Loading buffer, 10X reducing agent (Life 
Technologies, Vic, Australia) and water to make 20µl solutions.  The protein solution 
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was heated at 70°C for 10 min. Samples were then analysed by SDS gel 
electrophoresis in 4 to 12 % Novex Bolt mini gels (Life Technologies, Carlsbad, CA, 
USA) and electroblotted to Hybond Nitrocellulose membranes (Amersham Pharmacia 
Biotech, Bucks, UK). Membranes were blocked in Tris-buffered saline containing 
0.2% Tween-20 (TBST) in 5% skim milk for 30 min and then incubated overnight at 
4°C with the following primary antibodies: MitoProfil Total OXPHOS Rodent WB 
antibody cocktail 1:250 (Abcam Ltd, Cambridge, UK), Tom 20 1:500 (Santa Cruz, 
Dallas, TX, USA), MnSOD 1:1000 (Millipore, Billerica, MA, USA) in TBST 
containing 5% skim milk. Membranes were washed with TBST and incubated with 
horseradish peroxidase conjugated secondary antibody. Protein bands were visualised 
using Luminata Western HRP Substrate (Millipore, MA, USA) in a LAS 4000 image 
reader (Fujifilm, Tokyo, Japan) All membranes were reprobed with β-actin 1:1000 
(Santa Cruz, Dallas, TX, USA) and results were corrected for β-actin as a loading 
control. Analysis was performed using Image J software (Java based software 
program, National Institutes of Health). 
 
2.6.3 Immunohistochemistry 
2.6.3.1 Immunohistochemistry on paraffin-embedded sections 	  
Four micron sections of formalin-fixed, paraffin embedded kidney tissue were 
deparaffinised in xylene, rehydrated in graded concentrations of ethanol and rinsed in 
water. Antigen retrieval was performed by boiling the sections at 98°C for 20 min in 
10mM citrate buffer (pH 6.0). The slides in the heated citrate buffer were cooled at 
room temperature for 30 minutes, rinsed in water, washed in Tris Buffered Saline 
(TBS) (50mM TBS, 0.05% Tween 20, pH 7.2) and exposed to 0.3% H2O2 for 5 
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minutes to quench endogenous peroxidases. The sections were blocked with Dako 
proteinblock (Dako, Carpinteria, CA, USA) for 10 minutes and incubated with the 
respective primary antibody at 4°C overnight. A detailed list of antibodies and 
negative controls are in the method section of each chapter. The following day the 
sections were washed in TBST and incubated with horseradish peroxidase anti-rabbit 
Envision–system. Following another wash in TBST the sections were exposed to a 
3.3’-diaminobenzidine (DAB) substrate-chromogen solution (Dako) for 10 minutes. 
The reaction was stopped by rinsing the sections in water for 3 minutes before 
counterstaining in Mayer’s haematoxylin followed by Scott’s solution. The sections 
were then rinsed in water, dehydrated in graded ethanol followed by xylene prior to 
coverslip mounting. The slides were examined using a Leica photomicroscope linked 
to a DFC 480 digital camera (Leica, Wetzlar, Germany). The quantitation was 
performed by capturing 6-10 non-overlapping fields of renal cortex from stained 
sections. Areas of staining were highlighted using a selective colour tool and the 
proportional area of the field with their respective color range was quantified using 
Image J (National Institutes of Health, Bethesda, MD, USA).  
 
2.6.3.2 Immunohistochemistry on frozen sections 	  
Six micron frozen sections were fixed in cold acetone for 10 min immediately after 
removal from the freezer. Sections were then washed in PBS three times, 5 min each, 
pre-incubated in Dako proteinblock (Dako, Carpinteria, CA, USA) for 15 minutes. 
Slides were then incubated in a rat anti-mouse F4/80 monoclonal antibody (Bio-Rad, 
Hercules, CA, USA, dilution 1:100) for one hour. Each section was washed three 
times in PBS before incubation with a secondary HRP tagged goat anti rat antibody 
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for 30 min (Bio-Rad, Hercules, CA, USA, dilution 1:200). The sections were washed 
with PBS and antigen-antibody reaction was visualised with chromogen 
diaminobenzidine (Dako, Carpinteria, CA, USA) Counter staining was performed 
using Mayer’s haematoxylin followed by Scott’s blue staining (Fronine Taren Point, 
NSW, Australia) and slides were dehydrated in graded ethanol followed by xylene. 
 
2.6.4 Cross-link assay 	  
2.6.4.1 Cross-link extraction  	  
Sections of kidney tissue were lyophilised and homogenised in PBS buffer. The 
homogenate was reduced with sodium borohydride (NaBH4) for 30 min at room 
temperature. The reaction was stopped by addition of 50 µL acetic acid. The reduced 
samples were washed twice with water and hydrolysed with 6M hydrochloric acid 
(HCl) for 24 hours at 105°C. The hydrolysates were dried to evaporate HCl and 
resuspended in 200 µL ultrapure H2O. Collagen crosslinks were extracted from the 
hydrolysate using an automated solid phase extraction system (GX-271 ASPEC 
system, Gilson, Middleton, WI, USA) set up with GracePure solid phase extraction 
(SPE) C18-Aq columns and GracePure SPE Cation-X columns (Grace Discovery 
Sciences, Epping, VIC, Australia). Briefly, 50 µL of the hydrolysate were applied to a 
C18-Aq column that was subsequently eluted with 10mM ammonium formate, 0.1% 
formic acid and 0.1% heptafluorobutyric acid (HFBA) in 40% methanol solution. 
Eluates from the C18-Aq column were then applied to the Cation-X column that had 
been activated with 500 µL of 0.1% formic acid in H2O solution. The Cation-X 
column was washed with 1 mL of ultrapure H2O and collagen crosslinks eluted using 
3 mL of 25% ammonia in H2O. The eluates were evaporated to a dry pellet at 60°C. 
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The residue was then converted into HFBA salt by addition of 5% HFBA in H2O 
solution and evaporated to a dry pellet at 60 °C. The final HFBA salts of extracted 
crosslinks were dissolved in 50 µL of mobile phase A (10 mM ammonium formate, 
0.1% formic acid, 0.1% HFBA in H2O).  	  
2.6.4.2 Cross-link quantitation by ultra-high performance liquid 
chromatography-electrospray ionisation tandem mass spectrometry 
(UHPLC-ESI-MS/MS) 	  
Cross-link quantitation was done by ultra-high performance liquid chromatography-
electrospray ionisation tandem mass spectrometry (UHPLC-ESI-MS/MS) in a 
Thermo Dionex UHPLC and TSQ Endura triple quad mass spectrometer 
(ThermoFisher Scientific, North Ryde, NSW, Australia). The following commercially 
available standards were used: For immature collagen cross-links, 
dihydroxylysionorleucine (DHLNL, Thermo Fisher Scientific, North Ryde, NSW, 
Australia), for trivalent mature cross-links pyridinoline (PYD, Quidel Corporation, 
San Diego, CA, USA) and hydroxyproline (Sigma-Aldrich, St Louis, MO, USA) to 
determine total collagen. UHPLC separation of cross-links was achieved with an 
Agilent RRHD SB-C18 2.1x50mm, 1.8um column (Agilent Tech, Santa Clara, CA, 
USA) using mobile phase A (10 mM ammonium formate, 0.1% formic acid, 0.1% 
HFBA in H2O) and mobile phase B (10 mM ammonium formate, 0.1% formic acid, 
0.1% HFBA in 80% methanol). UHPLC was performed using a 12 minutes gradient 
flow of the mobile phase A from 96.2 to 0% and mobile phase B from 3.8 to 100% at 
a flow rate of 0.3 mL/min. The temperature of the UHPLC column was set at 40°C. 
Positive ESI-MS/MS with selected reaction monitoring (SRM) mode was performed 
using the following parameters: spray voltage 4000 v, sheath gas 35 (Arb), aux gas 20 
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(Arb), sweep gas 0 (Arb), ion transfer tube temperature 350°C, vaporiser temperature 
300°C. Quantitation of the collagen crosslinks and total collagen was achieved by 
comparing to a standard curve generated using the commercially-available standards 
described above. 
Collagen crosslinks and total collagen were normalised to total protein content in 
hydrolysates. Quantitation of total protein was performed using the QuickZyme total 
protein assay kit (QuickZyme Biosciences, Leiden, The Netherlands) according to the 
manufacturer’s instructions. 	  
2.7 Mitochondrial studies 	  
2.7.1 Mitochondrial protein extraction 	  
Mitochondrial protein fractions were obtained by differential centrifugation. Kidney 
tissue was homogenised and centrifuged at 1.500 x g for 5 min at 4°C as previously 
described in section 2.6.1. The supernatant was again centrifuged for 15 min at 10000 
x g at 4°C. The resultant supernatant containing cytosolic protein was kept for 
reference while the pellet containing the mitochondrial fraction was suspended in the 
homogenisation buffer. Mitochondrial protein was quantified using the Bradford 
assay. 
 
2.7.2 Mitochondrial DNA extraction and mitochondrial copy number 	  
Genomic DNA was extracted from renal tissue using the DNeasy blood and tissue kit 
(Qiagen) and quantified using Nanodrop. The content of mtDNA was calculated using 
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real-time quantitative PCR by measuring the threshold cycle ratio (ΔCt) of a 
mitochondrial-encoded gene (COX1, forward 5′-ACTATACTACTACTAA-
CAGACCG-3′, reverse 5′-GGTT-CTTTTTTTCCGGAGTA-3′) versus a nuclear-
encoded gene (cyclophilin A, forward 5′-ACACGCCATAATGGCACTGG-3′, 
reverse 5′-CAGTCTTGGCAGTGCAGAT-3′). 
 
2.7.3 Manganese Superoxide Dismutase (MnSOD) activity assay 	  
The activity of MnSOD was determined in the mitochondrial protein fraction by a 
standard kit from Calbiochem (Merck Millipore, Darmstadt, Germany) following the 
manufacturer’s instructions. The MnSOD activity was expressed as the amount of 
enzyme causing a 50% inhibition of formazan dye, employing hypoxanthine and 
xanthine oxidase to generate superoxide radicals.  
 
2.7.4 Electron microscopy 	  
Kidney tissue was fixed in a mixture containing 2.5% glutaraldehyde in 0.1M sodium 
cacodylate buffer, pH 7.4 and subsequently sliced into 15µm thick sections, then 
mounted on a silicon (conductive) substrate for electron microscope imaging of 
mitochondria. Electron microscopy was kindly performed by Associate Professor 
Murray Killingsworth as previously described (136). 
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2.8  Localisation of oxidative stress 	  
Oxidative stress was determined by immunohistochemistry for 8-hydroxy-2’-
deoxyguanosine (8-OHdG), which is formed when DNA is oxidatively modified by 
ROS. To further localise oxidative stress within the cell compartments frozen sections 
where incubated with a fluorogenic probe (CellROX, Molecular Probes, Eugene, OR, 
USA) which detects total ROS. The sections were then co-stained using a Mitotracker 
assay (Molecular Probes) to detect specifically the mitochondrial ROS. 
 
2.8.1 CellROX assay  	  
Frozen kidney sections were stained according to the manufacturers instruction and 
imaged using a Leica SP2 confocal laser scanning microscope (Leica, Wetzlar, 
Germany). All imaging parameters including laser intensities, photomultiplier tubes 
voltage and pinhole were kept constant during imaging. For total ROS detection, 
CellROX Deep Red (Molecular Probes, Australia) was used at 5µM final 
concentration, images were collected at 633nm excitation wavelength and detected in 
the 640-680 nm emission range. 
 
2.8.2 Mitotracker assay 	  
MitoTracker Green (Molecular Probes, Eugene, OR, USA) was used on frozen kidney 
sections to visualise the mitochondria at 200nM final concentration.  Images were 
collected at 458 nm excitation wavelength and detected in the 480-505nm emission 
range.  	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2.9  Epigenetic studies 	  
2.9.1 DNA extraction from kidney tissue and bisulfite modification 
 
DNA was extracted from kidney tissue using the Qiagen DNeasy blood and tissue kit 
with on column RNAse treatment (Qiagen, Hilden, Germany). To quantify 
methylation profiles at individual CpG sites, DNA was denatured and bisulfite 
treated, a process, which converts unmethylated cytosines to uracil while methylated 
cytosines remain unchanged. Once converted, the methylation was quantified by PCR 
amplification followed by DNA sequencing. DNA bisulfite modification was 
performed on 500ng input DNA using the EZ DNA Methylation-Gold™ Kit (Zymo 
Research, Irvine, CA, USA). Converted DNA was quantitated as single stranded 
DNA using a UV spectrophotometer (NanoDrop Technologies, Wilmington, DE, 
USA) with A260 1.0 = 40 µg/ml. 
 
2.9.2 DNA methylation analysis of CpG sites in the PGC-1α promotor 
 
The methylation profile of four CpG sites in the PGC-1α promotor were analysed by 
PCR amplification and subsequent sequencing. A mastermix was prepared for the 
PCR containing 1X PyroMark PCR Master Mix (Qiagen, Hilden, Germany), 1X 
Coral CoralLoad concentrate (Qiagen), 300nM Forward Primer, 300nM Reverse 
Primer, 19ng bisulfite converted DNA and water to make up a final volume of 25µl.  
The PCR conditions were as follows: 
 
1. Polymerase activation 95°C     15 minutes 
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2. Three-step cycling at 40 cycles: 
• Denaturation 
• Annealing 
• Extension 
 
94°C     20 seconds 
55°C     30 seconds 
72°C     30 seconds 
• Final Extension 72°C       5 minutes 
30°C       3 minutes  
 
The sequencing was performed in a Qsec sequencer (BioMolecular Systems, Upper 
Coomera, QLD, Australia). Nucleotides, annealing buffer, binding buffer, wash 
buffer, DS-denaturation solution, enzyme and substrate mix supplied in the 
PyroMark®Q24 Advanced CpG Reagents Kit (Qiagen, Hilden, Germany) as well as 
the PGC-1α sequencing primer (Sigma, St.Louis, MO, USA) were loaded into the 
cartridges of the sequencer. 2µl magnetic Strepavidin Mag Sepharose™ beads (GE 
Healthcare Life Sciences, Parramatta, NSW, Australia) per reaction were loaded onto 
the 48 well disc (BioMolecular Systems) and 10µl PCR product added to each well. 
The quantification of the methylation at the chosen CpG sites was done with software 
from BioMolecular Systems. 
 
Table 2.1   Primer Sequence  
Target Sequencing Primer 
PGC-1α 5’-GAGATAGAATGATAATTTAGTAAGT-3’ 
 
2.9.3 Global DNA methylation  	  
Global DNA methylation status in DNA from renal tissues was analysed with the 
MethylFlash™ methylated DNA quantification kit (Epigentik, Farmingdale, NY, 
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USA) according to the manufacturer’s instructions. 100ng input DNA were used and 
the methylated fraction detected using an antibody assay with high specificity for 5-
methylated cytosine and subsequent colorimetric detection. The absorbance was read 
at 450nm in LP400 microplate reader (Anthos Labtec Instruments, Austria). 
 
2.10 Statistical analysis 	  
 
Statistical comparisons between groups were made by ANOVA with Bonferroni 
correction for multiple comparisons and unpaired student t-tests when two groups 
were compared. For not normally distributed values Mann-Whitney U tests were 
applied. Analyses were performed using the software package, GraphPad Prism 
version 6 (GraphPad Software Inc, La Jolla, California, USA). For the confocal 
CellROX and Mitotracker study, the data distribution was assessed using a non-
parametric test of different source distributions (Kolmogorov-Smirnov) as previously 
described (94).	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3.1 Background and objectives 	  
 
Evidence has emerged that some diseases known to manifest in adulthood, e.g. type 2 
diabetes, obesity, cardiovascular disease and hypertension may have their origins in 
fetal development.  This concept commonly referred to as “fetal origins of disease” 
evolves around the hypothesis that perturbations to the intra-uterine or early postnatal 
environment program the developing individual to an increased susceptibility to 
chronic diseases later in life. Low birth weight is a surrogate marker for such 
unfavorable in-utero conditions and is strongly associated with development of 
chronic kidney disease (CKD) in later life (259). As the prevalence of end-stage 
kidney disease continues to increase (60), this is not always explained by traditional 
risk factors. In fact, it often remains unclear why the rate of CKD progression shows 
substantial variation from patient to patient even among individuals with similar 
comorbidities and fetal programming may be a contributor. Although a reduced 
nephron endowment has been implicated (41, 114), the underlying molecular 
mechanisms for fetal programming of adult onset kidney disease are largely 
unknown. 
 
Maternal smoking remains the most common modifiable adverse fetal exposure 
despite population-wide efforts to reduce smoking. In a nationwide survey in 2010 
approximately 10.7% of women in the US reported smoking during the last 3 months 
of pregnancy (244).  12% of Australian women smoked during their pregnancy in 
2013 with higher numbers in lower socioeconomic groups, including 47% of 
indigenous mothers (10). Developmental cigarette smoke exposure frequently results 
in low birth weight (122). Epidemiological studies have shown that maternal smoking 
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also alters the in-utero growth pattern of kidneys and leads to a reduced kidney 
volume in fetal and postnatal life (144, 236). Cigarette smoke is a major source of 
reactive oxygen species (ROS). High concentrations of ROS cause lipid peroxidation 
and may damage cell membranes, proteins, and DNA. Evidence is mounting that 
maternal smoking causes an increase in oxidative stress in fetal cord blood and 
placenta (12, 218). Mitochondria are the main intracellular source but also a primary 
target of ROS, which are generated as by-products of ATP synthesis through the 
oxidative phosphorylation system (OXPHOS). Mitochondria serve a crucial role in 
development by providing energy for the rapid fetal growth (176). Disruption of 
mitochondrial homeostasis may lead to long-lasting detrimental effects and failure of 
organ function over time. The role of mitochondrial dysfunction and ROS production 
is clearly established in a number of chronic adult onset diseases including 
Parkinson’s disease (127), Alzheimer’s disease (4), atherosclerosis (105), diabetes 
(97, 189) as well as aging (116, 216). Evidence for mitochondrial dysfunction in 
chronic kidney disease is emerging from high throughput genome-based microarray 
technology (96) and a number of experimental studies (230, 273, 278, 281). It remains 
to be shown whether the mitochondrial perturbations are present already at birth as a 
consequence of an adverse in-utero environment and increased oxidative stress. 
 
Epigenetics provide another potential link between environment and disease 
susceptibility in later life. Cells use epigenetic modifications to regulate gene 
expression, thereby modifying the phenotype. DNA methylation is the most studied 
epigenetic modification and describes the covalent addition of a methyl group to the 
5th carbon of a cytosine (5-mC) residue that is located adjacent to a guanine 
nucleotide (CpG dinucleotide). Methylation of DNA modulates gene transcription by 
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influencing binding of proteins to DNA that initiate transcription. DNA 
hypermethylation is generally considered an inhibitor of transcription while 
hypomethylation activates transcription. Diabetes is an example where altered DNA 
methylation has been implicated in its disease pathogenesis. Studies have 
demonstrated that altered mitochondrial activity is a hallmark of the insulin resistant 
state and this was linked to hypermethylation of PGC-1α, a transcription co-activator 
and major regulator of mitochondrial biogenesis (25, 160).  
 
The correct creation of the individual epigenetic code is crucial for the developing 
fetus. The establishment of the epigenetic program starts soon after fertilisation when 
all DNA methylation marks are erased in the preimplantation embryo with subsequent 
resetting of the genome-wide methylation pattern in a cell-type specific manner to 
help programming somatic development. Exposure to an adverse intrauterine 
environment, i.e smoke exposure during this critical time of development may lead to 
alterations in the epigenome and mitochondrial alterations that have long lasting 
consequences 
 
The first aim of the study was to test the hypothesis that maternal smoking causes 
increased ROS production and mitochondrial perturbations in renal tissue in the 
offspring at birth and that this effect is sustained into adulthood. The second aim was 
to determine whether epigenetic modifications occur as a result of developmental 
smoke exposure. Both global methylation patterns and site-specific methylation in the 
promoter region of PGC-1α were examined.   
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3.2 Material and methods 	  
3.2.1 Animal model 	  
Female Balb/c mice (Animal Resources Centre, Perth, Australia) were housed at 
20±2°C, and maintained on a 12:12h light/dark cycle, with free access to water and 
standard laboratory chow (11kJ/g, Gordon’s Specialty Stockfeeds, NSW, Australia). 
Twice daily (5 days/week) they underwent smoke exposure (SE) in a Perspex 
chamber with smoke generated from 2 cigarettes (nicotine<1.2mg, CO<15mg). 
Smoke exposure started 6 weeks before mating and continued throughout gestation 
and lactation.  The control mice were put in an identical chamber of air for the same 
period. During lactation the offspring remained in the home cage without SE. Pups 
were weaned at postnatal day 20.  A terminal urine collection was undertaken via 
direct bladder puncture at the end points: postnatal day 1, day 20 (weaning) and week 
13 (mature age). Blood was collected via cardiac puncture after mice were 
anaesthetised. Then animals were sacrificed by cervical dislocation. Plasma was 
separated immediately and stored at -20°C for creatinine measurements. Kidneys 
were harvested, snap frozen and stored at -80° for further processing, fixed with 10% 
formalin (Sigma, Vic) for paraffin embedding or 2.5% glutaraldehyde in 0.1M 
sodium cacodylate buffer (Sigma) for electron microscopy. Only male offspring were 
used for this study. 
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3.2.2 Detection of oxidative stress 
3.2.2.1 Confocal microscopy 	  
Frozen kidney sections were stained with CellROX Deep Red (Molecular Probes, 
Australia) at 5µM final concentration for detection of total ROS. Images were 
collected at 633 nm excitation wavelength and detected in the 640-680 nm emission   
range using a Leica SP2 confocal laser scanning microscope (Leica, Wetzlar, 
Germany). Data was generated from three independent experiments, each in 
triplicates. Fifty images were taken from each slide and averaged before the analysis. 
All imaging parameters including laser intensities, photomultiplier tubes voltage and 
pinhole were kept constant during imaging. CellROX Deep Red (Molecular Probes, 
Australia) was at a 5µM final concentration, images were collected at 633nm 
excitation wavelength and detected in the 640-680nm emission range. MitoTracker 
Green (Molecular Probes, Australia) was used to visualise the mitochondria at 200nM 
final concentration.  Images were collected at 458 nm excitation wavelength and 
detected in the 480-505nm emission range. Lysosomes were visualised using 
Lysotracker Red DND-99 (Molecular Probes, Australia) at 100nm final concentration. 
Images were collected at 514nm excitation wavelength and detected in the 525-
550nm emission range. To calculate the correlation between CellROX and 
Mitotracker, dual staining using CellRox and Mitotracker was performed and images 
were taken sequentially using separate confocal channels over a time not greater than 
30 seconds. The image pixel intensity value correlation was then calculated using 
Pearson's correlation for all pixels excluding any pairs containing zero values.  
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3.2.2.2 Immunohistochemistry 	  
Formalin-fixed paraffin-embedded sections were deparaffinised and boiled for 20 min 
in 10mM citrate buffer (pH 6.0). Sections were washed in TBST and exposed to 0.3% 
H2O2 for 5 min to quench endogenous peroxidases. Immunohistochemistry was 
performed using rabbit anti-8-hydroxydeoxyguanosin (8-OHdG) polyclonal antibody 
(1:100, BIOSS, Woburn, MA, USA). Concentration-matched rabbit IgG was used as 
an isotype-negative control. The sections were blocked with Dako proteinblock 
(Dako, Carpinteria, CA, USA) for 10 min and incubated with primary antibody 
overnight. The slides were then incubated with horseradish peroxidase anti-rabbit 
Envision–system followed by a 3.3’-diaminobenzidine (DAB) substrate-chromogen 
solution (Dako) and counterstained with Harris haematoxylin. The slides were then 
examined using a Leica photomicroscope linked to a DFC 480 digital camera (Leica, 
Wetzlar, Germany). The quantitation was performed by capturing 6-10 non-
overlapping fields of renal cortex from stained sections. The percentage of the stained 
area relative to the whole area in each field was determined using Image J (National 
Institute of Health, USA). 
 
3.2.3 Mitochondrial assessment 
3.2.3.1 Mitochondrial protein extraction 	  
Mitochondrial protein fractions were obtained by differential centrifugation. Prior to 
protein extraction, tissue was rinsed with phosphate buffered saline (PBS), pH7.4, 
containing 0.16mg/ml heparin to remove any red blood cells and clots. Tissue was 
homogenised with a Quiagen TissueRuptur  (Quiagen, Limburg, Netherlands) in 1.5 
ml of cold 20mM HEPES buffer, pH 7.2, containing 1mM EGTA, 210mM mannitol, 
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70mM sucrose and centrifuged at 1500g for 5 min at 4°C. The supernatant was 
centrifuged for 15 min at 10000g at 4°C. The pellet containing the mitochondrial 
fraction was suspended in 20mM HEPES buffer, pH 7.2 with 1mM EGTA, 210mM 
mannitol and 70mM sucrose. Protein quantification (BioRad, CA, USA) was carried 
out to determine the protein concentration.  
 
3.2.3.2 Western blot of mitochondrial proteins 	  
10 µg of protein were mixed with 4X Loading buffer, 10X reducing agent (Life 
Technologies, Vic, Australia) and water to make 20 µl solutions; and heated at 70°C 
for 10 min. Samples were then analysed by SDS gel electrophoresis (Life 
Technologies, Vic, Australia) and electroblotted to Hybond Nitrocellulose membranes 
(Amersham Pharmacia Biotech, Bucks, UK). Membranes were blocked in Tris-
buffered saline containing 0.2% Tween-20 (TBST) in 5% skim milk for 30 min and  
incubated overnight at 4°C with the primary antibodies against subunits of the 
mitochondrial OXPHOS complexes, an antibody against a mitochondrial import 
receptor and against the mitochondrial antioxidant manganese superoxide dismutase 
(MnSOD). The following antibodies and concentrations were used: MitoProfil Total 
OXPHOS Rodent WB antibody cocktail 1:250 (Abcam Ltd, Cambridge, UK), 
translocase of outer membrane (TOM20) antibody 1:500 (Santa Cruz, CA, USA) and 
MnSOD antibody 1:1000 (Millipore, Billerica, MA, USA) in TBST containing 5% 
skim milk. Membranes were washed with TBST and incubated with horseradish 
peroxidase conjugated secondary antibody. Proteins were visualised using Luminata 
Western HRP Substrate (Millipore, MA, USA) in a LAS 4000 image reader (Fujifilm, 
Tokyo, Japan). All membranes were re-probed with β-actin 1:1000 (Santa Cruz, CA, 
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US) and results were expressed as percentage of protein expression relative to β-actin. 
Analysis was performed using Image J software (Java based software program, 
National Institutes of Health). 
 
3.2.3.3 Mitochondrial superoxide dismutase (MnSOD) activity 	  
Superoxide dismutase (SOD) is a crucial component of the cellular antioxidant 
defense. While other isoforms of SOD are located in the cytosol, manganese SOD 
(MnSOD) is mostly located in the mitochondria. The activity of MnSOD was 
determined in the mitochondrial protein fraction with an analysis kit from Calbiochem 
(Merck Millipore, Darmstadt, Germany) following the manufacturer’s instructions. 
The MnSOD activity was expressed as the amount of enzyme causing a 50% 
inhibition of formazan dye, employing hypoxanthine and xanthine oxidase to generate 
superoxide radicals. 
 
3.2.3.4 Mitochondrial copy number 	  
Genomic DNA was extracted from renal tissue using the DNeasy blood and tissue kit 
(Quiagen). The content of mtDNA was calculated using real-time quantitative PCR 
by measuring the threshold cycle ratio (ΔCt) of the mitochondrial-encoded gene 
cytochrome c oxidase subunit 1 (COX1), (forward primers 5′-
ACTATACTACTACTAA-CAGACCG-3′, reverse primers 5′-
GGTTCTTTTTTTCCGGAGTA-3′) versus the nuclear-encoded gene cyclophilin A 
(forward primers 5′-ACACGCCATAATGGCACTGG-3′, reverse primers 5′-
CAGTCTTGGCAGTGCAGAT-3′). 
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3.2.3.5 Electron microscopy 	  
Kidney tissue was fixed in 2.5% glutaraldehyde in 0.1M sodium cacodylate buffer 
(Sigma) pH7.4 and subsequently sliced into 100 nm thick ultrathin sections, then 
mounted on 300 mesh copper grids for imaging of mitochondria with an FEI 
Morgagni 268D transmission electron microscope (FEI, Eindhoven, The 
Netherlands). 
 
3.2.4 Epigenetic investigations 
3.2.4.1 Global methylation assay 	  
DNA was extracted from the offspring kidneys of smoke exposed mothers and control 
using the Qiagen DNeasy blood and tissue kit with on column RNAse treatment 
(Qiagen, Hilden, Germany). Global DNA methylation status was analysed with the 
MethylFlash™ methylated DNA quantification kit (Epigentik, Farmingdale, NY, 
USA) according to the manufacturer’s instructions. 100ng input DNA were used and 
the methylated fraction detected using an antibody assay with high specificity for 5-
methylated cytosine and subsequent colorimetric detection. The absorbance was read 
at 450nm in a LP400 microplate reader (Anthos Labtec Instruments, Austria). 	  	  
3.2.4.2 Gene-specific DNA methylation analysis in the PGC-1α promotor 	  
The study built on pilot experiments that demonstrated reduced PGC-1α mRNA 
expression in offspring kidneys from smoke exposed mothers at weaning and 
hypermethylation at -504 CpG of the PGC-1α promotor (unpublished data). The 
methylation profile of three additional CpG sites in the PGC-1α promotor were 
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analysed in control and smoke exposed offspring. 500ng genomic DNA for each 
sample was denatured and bisulfite treated using the EZ DNA Methylation-Gold™ 
Kit (Zymo Research, Irvine, CA, USA). Bisulfite converted DNA was quantitated as 
single stranded DNA using a UV spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA) with A260 1.0 = 40 µg/ml. 19ng bisulfite converted DNA was 
amplified in a PCR using 1XPyroMark PCR Master Mix (Qiagen, Hilden, Germany) 
and predesigned PGC-1α primer (Sigma-Aldrich, NSW Australia) as described in 
detail in Chapter 2.9.2.  
 
Table 3.1  Mouse-specific PGC-1α primer 
Target Forward (5’-3’) Reverse (5’-3’) 
PGC-1α TTTGGAGGTTTTTGGTGATAGT TACCCCCAAATCCTCACATATATAC 
 
The sequencing was performed in a Qsec sequencer (BioMolecular Systems, Upper 
Coomera, QLD, Australia) using PyroMark®Q24 Advanced CpG Reagents Kit 
(Qiagen, Hilden, Germany), PGC-1α sequencing primer (Sigma, St.Louis, MO, USA) 
2µl magnetic Streptavidin Mag Sepharose™ beads (GE Healthcare Life Sciences, 
Parramatta, NSW, Australia) and 10µl PCR product. The quantification of the CpG 
methylation was done with software from BioMolecular Systems (Upper Coomera, 
QLD). 
 
Table 3.2   Pyrosequencing Primer 
Target Sequencing Primer 
PGC-1α 5’-GAGATAGAATGATAATTTAGTAAGT-3’ 
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3.2.5 Statistical analysis  	  
Statistical comparisons between groups were made by unpaired student t-tests unless 
otherwise stated in the figure legend. For not normally distributed values Mann-
Whitney U test was used. Analyses were performed using the software package, 
GraphPad Prism version 6 (GraphPad Software Inc, La Jolla, California, USA). For 
the confocal study, the data distribution was assessed using a non-parametric test of 
different source distributions (Kolmogorov-Smirnov) as previously described (94). 
Fifty images were taken for over 100 cells in each tissue in 3 replicates of 3 
independent samples/group. Pearson's correlation method was used to determine the 
correlation factor and p values for the correlation study.  
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3.3 Results 
3.3.1 Maternal smoking induces low birth weight and albuminuria in adult 
offspring mice 
The physiological characteristics of mice offspring are summarised in table 3.1. In 
keeping with the known adverse effect of maternal cigarette smoke exposure during 
gestation a reduced birth weight (day 1) was observed in offspring of smoke-exposed 
(SE) mothers. There was no difference in weight between control and SE mice at 
weaning (day 20) and at adulthood (week 13). Kidney weight was reduced at day 1 in 
the SE offspring but had normalised by day 20. Serum creatinine remained normal in 
both groups at adulthood, however offspring of smoke-exposed mothers developed an 
increased urinary albumin/creatinine ratio at week 13. The kidneys of SE offspring 
had minor glomerulosclerosis and minor tubular dilatation, although this did not reach 
statistical significance (data not shown). 
Table 3.3   Characteristics of offspring mice.  
 Control SE 
Day 1 
   Body weight (g) 
   Kidney weight (g) 
   Kidney/body weight (%) 
 
Day 20 
   Body weight (g) 
   Kidney weight (g) 
   Kidney/body weight (%) 
   Albumin/creatinine ratio (µg/mg) 
   Serum creatinine (µmol/l) 
 
Week 13 
   Body weight (g) 
   Kidney weight (g) 
   Kidney/body weight (%) 
   Albumin/creatinine ratio (µg/mg) 
   Serum creatinine (µmol/l) 
 
1.55 ± 0.05 
0.0081 ± 0.0004 
0.52 ± 0.02 
 
 
9.97 ± 0.16 
0.067 ± 0.001 
0.67 ± 0.01  
8.69 ± 2.00 
10.4 ± 0.7 
 
 
25.5 ± 0.3 
0.20 ± 0.01 
0.77 ± 0.01 
7.00 ± 2.3 
15.2 ± 1.3 
 
1.35 ± 0.06* 
0.0069 ± 0.0004* 
0.51 ± 0.04 
 
 
9.71 ± 0.14 
0.062 ± 0.003 
0.64 ± 0.03 
6.12 ± 1.45 
12.1 ± 1.2 
 
 
25.1 ± 0.6 
0.19 ± 0.01 
0.76 ± 0.02 
38.0 ± 6.3* 
14.2 ± 0.5 
 
Control=offspring from sham exposed dams, SE=offspring from smoke exposed 
dams, n=5-10, mean ± SEM, *P < 0.05 vs. control. 
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3.3.2 Maternal smoking induces mitochondrial dysfunction and oxidative stress 
in the offspring kidney 	  
3.3.2.1 Mitochondrial oxidative stress 
 
Products from cigarette smoke are known inducers of oxidative stress in various 
tissues and are able to cross the placenta. In order to investigate whether maternal 
smoking causes oxidative stress in the offspring, frozen renal sections were stained 
with CellRox Red. There was a significant increase of total ROS in SE offspring at 
day 20 and week 13 (P<0.001; Figure 3.1). To further demonstrate the localisation of 
ROS, frozen sections were co-stained for CellROX with Mitotracker stain, a 
mitochondrial selective fluorescent probe. The correlation coefficient of the mean 
fluorescent intensities of both stains was significantly higher in the kidney of the SE 
offspring at day 1 and week 13 (P < 0.01, Figure 3.2) suggesting that at these time 
points ROS was localised within or within close proximity to the mitochondria. 
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Figure 3.1   Detection of oxidative stress 
(A) CellROX stain for total ROS in frozen sections of offspring kidneys of smoke-
exposed mothers (SE) and control at postnatal day 1, day 20 and week 13. (B) 
Quantitative representation of Mean Fluorescent Intensity (MFI) for ROS. Data are 
expressed as mean± SEM, n= 3, ***P < 0.001 vs. control using non-parametric test 
of different source distributions (Kolmogrov–Smirnov). Scale bars represent 50µm.                      
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Figure 3.2   Mitochondrial ROS 
Pixel intensity scatter plot for dual stain with CellROX and Mitotracker at day 1, day 
20, week 13 and Pearson correlation coefficient (r). Colours red, green and yellow 
reflect CellROX, Mitotracker and co-localised pixels. The strongest correlation 
between Mitotracker (green) and CellRox (red) was detected in SE offspring at day 1 
and week 13 suggesting that at these time points most ROS is located within or within 
close proximity to the mitochondria of SE mice. 
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3.3.2.2 ROS mediated DNA oxidation 	  
8-OHdG reflects oxidative stress-mediated DNA damage. 8-OHdG expression was 
significantly increased in paraffin-embedded kidney sections from smoke-exposed 
offspring at all time points. Both proximal and distal tubules stained positive for 8-
OHdG with sparing of the glomeruli. However, the most intense staining was noted in 
distal tubules with predominantly cytoplasmic staining (Figure 3.3). 
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Figure 3.3   Immunostaining of 8-OHdG  in offspring kidneys 
(A) Representative images of 8-OHdG expression in renal cortex at day 1, day 20 and 
week 13. Original magnification: x 200, arrow indicates strong staining in distal 
tubules. (B) Quantitation of 8-OHdG. Data is expressed as mean % of stained area ± 
SEM, n=5-6 *P < 0.05 vs control. 
 
 
  
A Week	  13 Day	  20 Day	  1 
Control Control Control 
SE SE SE 
Control SE
0
5
10
15
20
8-
O
H
dG
 (%
Ar
ea
)
Day 1
*
Control SE
0
2
4
6
8
8-
O
H
dG
 (%
Ar
ea
)
Day 20
*
Control SE
0
5
10
15
8-
O
H
dG
 (%
Ar
ea
)
Week 13
*
B 
	   82	  
3.3.2.3 Mitochondrial antioxidants 	  
To investigate whether the increased mitochondrial ROS in offspring kidneys is 
linked to a reduction in antioxidant defense mitochondrially located MnSOD was 
determined.  Both MnSOD protein and activity were significantly reduced at day 1 
and week 13 but not at day 20 (Figure 3.4).  
 
 
 
Figure 3.4	  	  	  MnSOD protein and activity in the mitochondria of offspring kidneys  
(A) MnSOD activity assay, (B) MnSOD Western blot. Results from postnatal day 1, 
day 20 and week 13 are expressed as mean ± SEM, n=5-8; *P<0.05 vs. control  
Control SE
0
2
4
6
M
nS
O
D
 a
ct
iv
ity
 (U
/m
g 
pr
ot
ei
n)
Day 1
**
Control SE
0
2
4
6
8
M
nS
O
D
 a
ct
iv
ity
 (U
/m
g 
pr
ot
ei
n)
Day 20
Control SE
0
2
4
6
8
10
M
nS
O
D
 a
ct
iv
ity
 (U
/m
g 
pr
ot
ei
n)
Week 13
**
A	  
β-­‐actin 
Control SE
0
50
100
150
M
nS
O
D
 / 
Ac
tin
 (%
 C
on
tro
l)
Day 1
*
Control SE
0
50
100
150
M
nS
O
D
 / 
Ac
tin
 (%
 C
on
tro
l)
Day 20
Control SE
0
50
100
150
M
nS
O
D
 / 
Ac
tin
 (%
 C
on
tro
l)
Week 13
*
B 
MnSOD 
GPx1 
β-Actin 
     Control       SE     SE + LC 
MnSOD 
GPx1 
β-Actin 
      Control        SE     SE + LC 
MnSOD 
GPx1 
β-Actin 
      Control       SE 
MnSOD 
GPx1 
β-Actin 
      Control        SE     SE + LC 
MnSOD 
GPx1 
β-Actin 
      Control       SE 
MnSOD 
GPx1 
β-Actin 
     Control       SE     SE + LC 
MnSOD 
	   83	  
3.3.2.4 Mitochondrial OXPHOS and TOM20 expression 	  
It was further examined whether the increased oxidative stress in the SE offspring 
affects the expression of mitochondrial OXPHOS complexes. Offspring kidneys from 
SE mothers and control were compared regarding the content in subunits of the 
mitochondrial respiratory chain using Western blot. At postnatal day 1 there was a 
significant reduction in subunits of complex I, II, III and V in the SE offspring 
compared to control (Figure 3.5). At day 1 the most marked differences were 
observed in complex V (P<0.01 vs. control). However, at weaning age (day 20) there 
was no statistically significant difference in any of the mitochondrial enzyme 
subunits. At a mature age (week 13) a significant protein reduction in all of the 
examined OXPHOS subunits was again observed. The most pronounced reduction at 
week 13 was demonstrated in complex II, IV and V (P<0.01 vs. control). In addition 
the protein expression of TOM20, a mitochondrial outer membrane receptor for 
translocation of cytosolically synthesised mitochondrial pre-proteins was examined. 
Similar to the OXPHOS subunits, TOM20 was significantly reduced in offspring 
from SE mothers at day 1 and week 13 (P<0.01 and P<0.001 respectively, Figure 
3.6). Similar to the OXPHOS protein expression, there was no change in TOM20 
protein levels at day 20.  
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Figure 3.5   Renal  OXPHOS subunits 
Western blot analysis of components of the OXPHOS complexes I – V in 
mitochondrial protein fractions from offspring kidneys of control and SE mothers at 
postnatal day 1, day 20 and week 13. Results are expressed as mean ± SEM, n=6-8. 
*P < 0.05, **P < 0.01 vs. control.  
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Figure 3.6  	  Renal TOM20 expression 
Western blot analysis of mitochondrial outer membrane protein TOM20 from 
offspring kidney tissues at day 1, day 20 and week 13. Data are expressed as mean ± 
SEM, n=3-5. **P < 0.01 vs. control.  
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3.3.2.5 Mitochondrial DNA copy number 	  
It has been suggested, that abnormal amounts of mitochondrial DNA, either depletion 
or elevation, are associated with mitochondrial dysfunction. Thus, the mitochondrial 
DNA copy number in SE offspring was determined. Offspring DNA from SE mothers 
had increased DNA levels of mitochondrial-encoded Cox1/ nuclear-encoded 
cyclophillin at postnatal day 1, day 20 and week 13 (P < 0.05 vs. control, Figure 3.7)  
 
 
 
 
 
Figure 3.7   Mitochondrial DNA copy number  
Mitochondrial DNA quantity calculated as ratio of  mitochondrial-encoded COX1 to 
nuclear-encoded cyclophilin A DNA determined by real-time PCR in offspring 
kidneys from control and smoke-exposed mothers at postnatal day 1, day 20 and week 
13. Results are expressed as fold increase ± SEM, n=4; *P<0.05 vs. Control using 
non parametric Mann-Whitney U test. 
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3.3.2.6 Mitochondrial structural changes 	  
The structure of renal mitochondria was examined using electron microscopy. 
Offspring kidneys from control mice had normal mitochondrial morphology as 
demonstrated by long filamentous mitochondria. In contrast, offspring from SE 
mothers exhibited mitochondrial enlargement and swelling at day 1 and week 13. 
Additionally, an increased number of small punctate mitochondria at day 1 and week 
13 was evident suggesting increased mitochondrial fragmentation.  However, this 
effect was not observed in the SE offspring at day 20 (Figure 3.8).  
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Figure 3.8 Electron microscopy of mitochondria in offspring renal proximal 
tubular cells from control and SE mothers at day 1, day 20 and week 13. 
White arrows show enlarged (circular shaped) mitochondria and black arrows show 
increased number of small punctate mitochondria at day 1 and week 13 in offspring 
kidney from SE mothers. Insets in the far left corner: high magnification view of 
mitochondria. Scale bar =10,000 nm. 
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3.3.2.7 Mitochondrial density 	  
Using Mitotracker, a mitochondrial selective fluorescent probe, it was confirmed that 
the cellular mitochondrial density is significantly increased in offspring kidneys from 
SE mothers at day 1 and week 13 compared to control (P < 0.05 and P < ).001 vs. 
control). However, there was a reduction (P < 0.05 vs. control) in the mitochondrial 
density at day 20 (Figure 3.9). 
 
3.3.2.8 Lysosome density 	  
Mitophagy is the selective degradation of mitochondria by autophagy and often 
occurs following damage or stress. The defective mitochondria are engulfed in 
autophagosomes that fuse with lysosomes. In order to investigate whether maternal 
smoke exposure induces mitophagy in the offspring kidneys, lysosomal density was 
determined. Lysosome density significantly increased in offspring from SE mothers at 
day 1 and week 13 (P < 0.05 and P < 0.001 vs. control respectively, Figure 3.10). The 
mean cellular lysosome levels were significantly decreased in offspring from SE 
mothers at day 20 (P < 0.001 vs. control) in accordance with the divergent results for 
the offspring at weaning for above parameters including antioxidant levels, 
mitochondrial structure, density and OXPHOS expression.  
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Figure 3.9   Mitochondrial density in offspring kidneys 
(A) Mitotracker staining, (B) mean fluorescence intensity (MFI) of Mitotracker stain 
in offspring kidney at postnatal day 1, day 20 and week 13. Results are expressed as 
mean ± SEM, n = 3; *P < 0.05, ***P < 0.001 vs. control using non-parametric test of 
different source distributions (Kolmogrov–Smirnov). Scale bars represent 50 µm. 
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Figure 3.10   Lysosome density in offspring kidneys 
(A) Representative image for Lysotracker stain in offspring kidneys from control and 
SE mothers at postnatal day 1, day 20 and week 13. (B) Mean fluorescence intensity 
(MFI) for lysotracker stain. Increased lysosomal density is shown in offspring kidney 
from SE mothers at day 1and week 13. Data is expressed as mean ± _SEM, n = 3, *P 
< 0.05, ***P < 0.001 vs. control using non-parametric test of different source 
distributions (Kolmogrov–Smirnov). Scale bars represent 50  µm.  
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3.3.3 Maternal smoking induces epigenetic alterations in the offspring kidney 
3.3.3.1 Global DNA methylation 	  
To investigate the role of epigenetic changes in response to maternal smoking the 
level of global DNA methylation was analysed in the offspring kidneys of smoke 
exposed mothers and compared to non-exposed control at different time points. 
Global DNA methylation in the control group was very low at birth (day 1) and 
increased 20-fold by day 20.  At birth there was a significant increase in global DNA 
methylation in the kidneys of smoke exposed offspring from 0.060 ± 0.030 in Ctrl to 
0.181± 0.032 in SE (P<0.05 vs. Ctrl). The increase in DNA methylation was lost by 
day 20 and was neither apparent at week 13.  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure 3.11   Global DNA methylation at birth, weaning and adulthood 
Methylation of the 5th carbon of a cytosine (5mC) in CpG dinucleotides throughout 
the genome, measured by ELISA in offspring kidneys. Data are expressed as mean ± 
SEM, n=4-5, *P<0.05 vs. control (Ctrl).  
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3.3.3.2 Gene specific methylation in the promotor of PGC-1α 	  
To determine whether mitochondrial biogenesis was epigenetically regulated, DNA 
methylation at four CpG sites in the promotor of PGC-1a was analysed in offspring 
kidneys at birth (day 1) and adulthood (week 13). The methylation varied between 
67.0% ± 1.4% to  84.8% ± 2.0% at the four CpG sites.  There was no difference in 
DNA methylation between Ctrl and SE animals at any of the four analysed CpG sites.  
Interestingly, the methylation profiles at each site appeared very stable over time until 
week 13. Furthermore, the methylation at the four CpG sites was analysed in the 
mother showing a methylation profile that was not statistically different to the 
offspring (Table 3.2).   
 
Table 3.4    PGC-1α promotor methylation 
 Offspring Maternal  
 Day 1 Week 13   
 Control SE Control SE Control SE P 
Site 1 82.8 ± 1.7 % 84.7 ± 1.6 % 83.5 ± 0.5 % 84.8 ± 2.0 % 83.6 ± 1.8 % 84.7 ± 0.9 % 0.466 
Site 2 73.1 ± 2.6 % 74.8 ± 0.4 % 74.0 ± 0.9 % 73.7 ± 1.1 % 70.8 ± 1.4 % 73.8 ± 0.8 % 0.563 
Site 3 68.1 ± 0.2 % 67.3 ± 1.2 % 67.8 ± 1.6 % 67.0 ± 1.4 % 70.8 ± 0.3 % 69.5 ± 0.6 % 0.529 
Site 4 75.9 ± 0.5 % 75.5 ± 1.0 % 77.1 ± 0.9 % 79.0 ± 0.8 % 79.2 ± 0.7 % 77.9 ± 0.6 % 0.739 	  
DNA methylation at four CpG sites in the promotor region of PGC-1α in the mother 
and in the offspring of control and SE mothers at postnatal day 1 and week 13. 
Results are expressed as mean ± SEM.                    
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3.4 Discussion 	  
Previous studies in our department demonstrated that maternal smoking results in 
renal underdevelopment and metabolic changes in the offspring (2). The aim of this 
study was thus to determine whether this leads to kidney disease susceptibility and to 
investigate the underlying cellular and molecular mechanisms.  
 
The present study demonstrates that offspring from SE mothers develop albuminuria 
at adulthood. In addition, they have increased oxidative stress of mitochondrial origin, 
reduced mitochondrial antioxidant activity as well as mitochondrial structural changes 
and reduced OXPHOS proteins at birth and adulthood. The findings suggest that fetal 
programming of CKD is regulated, at least in part by maternal-cigarette smoke-
mediated production of oxidative stress and mitochondrial perturbation. Furthermore 
global methylation was increased at birth in smoke exposed offspring supporting the 
notion that epigenetic modifications may add an additional layer of complexity to the 
fetal programming of disease. 
 
The effect of smoking on development of albuminuria is well described (102, 112, 
203). However, the effect of prenatal smoke exposure on offspring kidneys is less 
studied. Increased proteinuria at adult age in smoke exposed offspring was also seen 
in rats using a similar model of smoke exposure (33). In addition, Block et al. 
demonstrated increased glomerular expression of TGF-β1 and enhanced deposition of 
fibronectin and total collagen in renal cortices of the adult smoke exposed rat 
offspring, thus providing evidence for a link of maternal smoke exposure and renal 
fibrogenesis in the next generation. Increased renal collagen content and tubular 
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injury scores along with increased expression of connective tissue growth factor 
(CTGF), a fibroblast mitogen and promoter of collagen deposition, were equally seen 
in a study on rats born to nicotine-treated dams (57). 
 
The presence of mitochondrial dysfunction in the placenta of smoking mothers has 
previously been demonstrated (36). However, mitochondrial perturbations in smoke 
exposed offspring kidneys have thus far not been described. An experimental study in 
Wistar rats demonstrated, similar to the present study, increased ROS formation and 
altered mitochondrial structure in adult offspring pancreatic tissue in response to 
maternal subcutaneous injections of nicotine during gestation and lactation (46). 
Bruin et al. found that mitochondrial structural defects were accompanied by a modest 
decline in OXPHOS complex IV activity at an adult age. In accordance with our 
results, Bruin et al. observed mitochondrial structural abnormalities as early as three 
weeks after birth (weaning age), which progressively worsened even though nicotine 
exposure was discontinued at weaning. Importantly these changes preceded decreased 
pancreatic beta cell function and glucose intolerance in adult life highlighting the role 
of fetal programming in the development of chronic adulthood diseases (46). In an 
atherosclerosis mouse model using Apolipoprotein E null mice, Fetterman et al. 
demonstrated that in-utero smoke exposure significantly accelerated adult 
atherosclerosis (80). Consistent with the present findings, the smoke-exposed 
offspring showed increased oxidative stress and a reduction in MnSOD levels at an 
adult age, which was associated with increased mitochondrial DNA copy number and 
the presence of mitochondrial DNA deletions in aorta tissue (80).  
 
The mitochondrial genome is more susceptible to ROS induced DNA damage than 
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the nuclear genome due to the lack of histone protection, reduced DNA repair 
capacity and close proximity to the ROS producing electron transport chain. 
However, it is suggested that even in the absence of detectable mitochondrial DNA 
mutations, alterations in mitochondrial DNA content, either depletion or elevation, 
may be an indicator of mitochondrial dysfunction (13). In this study an increase in 
mitochondrial DNA content in SE offspring was detected. The mechanism by which 
mitochondrial DNA increases in response to oxidative stress is not well understood. It 
is hypothesised that this is a compensatory mechanism for the decline in 
mitochondrial function by inducing the proliferation of mitochondria and/ or 
mitochondrial DNA amplification (13, 151). An increase in mitochondrial DNA 
levels have been shown in vitro in response to oxidative stress (1, 151), in placentas 
of pregnancies with intra-uterine growth restriction (IUGR) (146), in age related 
mitochondrial alterations (26, 150) and in smokers (17, 150, 175). Masayesva et al. 
detected not only an age-independent elevation of mitochondrial DNA levels in 
current smokers but also in former smokers with mean cessation intervals of two 
decades (175). The persistence of these changes is consistent with this in-utero smoke 
exposure model where elevated mitochondrial DNA content was detectable long after 
the intra-uterine smoke exposure.  
 
8-OHdG reflects the oxidative damage to DNA by ROS.  The present study 
confirmed that smoke exposure induces oxidative modification of DNA in the 
offspring from birth and this was persistent till adulthood. The localisation of  8-
OHdG staining in the cytoplasm rather than the nucleus may suggest increased 
oxidative damage to the mitochondrial DNA (190). Although 8-OHdG was expressed 
in the proximal tubule, its level of expression was more intense in distal tubules. A 
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possible explanation is the fact that ROS detoxifying enzymes are more abundant in 
proximal tubular cells than distal tubules, which may indicate a diminished ability to 
detoxify reactive metabolites in this part of the nephron and a higher intrinsic 
susceptibility of distal tubular cells to oxidative injury (145). 
 
Although there was persistence of DNA oxidation and changes in mitochondrial DNA 
copy number in smoke-exposed offspring at all time points from day 1 till week 13, 
mitochondrial structural changes and OXPHOS as well as TOM20 protein depletion 
were seen at birth and adulthood without any significant change at day 20. MnSOD 
protein content and activity mirrored the OXPHOS protein content changes with a 
significant MnSOD reduction demonstrated at day 1 and week 13 and equally no 
significant change at weaning age. It is possible that the deleterious effects on 
mitochondria observed at birth and in adulthood may be mitigated at weaning due to 
antioxidants in the breast milk (77, 275). However, further studies to investigate this 
hypothesis are needed. 
  
MnSOD is the primary mitochondrial ROS scavenging enzyme that transforms toxic 
superoxide free radicals to hydrogen peroxide, which is subsequently converted to 
water by catalases and other peroxidases. MnSOD has also recently been 
demonstrated to be part of a protein complex necessary for mitochondrial DNA repair 
(16), thus playing a pivotal role in multiple aspects of mitochondrial protection. 
Cigarette smoke has previously been shown to reduce MnSOD levels in circulating 
blood cells (172), while in-utero smoke exposure caused a reduction of MnSOD 
levels in aortic tissue in the offspring (80). This study is the first to demonstrate 
reduced MnSOD levels in offspring kidneys in response to maternal smoking. Of note 
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is the occurrence of reduced MnSOD levels in offspring long after smoke exposure at 
adulthood both in this model and in the study of Fetterman et al.(80) highlighting the 
long-term toxic effects of cigarette smoke as the basis for fetal programming. 
 
The smoke exposed group exhibited mitochondrial enlargement and a higher number 
of small punctate mitochondria suggestive of increased mitochondrial fragmentation 
at day 1 and week 13. The presence of structural mitochondrial abnormalities is in 
accordance with other studies of direct smoke exposure (104) and in-utero nicotine 
exposure (46). Damaged mitochondria are removed by mitophagy during which 
autophagosomes selectively enclose damaged mitochondria and fuse with lysosomes 
for degradation. Indeed, cellular lysosome density was increased in SE offspring at 
day 1 and week 13.  
 
Mitochondria serve a crucial role in development by providing energy for the rapid 
fetal growth and play key roles in cell signaling (69, 176). Environmental exposures 
that result in mitochondrial perturbations may have long-lasting effects resulting in 
failure of organ function over time. The kidney as a highly metabolic organ has an 
abundance of mitochondria. Recent studies implicate mitochondrial abnormalities in 
the pathogenesis of CKD and acute kidney injury (AKI). High throughput genomic 
analysis of blood samples from CKD patients revealed differential expression of 
genes encoding OXPHOS and reduced complex IV levels (96). Mitochondrial 
dysfunction has been implicated as an early event in experimentally induced podocyte 
dysfunction (274) as well as epithelial to mesenchymal transition (EMT), both 
contributing to renal fibrosis (273, 278). In AKI it is increasingly recognised that cell 
death is disproportionately low despite often severely impaired renal function (237, 
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245). Instead, the slight vacuolisation in proximal tubular cells that are frequently 
demonstrated as the only structural lesions, were electron-microscopically identified 
as swollen mitochondria (237, 245). Further support came from experimental models 
of AKI that have shown a reduction of OXPHOS protein and activity (84, 208). The 
long-lasting mitochondrial perturbations demonstrated in this study may place the 
offspring at increased risk for renal pathology especially in the setting of additional 
insults, such as sepsis or toxins. A history of maternal smoke exposure in-utero may 
thus predispose to more severe forms of AKI or irreversible damage that leads to 
progression of CKD, consistent with what was shown in our study. 
 
Cigarette smoke is considered a strong modifier of DNA methylation (39). The effect 
of prenatal smoke exposure on global DNA methylation has been investigated in 
previous studies. While some studies observed global hypomethylation in exposed 
individuals (43, 100), the findings of Terry et al., who reported DNA 
hypermethylation in response to prenatal smoke exposure, are consistent with our 
observations (241). The differential effect may be due to potential species and tissue 
variability. Most studies used DNA from human peripheral leucocytes, cord blood or 
buccal cells, as these are easy to obtain. To our knowledge, this is the first report of 
cigarette smoke-induced DNA methylation changes in offspring kidneys. The 
differential methylation in smoke exposed offspring did not last over time. At week 
20 no difference between smoke exposed offspring and control were seen. 
Nevertheless, aberrant DNA methylation profiles in the early period of life can 
potentially influence organ development and predispose to disease susceptibility at 
later stages of life. Further investigations into the gene specific methylation patterns 
are required.  To investigate a link between epigenetic modifications and 
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mitochondrial perturbations, the DNA methylation pattern of the mitochondrial 
biogenesis regulator PGC-1α was examined.  The quantification of the methylation 
levels at four different CpG sites of the PGC-1α promoter did not reveal any changes 
between smoke exposed offspring and control. In fact, the methylation profiles 
appeared very stable over time and were strongly correlated with the maternal 
methylation profile. The study focused on four CpG sites. However, differential 
methylation at other sites in the PGC-1α promoter cannot be excluded. The 
development of epigenome wide DNA methylation studies in recent years using a 
BeadChip assay that can interrogate 450,000 CpG sites has already led to the 
discovery of numerous differentially methylated loci in newborns in relation to 
maternal smoking. Pathway and functional analysis implicated many of the genes to 
be involved in embryogenesis and developmental pathways (129). Among the 
differentially methylated genes that have thus far been identified in the smoke 
exposed offspring are BMP-4, BMP-6 and TIMP2 (129), which play a role in both 
renal development (153, 255) and renal fibrosis (125, 256). The discovery of 
differential methylation of these genes may only represent the tip of the iceberg and 
more will likely emerge connecting epigenetic modifications to an unfavorable in-
utero environment and to renal pathology.  
 
The study links the effect of maternal smoking with the offspring’s future risk of 
kidney disease progression through epigenetic alterations, oxidative stress and 
mitochondrial perturbations. It provides a better understanding on how an 
environmental factor (smoking) can affect future health in the next generation. It 
emphasises the need to prompt more rigorous public health interventions that support 
smoking cessation during and prior gestation. Children born to smoking mothers may 
	   101	  
need regular screening for renal disease from early adulthood and research into a 
beneficial role of mitochondria-targeted therapies and antioxidants is needed.  
 
 
 
Figure 3.12   Proposed mechanism of in utero smoke exposure on fetal 
programming of CKD.  Cigarette toxins affect the fetus through a direct effect on the 
placenta and induce oxidative stress and mitochondrial perturbations in fetal tissue. 
The resulting low birth weight is associated with impaired nephrogenesis and reduced 
nephron numbers leading to glomerular hyperfiltration and ultimately 
glomerulosclerosis. Persistent mitochondrial perturbations in the kidney may lead to 
CKD over time, especially in the setting of additional insults. Epigenetic 
modifications such as aberrant DNA methylation provide an additional layer of 
complexity.  
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Chapter 4 	  
 
Lysyl oxidase-like 2 inhibition in a unilateral ureteral 
obstruction model   
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  Background and objectives 4.1
 
CKD is a substantial public health burden and while the identification of risk factors 
and design of preventative strategies discussed in Chapter 3 are important, the disease 
is often diagnosed at a late stage when renal fibrosis is already established. Despite 
advances in recent years in identifying cellular events and molecular signaling 
pathways in renal fibrosis, effective therapies to halt the progressive decline in renal 
function are lacking. RAAS blockade remains the mainstay of renal antifibrotic 
therapy but is at best only partially effective in delaying the progression to end-stage 
kidney disease. The identification of new treatment targets and their clinical 
translation is critically needed. 
 
In healthy tissues the extracellular matrix is a scaffold to maintain tissue integrity and 
a reservoir for mediators of cell signaling and cell growth. In renal fibrosis it becomes 
the principal underlying structure replacing normal renal parenchyma. It is a highly 
dynamic structure that is in constant flux of remodeling through matrix synthesis and 
degradation.  Dysregulation of this tightly regulated balance will lead to exaggerated 
matrix deposition and an exacerbation of disease progression. Indeed, it has been 
reported that a fibrotic ECM can perpetuate fibrogenesis by stimulating fibroblasts to 
synthesise further ECM proteins in a positive feedback loop (196). Targeting 
mediators of the dysregulated ECM remodeling process may offer a promising 
therapeutic opportunity. 
 
  
Lysyl oxidase like 2 (LOXL2) is a member of the lysyl oxidase family, a group of 
copper-dependent amine oxidases that play a crucial role in ECM modulation. Lysyl 
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oxidases catalyse the oxidative deamination of lysine residues in collagen to highly 
reactive aldehydes that form intra- and intermolecular cross-links between the 
collagen fibrils. These bonds are initially formed between telopeptide residues or 
between a telopeptide residue and a helical residue to produce immature (divalent) 
cross-links such as dihydroxylysinonorleucine (DHLNL). When these immature 
cross-links react with additional amino acid residues mature or trivalent cross-links 
including pyridinoline (PYD) develop in a non-enzymatic fashion (267).    
 
The cross-linked collagen renders the ECM resistant against proteolytic enzymes and 
the resulting tissue stiffness is a prerequisite for the activation of myofibroblasts. In 
addition, LOXL2 promotes EMT by stabilising Snail, a key EMT transcription factor 
(199). LOXL2 is a downstream-target of HIF-1α and is induced by TGFβ, both of 
which play key roles in the pathogenesis of tissue fibrosis (110, 221). Indeed, an 
increase of LOXL2 expression has been extensively investigated in fibrotic diseases 
of lung (27, 58) and liver (27, 246). However, their role in renal fibrosis is limited to a 
few studies.  LOX and/or LOXL2 were found to be elevated in rodent renal fibrosis 
models such as in adriamycin nephropathy (66), in the hereditary nephrotic mouse 
(95) and in unilateral ureteral obstruction (UUO) models (110). In addition, LOXL2 
mRNA was upregulated in one small renal biopsy study of patients with renal fibrosis 
from diabetic nephropathy, IgA nephropathy and hypertensive nephrosclerosis (110). 
It thus appears to have multifaceted roles in ECM remodeling making it a potentially 
suitable target of antifibrotic therapy.  
 
The aim of the study was to explore the role of LOXL2 in renal fibrosis using a UUO 
model and to examine the therapeutic potential of a novel LOXL2 inhibitor as a 
renoprotective small molecule.   
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 Material and methods 4.2	  
4.2.1 UUO model 	  
C57BL/6 mice underwent UUO surgery or a sham procedure at 6-8 weeks of age as 
described in Chapter 2. All animals were housed in a stable environment maintained 
at 20±2°C with a 12 hour light/dark cycle and free access to water and standard chow 
diet. PXS-S2B, a small molecule LOXL2 inhibitor (56) (courtesy of Pharmaxis Ltd, 
Frenchs Forest, NSW, Australia) was dissolved in sterile water and given as daily 
intraperitoneal dose of 10mg/kg. Telmisartan (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) was given at a dose of 3mg/kg in drinking water as comparative limb of 
current best practice. Animals were divided into the following groups: 1. Sham 
operated, 2. UUO (n=6), 3. UUO+LOXL2i (n=7), 4. UUO+telmisartan (n=5), 5. 
UUO+LOXL2i +telmisartan (n=7). Mice were culled after 7 days of treatment under 
anaesthesia with 2% isoflurane and kidneys were harvested after perfusion with ice-
cold PBS.  
 
4.2.2 LOXL2 inhibitor compound characteristics 	  
PXS-S2B is a haloallylamine-derived, mechanism-based amine oxidase inhibitor. It 
distributes well into tissues and forms PXS-S2A, which has high selectivity for 
LOXL2 over LOX.  It is characterised by high plasma stability and low plasma 
protein binding. The compound characteristics have been described in detail 
previously (56). 	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4.2.3 Histology 	  
Paraffin embedded kidneys sections (2 micron) were stained with Masson’s 
Trichrome.  Assessment of tubulointerstitial fibrosis was done by two independent 
examiners. Ten non-overlapping fields were captured under an Olympus photo light 
microscope linked to a Leica DFC 480 digital camera. A semiquantitative 
tubulointerstitial fibrosis index (TFI) score of cortical areas was graded on a scale of 
zero to four (0_normal; 1_involvement of <25% of the field of view, 2_ involvement 
of 25-50%, 3_involvement of 50-75% and 4_>75%). The features of tubulointerstitial 
fibrosis included tubular atrophy or dilatation, widening of interstitial spaces with 
deposition of extracellular matrix and interstitial cell proliferation. The whole kidney 
average TFI score was obtained by averaging scores from all counted sections (279).  
Paraffin sections of liver, lung and heart from control and control animals treated for 
24 weeks with the LOXL2 inhibitor were stained with haematoxylin and eosin (HE) 
and evaluated for structural damage by an independent pathologist.  
 
4.2.4 Quantitative real-time PCR of LOXL2, fibrosis, EMT and inflammatory 
markers 	  
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, CA, USA) according 
to the manufacturer’s instruction. cDNA was synthesised using the Transcriptor First 
Strand cDNA synthesis kit (Roche Diagnostics, Mannheim, Germany). The 
predesigned primers (Sigma-Aldrich, NSW Australia) are listed in table 1. 
Quantitative real-time PCR was performed with SensiMix SYBR hiROX (Bioline, 
Eveleigh, NSW) on the AB7900 machine (Applied Biosystems, Australia) as outlined 
in chapter 2. Gene expression is presented as fold-change compared with control after 
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normalisation to the housekeeping gene actin. The primer sequence of LOX and 
LOXL2 was checked against the entire gene sequences of both LOX and LOXL2 
using the program Nucleotide-BLAST (National Center for Biotechnology 
Information, USA) to ensure specificity of the primers to the different LOX isoforms. 
 
Table 4.1 Mouse-specific primer sequences 
Target Forward (5’-3’) Reverse (5’-3’) 
LOXL2 ATTAACCCCAACTATGAAGTG CTGTCTCCTCACTGAAGGCTC 
LOX TCTTCTGCTGCGTGACAACC GAGAAACCAGCTTGGAACCAG 
Fibronectin ACAGAAATGACCATTGAAGG TGTCTGGAGAAAGGTTGATT 
COL1A1 CATGTTCAGCTTTGTGGACCT GCAGCTGACTTCAGGGATGT 
Collagen IV TTAAAGGACTCCAGGGACCAC CCCACTGAGCCCTGTCACAC 
aSMA ATAGGTGGTTTCGTGGATGC ACTCTCTTCCAGCCATCTTTCA 
E-Cadherin CAAAGTGACGCTGAAGTCCA TACACGCTGGGAAACATGAG 
Snail CCACTGCAACCGTGCTTTT TCTTCACATCCGAGTGGGTTT 
MCP-1 CATCCACGTGTTGGCTCA GATCATCTTGCTGGTGAATGAG 
β-Actin CTAAGGCCAACCGTGAAAAG ACCAGAGGCATACAGGGACA 	  	  	  
4.2.5 Immunohistochemistry 
Paraffin-embedded kidney sections (4 micron) were dewaxed in xylene and 
rehydrated in graded concentrations of ethanol before heat epitope retrieval in 10 mM 
citrate buffer, pH6. Endogenous peroxidase activity was blocked by incubation in 
0.3% hydrogen peroxide. After a 10min pre-incubation with 10% protein block 
(Dako, CA) the sections were incubated overnight at 4°C with primary antibodies 
against fibronectin (dilution 1:1000, ab45688, Abcam, Cambridge, UK), collagen I 
(dilution 1:500, ab34710, Abcam), collagen IV (dilution 1:500, ab6586, Abcam). 
Immunohistochemistry for F4/80 staining was done on 6 micron frozen sections that 
were fixed in acetone after removal from the freezer. Following three wash steps in 
phosphate buffered saline (PBS) they were incubated for 1 hour with rat anti-mouse 
monoclonal F4/80 antibody (dilution 1:1000, MCA497R, ABD Serotec, USA). The 
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sections were developed with 3,3’-diaminobenzidine chromogen (Dako, CA, USA) 
after incubation with the respective horseradish-peroxidase (HRP) tagged secondary 
antibodies (Dako) and then counterstained with haematoxilin. The quantification was 
performed by capturing 10-12 non-overlapping fields of renal cortex from stained 
sections at 200x magnification with a Leica microscope linked to a DFC 480 digital 
camera (Leica, Wetzlar, Germany). The percentage of stained area relative to the 
whole area in each field was assessed with image J software (Java-based software 
program, National Institutes of Health). 
 
 
4.2.6 Cross-linking assay 	  
Lyophilised kidney tissue was homogenised in PBS buffer and reduced with sodium 
borohydride. Samples were treated with acetic acid to stop the reaction, washed twice 
with distilled water and hydrolysed under vacuum with 6M hydrochloric acid (HCl) 
for 24 hours at 105°C. The hydrolysate from each sample was resuspended in 200 µL 
distilled water. Collagen crosslinks were extracted from the hydrolysate using an 
automated solid phase extraction system (GX-271 ASPEC system, Gilson, Middleton, 
WI, USA) set up with GracePure solid phase extraction (SPE) C18-Aq columns and 
GracePure SPE Cation-X columns (Grace Discovery Sciences, Epping, VIC, 
Australia) as outlined in detail in Chapter 2.6.4. Briefly, the hydrolysate was applied 
to the C18-Aq columns, eluted with with 10mM ammonium formate, 0.1% formic 
acid and 0.1% heptafluorobutyric acid (HFBA) in 40% methanol solution, and then 
applied to the Cation-X colums. The cross-links were eluted from these columns with 
25% ammonia in H2O and dried to a pellet at 60°C. 5% HFBA in H2O solution was 
added to each sample and again evaporated to a dry pellet at 60 °C. The final HFBA 
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salts of extracted crosslinks were dissolved in 50 µL of mobile phase A (10 mM 
ammonium formate, 0.1% formic acid, 0.1% HFBA in H2O). 
 
Cross-link quantitation was done by ultra-high performance liquid chromatography-
electrospray ionisation tandem mass spectrometry (UHPLC-ESI-MS/MS) in a 
Thermo Dionex UHPLC and TSQ Endura triple quad mass spectrometer 
(ThermoFisher Scientific, North Ryde, NSW, Australia) with commercially available 
standards for dihydroxylysionorleucine (DHLNL, Thermo Fisher Scientific, North 
Ryde, NSW, Australia), pyridinoline (PYD, Quidel Corporation, San Diego, CA, 
USA) and hydroxyproline (Sigma-Aldrich, St Louis, MO, USA) as outlined in detail 
in Chapter 2.6.4.2. Collagen crosslinks and hydroxyproline were normalised to the 
total protein content in the hydrolysates, which was quantified using the QuickZyme 
total protein assay kit (QuickZyme Biosciences, Leiden, The Netherlands). 	  	  
4.2.7 Statistical analysis 	  
Statistical analysis was performed as outlined in Chapter 2 using ANOVA with 
Bonferroni correction in Prism software V 6.0 (GraphPad, La Jolla, CA,USA) For 
non-normally distributed data Mann-Whitney U test was used as indicated in the 
figure legends. Data are expressed as mean ± SEM with P-values less than 0.05 
considered to represent statistical significance. 	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 Results 4.3	  
4.3.1 Expression of lysyl oxidases in the UUO kidney 	  
Both LOX and LOXL2 mRNA was significantly increased in UUO kidneys (P<0.01 
vs. sham), which was not altered by treatment with the LOXL2 inhibitor, telmisartan 
or the combination of both (Figure 4.1).  
      
 	    
  
                                   
Figure 4.1   LOX and LOXL2 mRNA expression in UUO kidneys 
Mice underwent UUO or a sham procedure and received either no treatment (UUO) 
or 7-day treatment with 10mg/kg i.p. PXS-S2B (UUO+LOXL2i), 3mg/kg oral 
telmisartan (UUO+Telmi) or both (UUO+LOXL2i+Telmi). LOX and LOXL2 mRNA 
is upregulated after UUO surgery. Results are represented as mean ± SEM, n=5-7. 
**P<0.01 vs. sham 
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4.3.2 Tubulointerstitial fibrosis scoring in the UUO kidney after treatment with 
the LOXL2 inhibitor 	  
To investigate the effect of LOXL2 inhibition on renal fibrosis, Masson trichrome 
stained kidney section were visually scored for tubulointerstitial fibrosis changes. 
Sham operated animals demonstrated back to back tubules and tubular epithelial cells 
were cuboidal in shape. The obstructed kidneys showed atrophic tubules, tubular 
dilatation and a widened tubulointerstitial space. All UUO groups demonstrated a 
cellular infiltrate and an increase in acellular ECM matrix (Figure 4.2). The 
tubulointerstitial fibrosis index, which was significantly increased in all UUO groups 
(P<0.01 vs. sham), was not reduced in any of the treatment groups.  
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Figure 4.2   Structural changes in UUO kidneys 
Representative images of interstitial fibrotic changes in sham (A), UUO (B), 
UUO+LOXL2i (C), UUO+Telmi (D), UUO+LOXL2i+Telmi (E). Tubulointerstital 
fibrosis scores (F) (n=5-7 per group)**P<0.01 vs. sham, scale bar = 100µm 	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4.3.3 Expression of fibrotic markers in the UUO kidney after LOXL2 
inhibition 	  
To determine the effect of treatment with the LOXL2 inhibitor on ECM deposition, 
the expression of fibronectin, collagen I and collagen IV was determined in the UUO 
model. Fibronectin is one of the first ECM proteins deposited in renal fibrosis. 
Consequently there was a significant increase in fibronectin mRNA in UUO kidneys 
(P<0.05 vs. sham). Neither the treatment with the LOXL2 inhibitor, telmisartan nor 
the combination of both reduced the expression of fibronectin (Figure 4.3). Collagen 
IV expression, which in healthy kidneys is restricted to the glomerular and tubular 
basement membranes, is also found in the interstitium of fibrosed kidneys.  The UUO 
kidneys demonstrated a significant increase in collagen IV mRNA and protein 
expression (P<0.01 vs. sham and P<0.05 vs. sham respectively). However, there was 
no reduction in collagen IV expression in any of the treatment groups (Figure 4.4). 
Collagen I is known to be highly expressed in the widened interstitial space where 
tubular cell death has occurred. It was significantly upregulated at both the mRNA 
and protein level in all UUO kidneys (P<0.01 vs. sham and P<0.05 vs. sham 
respectively). Treatment with the LOXL2 inhibitor or telmisartan did not reduce 
collagen I mRNA. However, there was a significant reduction in the combined 
treatment group (P<0.05 vs. UUO). Immunostaining of collagen I revealed a trend for 
reduction in UUO kidneys treated with the LOXL2 inhibitor (P=0.073 vs. UUO) and 
in the combined treatment group, although none of them reached statistical 
significance (Figure 4.5).  
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Figure 4.3   Fibronectin expression in the UUO model 
Representative photographs for fibronectin immunostaining in Sham (A), UUO (B), 
UUO+LOXL2i (C), UUO+Telmi (D) and UUO+LOXL2+Telmi (E). Fibronectin 
mRNA (F) and quantification of immunostaining (G). Scale bar = 50µm, Mann 
Whitney test was used for mRNA analysis. *P<0.05 vs. sham, n=5-7. 
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Figure 4.4   Collagen IV in the UUO model 
Representative photographs for collagen IV immunostaining in Sham (A), UUO (B), 
UUO+LOXL2i (C), UUO+Telmi (D) and UUO+LOXL2+Telmi (E). Collagen IV 
mRNA (F) and quantification of immunostaining (G). Scale bar = 50µm, Mann 
Whitney test was used for mRNA analysis. *P<0.05 vs. sham, **P<0.01 vs. sham. 
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Figure 4.5   Collagen I expression in the UUO model 
Representative photographs for collagen I  immunostaining in Sham (A), UUO (B), 
UUO+LOXL2i (C), UUO+Telmi (D) and UUO+LOXL2+Telmi (E). Collagen I 
mRNA (F) and quantification of immunostaining (G). Scale bar = 50µm, Mann 
Whitney test was used for mRNA analysis. *P<0.05 vs. sham, **P<0.01 vs. sham. 
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4.3.4 Expression of EMT markers in the UUO kidney after LOXL2 inhibition 	  
LOXL2 regulates EMT through a conformational change of the EMT transcription 
factor Snail protecting it from subsequent GSK-3β mediated degradation (199). As 
LOXL2 expression is upregulated in the UUO kidney, the mRNA expression of Snail 
and Snail’s downstream target E-Cadherin as well as the mesenchymal marker αSMA 
were determined.  There was evidence for EMT in the UUO group given the 
significant upregulation of Snail (P<0.05 vs. sham) and repression of E-Cadherin 
(P<0.01 vs. sham). However, there was no change in the treatment groups 
(UUO+LOXL2i, UUO+Telmi, UUO+LOXL2i+Telmi) compared to UUO alone 
(Figure 4.6).  There was a trend towards upregulation of αSMA in the UUO kidneys. 
Although treatment with the LOXL2 inhibitor or telmisartan did not alter this trend, 
the combination of both treatments significantly reduced αSMA mRNA expression 
(P<0.01 vs. UUO, Figure 4.7).  
	  
Figure 4.6   Regulation of EMT in the UUO kidneys  
Upregulation of Snail mRNA (A) and repression of downstream target E-cadherin 
mRNA (B) in all UUO kidneys, which was not affected by any treatment. Data are 
expressed as mean ± SEM, n=5-7, *P<0.05, **P<0.01 vs. sham. 	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Figure 4.7   Mesenchymal and myofibroblast marker αSMA in the UUO kidney 
αSMA mRNA after 7 days of treatment with the LOXL2 inhibitor, telmisartan or both. 
Results are expressed as mean ± SEM, n=5-7, P<0.01 vs. UUO using Mann-Whitney 
test.  
 
4.3.5 Expression of inflammatory markers in the UUO kidney after LOXL2 
inhibition 	  
Among the cellular interactions in response to unilateral ureteral obstruction is a 
mononuclear infiltrate consisting predominantly of macrophages and lymphocytes, 
which in turn release chemokines and cytokines. MCP-1, a monocyte/macrophage 
chemoattractant, plays a key role in perpetuating the tubulointerstitial damage (251). 
To determine whether LOXL2 inhibition has an anti-inflammatory effect after UUO, 
the expression of MCP-1 mRNA and the macrophage marker F4/80 was determined. 
LOXL2 inhibition did not alter the expression of the upregulated macrophage cell 
surface marker F4/80 (P<0.01 vs. sham) nor was the renal expression of MCP-1 
suppressed (Figure 4.8).       	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Figure 4.8   Inflammatory and macrophage marker  
MCP-1 mRNA expression (A) and F4/80 immunostaining (B) after LOXL2 or 
telmisartan treatment in the UUO kidney, n=4-5, mean ± SEM, *P<0.05 vs. sham, 
**P<0.01 vs. sham. 
 
 
4.3.6 Collagen cross-linking in the UUO kidney after treatment with the 
LOXL2 inhibitor  	  
The UUO model is a potent fibrotic model that induces large amounts of collagen 
deposition and is therefore well suited to study collagen cross-linking. 
Hydroxyproline levels were upregulated in all UUO groups compared to sham 
operated animals reflecting the increased total collagen content in the obstructed 
kidney. Once lysyl oxidases catalyse the formation of aldehydes from lysine residues, 
these spontaneously form bonds with other aldehydes or unmodified lysine residues 
resulting in immature, divalent cross-links. Immature cross-links as measured by the 
ratio of dihydroxylysinonorleucine (DHLNL) to hydroxyproline (HYP) content were 
significantly elevated in all UUO groups (Figure 4.9 C). Surprisingly, treatment with 
the LOXL2 inhibitor did not alter this upregulation (Figure 4.9 A). The immature 
divalent cross-links can further mature by forming non-enzymatically bonds with 
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additional amino acid residues.	   Although absolute levels of mature pyridinoline 
(PYD) cross-links were elevated 1.5-fold in the UUO group, the ratio of PYD to 
hydroxyproline and the ratio of PYD to DHLNL was significantly downregulated in 
all UUO treated mice, suggesting that the newly deposited collagen matrix had 
predominantly immature rather than mature cross-links (Figure 4.9 B and D). Neither 
of the treatments affected the mature cross-link density or the ratio of mature to 
immature cross-links (maturity ratio, Figure 4.9 D).	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Figure 4.9   Collagen cross-links in UUO model 
(A) Averaged dihydroxylysinonorleucine (DHLNL) content as marker for immature 
cross-links and pyridinoline (PYD) content as marker for mature cross-links (B) 
normalised to hydroxyproline (HYP). (C) Hydroxyproline content per dry weight of 
kidney tissue. (D) ratio of mature (PYD) to immature (DHLNL) cross-links. Data are 
mean ± SEM, *p<0.05, **p<0.01 vs. sham, n=5-7.  
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  Discussion 4.4
 
Renal fibrosis is characterised by an excessive accumulation of ECM replacing 
normal renal parenchyma. Enzymes such as lysyl oxidases that post-translationally 
modify the ECM by promotion of collagen cross-links are of particular interest as 
potential antifibrotic treatment targets. LOXL2, in particular has gained attention as it 
has additional effects on ECM modification through regulation of EMT and activation 
of myofibroblasts.   
 
This study demonstrated significantly upregulated LOX and LOXL2 levels in UUO 
kidneys that were characterised by tubulointerstitial fibrosis as well as increased 
fibronectin and collagen deposition. In addition, the UUO kidneys had 
downregulation of epithelial cell adhesion protein E-Cadherin consistent with EMT 
and increased expression of macrophage surface proteins in keeping with a 
macrophage infiltrate. For the first time it was also demonstrated that unilateral 
ureteral obstruction induces the upregulation of collagen cross-links.  
 
The upregulation of LOX and LOXL2 in the UUO model is consistent with other 
rodent experimental models of renal fibrosis (66, 95, 110). In addition, a small human 
biopsy study found LOXL2 levels upregulated in renal fibrosis of various aetiologies 
(110). Targeting LOXL2 with a monoclonal antibody in a previous study of liver and 
lung fibrosis significantly reduced matrix deposition and fibrosis scores (27). On the 
other hand, the authors demonstrated a more constitutive LOX expression in healthy 
tissues and a lack of effectiveness targeting LOX with a specific but non-functional 
antibody, which led to the conclusion that LOXL2 may be the superior therapeutic 
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target. LOXL2 inhibition has to date not been studied in the kidney. We thus aimed to 
test the hypothesis that collagen cross-links would be reduced and renal fibrosis 
scores diminished with LOXL2 inhibitor treatment. 
 
Surprisingly, using PXS-S2B, a small molecule mechanism-based compound, that has 
better activity and selectivity than the pan-lysyl oxidase inhibitor BAPN when tested 
against recombinant LOXL2 (56), did not ameliorate tubulointerstitial fibrosis in the 
UUO model. While our findings clearly confirmed that unilateral ureteral ligation 
induced LOXL2 and a fibrotic response in the obstructed kidneys, 7 day treatment 
with either the LOXL2 inhibitor or telmisartan did not effectively reduce ECM matrix 
proteins, EMT markers, collagen cross-links or overall tubulointerstitial fibrosis 
scores. However, the combined blockade of the angiotensin receptor blocker and 
LOXL2 inhibitor resulted in a significant reduction of collagen I protein and αSMA 
mRNA. 
 
There are several possibilities that could explain the lack of antifibrotic response after 
administration of the LOXL2 inhibitor in this study. Firstly, the UUO model is an 
aggressive fibrosis model with a rapid sequence of events leading to tubulointerstitial 
fibrosis within only 7 days. The mechanisms underlying this brisk fibrogenic response 
include increased capillary permeability, an inflammatory infiltrate, upregulation of 
TGF-β and other pro-fibrotic mediators. It leads to an increase in the myofibroblast 
pool resulting in an exaggerated ECM synthesis and loss of normal tubular 
parenchyma. Progressive interstitial capillary rarefaction augments hypoxia, which 
has been shown to be an inducer of LOXL2 synthesis. Correspondingly to the LOXL2 
increase, we demonstrated an increase in predominantly immature collagen cross-
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links in the UUO kidneys. However, in view of the rapid and overwhelming fibrotic 
response in the UUO model, the treatment time for the compound to exert a protective 
effect may have been simply too short.  
 
Secondly, renal fibrosis is the consequence of an orchestrated system of fibrogenic 
pathways that is known to have many redundancies. The rapid pace with which 
fibrosis appears in the UUO model suggests that many fibrogenic signaling pathways 
are upregulated simultaneously. Potential redundancies in this system may thus 
prevent an effective response to the treatment of only one target. With respect to the 
lysyl oxidase family there is to date little reported redundancy in biological function 
despite strong sequence homology of the highly conserved catalytic domain of all 
LOX family members. The LOXL2 inhibitor compound used in this study has greater 
affinity to LOXL2 with lesser affinity for LOX.  As we demonstrated a significant 
upregulation of LOX in addition to LOXL2, this may explain the increase in collagen 
cross-links and may contribute to the accelerated renal fibrosis despite LOXL2 
inhibition. Selective in vitro LOXL2 silencing studies could further shed light on the 
effectiveness in targeting LOXL2 alone. Chapter 6 is therefore dedicated to the in 
vitro silencing of LOXL2. Since our experiments were conducted a LOXL2 mouse 
knockout model has been developed. Although this is useful to assess the phenotype 
in health and models of organ fibrosis, the applicability to human disease remains 
limited, as inhibitors will invariably not completely ablate a signaling pathway. 
 
An additional possibility is that the dose of the LOXL2 inhibitor may not have been 
adequate. The dose was based on previous pharmacokinetic dosing studies showing 
high tissue levels of the compound in the kidney at both 1 and 4 hours post dosing. 
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The compound has no known first pass effect in the liver and low protein binding, so 
an adequate proportion of non-protein-bound drug should be able to penetrate and 
equilibrate with the extravascular space. However, an increase of renal vascular 
resistance after UUO surgery has been reported previously, resulting in a significant 
reduction in renal blood flow (138). A reduction in renal blood flow may have 
influenced the delivery rate of this compound to the renal microvasculature and thus 
to the tubulointerstitium. 
 
Finally, it is unclear whether the compound’s activity varies in the different kidney 
compartments. The kidney is a highly compartmentalised organ divided into 
glomeruli and the tubules with several differentiated segments. Transport of drugs to 
these different localisations varies depending on the degree of passive diffusion, 
transport proteins and carrier-mediated membrane processes along the different 
segments of the tubules.  It is conceivable that the compound has greater effect on the 
glomerular compartment but this was not explicitly tested as UUO-mediated renal 
fibrosis is only elicited in the tubulointerstitial compartment with sparing of the 
glomeruli.  
 
Notably, telmisartan did not have a renoprotective effect in our UUO model, that 
could be due to similar reasons as discussed above. A previous study demonstrated 
reduction in tubulointerstitial injury scores with telmisartan. In contrast to our study, 
treatment duration was longer with mice undergoing pretreatment for 8 days prior to 
UUO surgery and continuation of treatment for 14 days (142). However, we were able 
to demonstrate that the combination treatment with the LOXL2 inhibitor and RAAS 
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blockade may have a potentiating effect in suppressing ECM after 7 days post 
unilateral ureteral obstruction. 
 
In order to investigate mechanistically whether the lack of renoprotection after 
treatment with the LOXL2 inhibitor was related to the compound itself or due to the 
aggressive nature of the UUO model, in vitro studies in kidney cells were conducted 
(Chapter 5). Further, treatment in a different model where a chronic insult takes place 
over several weeks may not only be better suited to determine subtle renoprotective 
effects of the compound but may also more accurately mirror the underlying 
pathogenesis of most human chronic kidney diseases. The effect of LOXL2 inhibition 
was therefore investigated over a 24-week period in a diabetic mouse model, which is 
characterised by both glomerulosclerosis and tubulointerstitial injury (Chapter 6). In 
contrast to the UUO model, treatment with the LOXL2 inhibitor reduced markers of 
matrix deposition and ameliorated proteinuria and glomerulosclerosis in the diabetic 
model, which may indicate the need for a longer treatment duration and a selective 
renoprotective effect on the glomeruli. 
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Chapter 5  
 
Regulation of LOXL2 by hypoxia, pharmacological and 
genetic inhibition of LOXL2 in human proximal tubule cells   
	   128	  
5.1 Background and objectives 	  
LOXL2 is upregulated in fibrotic conditions of various tissues including heart, lung, 
liver and kidney (27, 110, 269) Higgins et al. determined in a small biopsy study of 
patients with renal fibrosis from diabetic nephropathy, IgA nephropathy and 
hypertensive nephrosclerosis a significant elevation of LOXL2 mRNA (110).  Further 
evidence for a direct link of LOXL2 in fibrogenesis comes from in vitro studies. 
Stimulation of fibroblasts with recombinant LOXL2 resulted in a significant increase 
in fibronectin expression as well as de-novo expression of αSMA, in keeping with 
their activation to a matrix producing myofibroblast phenotype (24). LOXL2 
stabilises ECM proteins via enzymatic cross-linking of collagen fibrils, thereby 
augmenting matrix stiffness. It has been demonstrated that increased matrix stiffness 
results in fibroblast proliferation and myofibroblast differentiation as well as 
enhanced synthesis and suppression of matrix-degrading proteases (162). In addition 
to its extracellular role on ECM modification, recent reports indicate an intracellular 
role for LOXL2 by promoting EMT. LOXL2 was shown to downregulate E-Cadherin 
in tumour cell lines through interaction with the key EMT transcription factor Snail 
(199, 219). Snail has been linked to renal fibrosis when overexpressed (37). Two 
lysine residues in Snail were shown to be substrates of LOXL2 (199). It is 
hypothesised that LOXL2 oxidises these lysine residues resulting in a conformational 
change that protects Snail from GSK3β phosphorylation and subsequent degradation 
(199). 
 
LOXL2 has been closely linked to hypoxia and is known to be a direct transcriptional 
target of HIF-1 (110, 219). Schietke et al. demonstrated in a renal cell cancer cell line 
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that the HIF-1α - (and to a lesser degree HIF-2α-) mediated induction of LOXL2 is 
required for the hypoxic repression of E-Cadherin, presumably via the above-
mentioned Snail stabilisation. Hypoxia has been recognised as one of the driving 
forces in fibrogenesis and is frequently encountered in renal fibrosis due to 
tubulointerstitial and glomerular capillary rarefaction (73). Higgins et al. 
demonstrated in a UUO model that genetic ablation of epithelial HIF-1α resulted in 
significant reduction of collagen accumulation. Pharmacological blockade with 
BAPN, an inhibitor of all lysyl oxidases phenocopied the effects of genetic 
inactivation of HIF-1α on ECM deposition underscoring the importance of lysyl 
oxidases in hypoxia and HIF-1α-mediated fibrosis (110).  Collectively these findings 
suggest lysyl oxidases to be suitable treatment targets in renal fibrosis. However, the 
study of Higgins et al. stands in contrast with our observations in the UUO model 
when LOXL2 is specifically pharmacologically targeted.  In order to investigate 
mechanistically whether the lack of renoprotection after treatment with the selective 
LOXL2 inhibitor in the UUO model was related to the experimental design, the 
compound itself or system redundancies, in vitro studies were proposed. We aimed to 
investigate the regulation of LOXL2 in a human proximal tubule cell line and to 
inhibit LOXL2 using both genetic knockdown and pharmacological blockade with the 
biochemically active form of the selective LOXL2 inhibitor used in the UUO model. 
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5.2 Material and Methods 	  
5.2.1 Human kidney 2 cell line (HK-2) 	  
HK-2 cells (ATCC, VA, USA), a cell line derived from human adult kidney proximal 
tubule epithelium were grown in keratinocyte serum-free medium (Life technologies, 
CA, USA) supplemented with 50µg/ml bovine pituitary extract and 5ng/ml 
recombinant epidermal growth factor (Life technologies, Carlsbad, USA). Cells were 
subcultured at 50-80% confluence. The growth medium was discarded and enough 
pre-warmed TrypLE Express solution (Life technologies, Carlsbad, USA) added to 
cover the cell layer. When more than 90% of cells had detached, the trypsinisation 
was stopped by adding an equal volume of pre-warmed growth medium to the culture 
dish.  The cell suspension was centrifuged at 1000rpm for 3 minutes and the pellet 
resuspended in keratinocyte serum-free medium and plated onto 6-well plates 
(Sarsted, Germany).  
 
5.2.2 MTS assay (non radioactive cell proliferation assay) 	  
The HK-2 cells proliferation rate was determined using the MTS assay. Cells were 
grown in 96-well dishes until reaching approximately 80% confluence, at which time 
growth medium containing the selective LOXL2 inhibitor in increasing 
concentrations between 0.3nM and 1000nM was applied to the cells. The cells 
remained in these defined conditions for 48hrs and 72 hours in both normoxia and 
hypoxia before the MTS assay was performed using the CellTiter96®Aqueous One 
Solution Cell Proliferation Assay (Promega, USA) as described in Chapter 2.  
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5.2.3 Stimulation of HK-2 cells with transforming growth factor-β1 (TGF-β1) 
in normoxic and hypoxic conditions 	  	  
Cells were grown to 80% confluence in 6-well plates (Sarstedt, Germany) and 
exposed to 1ng/ml TGF-β1 (R&D Systems, Noble Park, VIC, Australia) while cells 
from the same passage remaining in keratinocyte medium served as control. Cells 
were cultured under ‘normoxic conditions’ (21% O2, 5% CO2, 95% humidity) at 
37°C prior to culture under hypoxic conditions for 48hrs. Hypoxic conditions were 
created using a CoyLabs hypoxia chamber (Edwards Instruments, Australia: 37°C, 
1% O2, 5% CO2, 94% Nitrogen, 95% humidity). Cells from the same passage, 
concurrently incubated under normoxic conditions, served as a control. Cells were 
collected in the same manner irrespective of the experimental conditions. 
 
5.2.4 Incubation of HK-2 cells with the LOXL2 inhibitor 	  
TGF-β-treated HK-2 cells were incubated with PXS-S2A (courtesy of Pharmaxis Ltd, 
Frenchs Forest, NSW, Australia) at a concentration of 300nM. PXS-S2A is a potent 
and highly selective LOXL2 inhibitor with excellent in vitro properties as well as high 
metabolic stability. It has been previously described in detail (56).  
 
5.2.5 In vitro LOXL2 silencing  	  
HK-2 cells at passage 13-16 were seeded onto 6 well plates  (Sarstedt, Numbrecht, 
Germany). Silencing experiments were performed the following day when they 
reached approximately 60% confluence. Prior to transfection the keratinocyte cell 
culture medium was changed to OPTI-MEM (Life technologies, Carlsbad, CA, USA). 
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The cells were transfected with either small interfering RNA (siRNA) targeting 
human LOXL2 (Gene Pharma, Shanghai, China) at a final concentration of 80nM or 
non-targeting control siRNA (Gene Pharma) using RiboJuice siRNA transfection 
reagent (Novagen, San Diego, USA) according to the manufacturer’s instructions. 5 
hours after transfection the siRNA containing medium was replaced with fresh 
keratinocyte serum-free medium (Life technologies, Carlsbad, USA) and 1ng/ml 
TGF-β1 (R&D Systems, Noble Park, VIC, Australia) added. Keratinocyte serum-free 
medium without TGF-β1 served as control. The cells were incubated for 48 hours 
under normoxic or hypoxic conditions. Cell lysates were then collected for further 
analyses. 
 
Table 5.1   LOXL2 and Control siRNA sequences 
LOXL2  
Sense 
5’-GGAGGACAGAAUGUGAATT-3’ 
LOXL2  
Anti-sense 
5’AUAAUGGACUUCUCAUUGCTT-3’ 
Non-targeting siRNA 
Sense 
5’-UUCUCCGAACGUGUCACGUTT-3’ 
Non-targeting siRNA  
Anti-sense 
5’-ACGUGAGUUCGGAGAATT-3’ 	  	  
5.2.6 RNA isolation and RT-PCR analysis 	  
RNA was extracted from cells using the ISOLATE II RNA Mini kit (Bioline, 
Alexandria, NSW, Australia) as outlined in Chapter 2.5.1. cDNA was generated with 
the Transcriptor First Strand cDNA synthesis kit (Roche Diagnostics, Mannheim, 
Germany) as per the manufacturer’s instructions. Quantitative real-time PCR was 
performed using SensiFAST SYBR Hi-ROX (Bioline, Eveleigh, NSW, Australia) 
with the pre-designed primers on an ABI-Prism-7900 Sequence Detection System 
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(Applied Biosystems, Foster City, USA).  The calculation of relative change in 
mRNA was performed using the delta-delta method, with normalisation to the 
housekeeping gene γ-tubulin. The predesigned primers are listed in table 5.2 
 
Table 5.2   Primer sequences against human target genes 	  
Target Forward (5’-3’) Reverse (5’-3’) 
LOXL2 TGTGCAGCGACAAAAGGATTC GTAGGTTGAGAGGATGGCTCGA 
Fibronectin GCGAGAGTGCCCCTACTACA GTTGTTGAATCGCAGGTCA 
Col IV TCGCCGGGTTCTGTAGGATTCAAA GCCTGCTTGTCCTTTGTCACCAAT 
E-Cadherin TCTTCAATCCCACCACG TCTCCAAATCCGATATGTTA 
Snail CACTATGCCGCGCTCTTTCC GTCGTAGGGCTGCTGGAAG 
MCP-1 CCAAAGAAGCTGTGATCTTCAA TGGAATC CTGAACCCACTTC 
Υ-tubulin ACACCGCTTTGCCGATAG CCACCAGCACGTACAGCA 	  	  
5.2.6 Statistical analysis 	  
Statistical analysis of data from two groups was performed by two-tail student t-test in 
Prism software V 6.0 (GraphPad, La Jolla, CA,USA). Data are expressed as mean ± 
SEM with P-values less than 0.05 considered to represent statistical significance. 	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5.3 Results 	  
5.3.1 LOXL2 is regulated by hypoxia in human kidney tubular epithelial cells 
HK-2 cells, a cell line derived from human proximal tubule cells, have previously 
been demonstrated to be a source of LOXL2 (232, 239). To identify the factors that 
induce LOXL2 expression in renal fibrosis, HK-2 cells were exposed to the 
profibrotic stimuli TGFβ (1ng/ml and 2ng/ml), high glucose (30mM) and hypoxia 
(1% O2). The 48-hour incubation under hypoxic conditions resulted in a two-fold 
increase in LOXL2 expression (P<0.05 vs. Ctrl). Neither high glucose nor TGFβ 
induced LOXL2 expression.  Concomitant exposure of HK-2 cells to TGFβ and 
hypoxia did not potentiate the LOXL2 expression beyond the expression achieved 
under hypoxic conditions (Figure 5.1A). These results imply that in HK-2 cells TGFβ 
or high glucose do not regulate LOXL2 expression at a mRNA level while hypoxia 
provides a strong stimulus. 
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Figure 5.1   Effect of TGFβ, high glucose and /or hypoxia on LOXL2 expression 
HK-2 cells were exposed for 48 hours to 1ng/ml TGFβ, 2ng/ml TGFβ or 30mM high 
glucose (HG) in normoxic and hypoxic conditions. LOXL2 mRNA was analysed by 
real-time PCR. Results are presented as means ± SEM after normalisation to γ-
tubulin, which did not change its expression under hypoxia. Only hypoxia was able to 
induce LOXL2 expression. *P<0.05 vs. Control (Crl), n=3.  
Ct
rl HG
TG
Fb
 1n
g/m
l
TG
Fb
 2n
g/m
l
Ct
rl_
hy
po
xia
TG
Fb
 2n
g/m
l_h
yp
ox
ia
HG
_h
yp
ox
ia
0
1
2
3
re
la
tiv
e 
LO
XL
2 
m
R
N
A
ex
pr
es
si
on
 to
 tu
bu
lin *
*
HypoxiaNormoxia
	   136	  
5.3.2 Exposure of HK-2 cells to the LOXL2 inhibitor  
 
Based on in vitro studies on tumour cell lines demonstrating a role for LOXL2 in 
promoting fibronectin expression (24) and E-Cadherin loss with completion of EMT 
(63), we hypothesised that PXS-S2A, a selective small molecule inhibitor of LOXL2, 
would effectively inhibit the upregulation of fibrotic markers (fibronectin and 
collagen IV) and inhibit regulation of Snail and E-Cadherin in renal tubular cells. HK-
2 cells were exposed to TGFβ to induce fibrotic changes both in the presence and 
absence of PXS-S2A.  In addition, cells were incubated at 1% O2 to specifically 
induce LOXL2 and study the effect of PXS-S2A in a hypoxic environment. The IC50 
of PXS-S2A is 10nM (courtesy of Pharmaxis Ltd, Frenchs Forest, NSW, Australia). 
However, to ensure maximun inhibition a concentration of 300nM was used in these 
experiments. An MTS assay demonstrated that PXS-S2A did not have a cytotoxic 
effect on cell viability at concentrations up to 1µM (Figure 5.2).  
 
TGFβ significantly increased fibronectin and Snail (P<0.01 vs. Ctrl). The same trend 
was seen for collagen IV without reaching statistical significance.  E-Cadherin was 
significantly repressed by TGFβ (P<0.01 vs. Ctrl). Concomitant exposure to PXS-
S2A did not abrogate any of these findings. Neither the expression of ECM markers 
fibronectin and collagen IV, nor the expression of EMT markers Snail and E-
Cadherin were affected by PXS-S2A. The lack of response was demonstrated in both 
normoxic and hypoxic conditions. It was noted that the previously shown hypoxia-
mediated increase in LOXL2 did not translate into a significant regulation of fibrosis 
or EMT markers. To elucidate whether the lack of treatment response was related to 
the compound itself, due to cell type, the experimental design or redundancies in 
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regulation of LOXL2 signalling pathways, selective silencing of LOXL2 was 
proposed (Chapter 5.3.3). 
 
 
 
                         
 
Figure 5.2   MTS assay 
Colorimetric quantification of viable cells in cultures incubated with increasing 
concentrations of the LOXL2 inhibitor PXS-S2A (LOXL2i). Reduction of MTS 
tetrazolium by NADPH-dependent dehydrogenase in metabolically active cells 
generated colored formazan, which was quantified by measuring the absorbance at 
492nm (n=3). Absorbance did not differ from control values in wells containing up to 
1000nM LOXL2 inhibitor. In the subsequent experiments a concentration of 300nM 
was used.  
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Figure 5.3   Effect of exposure to the LOXL2 inhibitor on fibrosis and EMT marker 
transcripts in human kidney proximal tubular epithelial cells 
PXS-S2A did not alter TGFβ-regulated mRNA expression of Snail (A), E-Cadherin 
(B), fibronectin (C) and collagen IV (D). The lack of response was consistent in 
normoxic and hypoxic conditions. Ctrl=control, H=hypoxia, LOXL2i=LOXL2 
inhibitor, *P<0.05 vs. Ctrl, **P<0.01 vs. Ctrl, n=3.  
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5.3.3 LOXL2 mRNA knockdown in HK-2 cells 	  
To determine whether LOXL2 is involved in promoting EMT and ECM remodeling 
in kidney fibrosis, HK-2 cells were transiently transfected with LOXL2 siRNA and 
exposed to TGFβ and/or hypoxia for 48 hours. The transfection efficiency of the 
LOXL2 siRNA was compared to HK-2 cells exposed to the same conditions and 
transfected with non-targeting siRNA. Realtime PCR for LOXL2 confirmed a 
transfection efficiency of 60% in cells without additional treatment and 61% in cells 
exposed to TGFβ. Cells cultured under hypoxic conditions had LOXL2 mRNA 
knockdown of 58% and 52% when concurrently exposed to TGFβ (Figure 5.4). 
 
    
                    
Figure 5.4   Effective knockdown of LOXL2 mRNA in HK-2 cells 
LOXL2 expression in HK-2 cells transfected with LOXL2 siRNA or non-targeting 
control siRNA (Ctrl siRNA) in the presence or absence of TGFβ yielding a LOXL2 
mRNA knockdown of 52%-61. Normoxic conditions (A) and hypoxic conditions (B), 
**P<0.01 vs. Ctrl siRNA, ##P<0.01 vs Ctrl siRNA + TGFβ, n=3. 
  
Ct
rl s
iR
NA
LO
XL
2 s
iR
NA
Ct
rl s
iR
NA
+T
GF
β
LO
XL
2 s
iR
NA
+T
GF
β
0.0
0.5
1.0
1.5
re
la
tiv
e 
LO
XL
2 
m
R
N
A
ex
pr
es
si
on
 to
 tu
bu
lin ** ##
A Normoxia B Hypoxia 
Ct
rl s
iR
NA
LO
XL
2 s
iR
NA
Ct
rl s
iR
NA
+T
GF
β
LO
XL
2 s
iR
NA
+T
GF
β
0.0
0.5
1.0
1.5
re
la
tiv
e 
LO
XL
2 
m
R
N
A
ex
pr
es
si
on
 to
 tu
bu
lin
** #
	   140	  
5.3.4 Expression of EMT marker in HK-2 cells exposed to LOXL2 siRNA 	  
To determine the effect of LOXL2 knockdown on EMT, transcripts of the genes for 
the EMT transcription factor Snail and its downstream target E-Cadherin were 
quantified. Snail mRNA was induced by TGFβ in both normoxic (P<0.01 vs. Ctrl 
siRNA) and hypoxic conditions (P<0.05 vs. Ctrl siRNA) and this was associated with 
a significant suppression in E-Cadherin gene transcripts (P<0.01vs. Ctrl siRNA). 
LOXL2 silencing did not alter the expression of Snail or E-Cadherin mRNA (Fig 5.5) 
 
Figure 5.5   LOXL2 silencing did not alter EMT marker expression 
Snail and E-Cadherin mRNA expression after transfection with LOXL2 siRNA and 
exposure to TGFβ under normoxic (A and C) and hypoxic (B and D) conditions. 
*P<0.05 vs. Ctrl siRNA **P<0.01 vs. Ctrl siRNA, n=3  
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5.3.5 Expression of fibrotic markers in HK-2 cells treated with LOXL2 siRNA 	  
The effect of LOXL2 silencing on expression of ECM markers was determined. Both 
fibronectin and collagen IV were induced by TGFβ. Silencing of LOXL2 did not 
change the expression of these markers in either normoxic or hypoxic conditions 
(Figure 5.6) 
 
 
Figure 5.6   Effect of LOXL2 silencing on fibronectin and collagen IV expression 
Fibronectin and collagen IV mRNA expression after transfection with LOXL2 siRNA 
and exposure to TGFβ under normoxic (A and C) and hypoxic (B and D) conditions. 
*P<0.05 vs. Ctrl siRNA **P<0.01 vs. Ctrl siRNA, n=3	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5.4 Discussion 	  
The present study clearly demonstrates that LOXL2 expression in renal proximal 
tubule cells is upregulated by hypoxia. Conversely, TGFβ was a stronger stimulus for 
EMT and fibrotic marker expression in these cells than hypoxia alone. Blockade of 
LOXL2 either by pharmacological means with a small molecule selective LOXL2 
inhibitor or genetic knockdown did not ameliorate any TGFβ-mediated effects on 
EMT markers, fibronectin and collagen IV.  
 
The induction of LOXL2 by hypoxia is expected as LOXL2 was discovered to have a 
HIF-1-binding domain and is directly regulated by this master transcription factor that 
controls cellular adaptation to hypoxia (219). The role of HIF in renal fibrosis remains 
debated with at least one study showing global activation of HIFs reducing 
tubulointerstitial injury in a rat model (238) while Higgins et al. demonstrated that 
HIF-1α knockout attenuates renal fibrosis in UUO kidneys (110). In the latter study 
the increase of HIFs in UUO kidneys was associated with increased LOX and LOXL2 
and the profibrotic effect of HIF-1α was partially attributed to lysyl oxidases because 
pharmacologic blockade with the lysyl oxidase inhibitor BAPN ameliorated collagen 
deposition.  Support for the hypothesis that LOXL2 plays a role in hypoxia-mediated 
fibrosis comes also from in vitro studies, in which LOXL2 knockdown was able to 
restore hypoxia-induced E-Cadherin repression in a renal cell carcinoma cell line 
(219). These findings are in contrast to our results and could be due to a number of 
factors. Firstly, the findings may be cell type dependent. HK-2 cells were chosen, as 
they are known to be renal producers of LOXL2 (232). Given the diversity of cell 
types within the kidney, LOXL2 downstream effects may differ in various parts of the 
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nephron or the tubulointerstitium. LOXL2 silencing in cardiac fibroblasts resulted in 
downregulation of collagen I, fibronectin and αSMA gene expression (269). It 
remains to be shown whether the regulation of LOXL2 expression is cell specific with 
a potentially similar effect in renal fibroblasts. Additional studies in cells from distal 
tubular segments, the endothelium and glomerulus may be of benefit. A recent study 
highlighted the role of LOXL2 in the glomerulus. Anazco et al. demonstrated in 
microdissected mouse glomeruli the predominance of LOXL2 above other lysyl 
oxidases and it’s involvement in collagen IV crosslinking in the glomeruli. As 
immunostaining localised LOXL2 to both the extracellular compartment and to the 
podocyte, we propose further assessment of the downstream effects of LOXL2 
inhibition in podocyte cultures or animal models with prominent glomerular 
pathology. Thus, studies in a diabetic nephropathy model, which is characterised by 
pronounced glomerulosclerosis were proposed. In Chapter 6 we will demonstrate that 
the dominant effect of the LOXL2 inhibitor was indeed on glomerular pathology and 
less on tubulointerstitial injury. 
  
Although HK-2 cells are an immortalised cell line, these cells have retained many 
functional characteristics of in vivo proximal tubules and have shown similar results 
in response to experimental injury compared to primary cultures of human PTC (213). 
HK-2 cells, as opposed to primary cultures of human PTCs, are able to survive serial 
passage. However, there remain phenotypic changes compared to primary cultures of 
human PTC and a recent study highlighted differential expression in basolateral 
uptake transport proteins in HK-2 cells that may alter pharmacological characteristics 
(126). Whether this may affect the uptake of the selective LOXL2 inhibitor into the 
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cell and thereby the intracellular activity of LOXL2 could be investigated with 
fluorescent dye retention assays as previously described (126). 
 
Additionally, in vitro cultures of a single cell type are unlikely to replicate in vivo 
events, which often are influenced by co-activators or co-suppressors and complex 
interactions of the environment.  ECM, in particular acts both as a support structure 
for cells and as an active component in cell signaling (89). Mechanical influences, 
such as tissue stiffness of the ECM are known to perpetuate tissue fibrosis by 
feedback mechanisms and fibroblast activation (162). In addition to its intracellular 
action of promoting EMT, LOXL2 is predominantly known as an enzyme that 
initiates collagen cross-linking in the extracellular space. The downstream effects of 
extracellular LOXL2 and its inhibition may be underestimated in a tubular epithelial 
culture that has minimal secreted ECM products such as collagen. Producing ECM in 
cell cultures that equals the in vivo fibrotic ECM in quality and quantity is difficult to 
achieve. Thus, for an enzyme like LOXL2 that acts extracellularly and modifies the 
ECM, in vivo studies may remain the best way to replicate more precisely the 
conditions encountered in organ fibrogenesis. We therefore proposed to test the 
LOXL2 inhibitor in an additional in vivo model that in contrast to the UUO model 
(Chapter 4) mimics a more chronic disease process and is characterised not only by 
tubulointerstitial fibrosis but also glomerulosclerosis. The diabetic nephropathy model 
fulfills these requirements and both a functional and structural benefit in the 
glomerulus after LOXL2 inhibition was indeed demonstrated in this model (Chapter 
6).  
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Chapter 6  
 
LOXL2 inhibition in a mouse model of diabetic nephropathy 
 
Stefanie Stangenberg, Sonia Saad, Heidi C. Schilter, Amgad Zaky, Anthony Gill, 
Carol A. Pollock and Muh Geot Wong. Lysyl oxidase-like 2 inhibition ameliorates 
glomerulosclerosis and albuminuria in diabetic nephropathy.  
Manuscript under review in Scientific Reports, July 2017. 	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6.1 Background and objectives 	  
Diabetic nephropathy is the leading cause of end-stage kidney disease (ESKD) 
worldwide and the incidence is expected to rise (165). Current treatment of diabetic 
nephropathy is limited to blockade of the renin-angiotensin-aldosterone system 
(RAAS). However, despite RAAS blockade a significant risk of progression to ESKD 
remains (40, 155). Clinical features include progressively increasing proteinuria, 
frequently accompanied by hypertension and an eventual decline in glomerular 
filtration rate. In early stages the histopathology is characterised by glomerular 
basement membrane (GBM) thickening, often paralleled by tubular basement 
membrane thickening, followed by mesangial expansion which can lead to nodular 
and diffuse glomerulosclerosis. Other features of diabetic nephropathy include 
arteriolar hyalinosis, atrophic tubules and tubulointerstitial fibrosis as a late 
manifestation (82). While the various lesions of diabetic nephropathy progress at 
varying rates, many of the characteristic manifestations are a consequence of 
extracellular matrix (ECM) accumulation.  
 
The ECM is a dynamic network of collagens, proteoglycans and glycoproteins. In 
healthy kidneys collagen IV, an integral component of glomerular and tubular 
basement membranes, is the most abundant collagen. Rather small amounts of 
collagen I and III are detected in the tubulointerstitial compartment but are virtually 
absent in the healthy glomerulus. In renal fibrosis collagen I and III expression 
increases and is found both in the tubulointerstitium and de-novo expressed in 
glomeruli along with excess collagen IV (3).  
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The amount of matrix deposition is tightly regulated by the balance between synthesis 
and degradation. Lysyl oxidases regulate ECM stabilisation by promoting collagen 
cross-links, thus conferring higher resistance to proteolytic degradation (249). As 
outlined in detail in Chapter 4 lysyl oxidases catalyse the oxidative deamination of 
lysine and hydroxylysine residues in collagen and elastin to highly reactive aldehydes.  
These aldehydes spontaneously condense with other LOX-derived aldehydes or 
unmodified lysine residues to generate intermolecular cross-links between collagen 
fibers. The resulting ECM stiffness appears to promote myofibroblast differentiation 
and enhances matrix deposition thereby creating a feed forward loop of self-
sustaining fibrosis (34, 162). In addition, LOXL2 has been demonstrated to regulate 
epithelial to mesenchymal transition (EMT) by stabilising the key EMT transcription 
factor Snail (199). As a consequence, an EMT derived mesenchymal phenotype may 
further promote fibrosis by contributing to excess ECM synthesis. Further support for 
a key role for lysyl oxidases comes from in vivo studies in a liver fibrosis model.  Liu 
et al demonstrated that the inhibition of lysyl oxidases with the pan-lysyl oxidase 
inhibitor BAPN affected not only the extent of collagen cross-links but also rendered 
fibrosis more readily reversible after cessation of the initial fibrogenic stimulus (163). 
This suggests that LOXL2, which is overexpressed in human kidney disease and in in 
vivo renal fibrosis models (110) may constitute a suitable treatment target. 
 
While the unilateral ureteral obstruction (UUO) model in Chapter 4 was used as an 
early fibrosis model to study the utility of LOXL2 as a treatment target, the diabetic 
model was chosen in this chapter to complement the UUO data in a chronic fibrosis 
model more relevant to human disease. In addition, the UUO model provided a robust 
model of intense tubulointerstitial fibrosis but lacked significant glomerular 
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pathology, which is an important hallmark of early and late stage CKD. The diabetic 
mouse model is characterised by both glomerular and tubular injury and as a chronic 
disease model may mimic better the functional and structural perturbation of CKD. 
 
The present study aimed to explore the role of LOXL2 in diabetic nephropathy and 
examined the therapeutic potential of the novel selective LOXL2 inhibitor PXS-S2B 
as a renoprotective small molecule alone and in addition to standard therapy with 
RAAS blockade. 
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6.2 Material and methods 	  
6.2.1 Mouse model of diabetic nephropathy 	  
Male eNOS knockout mice (eNOS-/-) on C57BL/6 background (Jackson laboratory, 
ME, USA) were housed in single cages at 22 ± 1°C with a 12/12hr light dark cycle 
and free access to standard chow and drinking water.  Diabetes mellitus was induced 
by intraperitoneal streptozotocin (STZ) (Sigma-Aldrich, MO, USA) injection 
(55mg/kg diluted in sterile 10mM citrate buffer, pH4.5 daily for 5 consecutive days) 
at 6-9 weeks of age. A group of mice receiving citrate buffer alone served as the non-
diabetic controls. Blood glucose levels (BGL) were determined by tail vein blood 
collection using an Accu-chek glucometer (Roche Diagnostics) after a 6-hour daytime 
fast. Mice with BGL > 16 mmol/L two weeks post STZ injection were considered 
diabetic. In order to prevent ketoacidosis a daily subcutaneous dose of 1 unit Insulin 
Glargine (Sanofi Aventis, Australia) was administered if blood glucose levels 
exceeded 28 mmol/L, 2 units insulin were administered if BGL exceeded 34 mmol/L.  
Body weight and blood glucose monitoring was performed fortnightly or at more 
frequent intervals if mice received insulin. The study was approved by the Animal 
Research Ethics Committee of the Royal North Shore Hospital (protocol number 
1309-003A) and was carried out according to the Australian Code of Practice for the 
Care and Use of Animals for Scientific Purposes.  Animals were anaesthetised using 
short inhalational anaesthesia with 2% isoflurane for minor procedures and were 
euthanised under 2% isoflurane anaesthesia using cardiac puncture terminally. 
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6.2.2 Experimental design 	  
The small molecule, selective LOXL2 inhibitor PXS-S2B (kindly provided by 
Pharmaxis Ltd., NSW, Australia) was administered at a dose of 10mg/kg by daily oral 
gavage through a flexible plastic gavage tube (Instech laboratories, PA, USA). 
Telmisartan (Santa Cruz, CA, USA) was mixed in drinking water at 2mg/kg/d 
(pH7.4). The agent was chosen as a standard therapeutic control and the dose is not 
known to have any blood pressure lowering effect (85). Animals were divided into the 
following groups: 1) Control (Ctrl), 2) Diabetes (DM), 3) Diabetes+PXS-S2B 
(DM+LOXL2i), 4) Diabetes+telmisartan (DM+Telmi), 5) DM+PXS-S2B 
+telmisartan (DM+LOXL2i+Telmi). A separate control group that received PXS-S2B 
was used to assess for unwanted off-target effects. Treatment was carried out for 24 
weeks from diagnosis of diabetes. Urine was collected in metabolic cages and urine 
albumin determined by ELISA (Albuwell, Exocell Inc., USA). Urine creatinine was 
measured using a picric acid method (Creatinine Companion, Exocell Inc, USA). The 
HbA1c from a final blood collection at the time of culling was determined using a 
DCA Vantage analyser (Siemens Healthcare, Bayswater, VIC, Australia) according to 
the manufacturer’s instructions. At the time of culling, kidneys were perfused in ice-
cold PBS before harvest and snap frozen in liquid nitrogen or fixed in 10% neutral 
buffered formalin for 24 hours prior paraffin embedding.  
 
6.2.3 Compound characteristics 	  
PXS-S2B is a haloallylamine-derived, mechanism-based amine oxidase inhibitor with 
high oral bioavailability. It distributes well into tissues and forms PXS-S2A, which 
has high selectivity for LOXL2 over LOX. It is characterised by high plasma stability 
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and low plasma protein binding. The compound characteristics have been described in 
detail previously (56). 	  
6.2.4 Histology 	  
Paraffin embedded kidneys sections (2 µm) were stained with Masson’s Trichrome 
and Periodic Acid Schiff (PAS). Assessment of glomerulosclerosis and 
tubulointerstitial fibrosis was done in an independent manner as outlined in Chapter 2. 
Twenty non-overlapping fields were graded according to a semiquantitative 
glomerulosclerosis index (GSI) score as previously described (169) and an average 
GSI score was obtained from all counted glomeruli in the twenty fields. For 
tubulointerstitial scoring ten non-overlapping fields of the Masson Trichrome stain 
were assessed using a grading system previously described (279). Paraffin sections of 
liver, lung and heart from control and control animals treated for 24 weeks with PXS-
S2B were stained with haematoxilin and Eosin (HE) and evaluated for structural 
damage by an independent pathologist.  
 
6.2.5 RNA extraction and quantitative real-time RT-PCR 	  
Total RNA was extracted from kidney tissue using the RNeasy Plus Mini extraction 
kit (Qiagen, CA, USA). cDNA was synthesised using the Transcriptor First Strand 
cDNA synthesis kit (Roche Diagnostics, Manheim, Germany). Predesigned primers 
(Sigma-Aldrich, NSW, Australia) are listed in table 5.1. Quantitative real-time PCR 
was performed using SensiMix SYBR hiRox (Bioline, NSW Australia) in an AB7900 
real-time PCR system cycler (Applied Biosystems, Australia). Gene expression is 
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presented as fold-change compared with control after normalisation to the 
housekeeping gene actin.  
 
Table 6.1 Mouse-specific primer sequences 
Target Forward (5’-3’) Reverse (5’-3’) 
LOXL2 ATTAACCCCAACTATGAAGTG CTGTCTCCTCACTGAAGGCTC 
Fibronectin ACAGAAATGACCATTGAAGG TGTCTGGAGAAAGGTTGATT 
COL1A1 CAGCCGCTTCACCTACAGC TTTTGTATTCAATCACTGTCTTG 
Col IV TTAAAGGACTCCAGGGACCAC CCCACTGAGCCCTGTCACAC 
aSMA ATAGGTGGTTTCGTGGATGC ACTCTCTTCCAGCCATCTTTCA 
E-Cadherin CAAAGTGACGCTGAAGTCCA TACACGCTGGGAAACATGAG 
Vimentin CCAACCTTTTCTTCCCTGAA TGAGTGGGTGTCAACCAGAG 
MCP-1 CATCCACGTGTTGGCTCA GATCATCTTGCTGGTGAATGAG 
β-Actin CTAAGGCCAACCGTGAAAAG ACCAGAGGCATACAGGGACA 	  	  	  
6.2.6 Immunohistochemistry 	  
Immunohistochemistry was performed on paraffin-embedded kidney sections (4 
micron) as described in Chapter 2. The sections were incubated overnight at 4°C with 
primary polyclonal antibodies against LOXL2 (1:500 dilution, sc-66950, Santa Cruz, 
USA), Collagen I (dilution 1:500, ab34710, Abcam), monoclonal antibody against 
fibronectin (dilution 1:1000, ab45688, Abcam, Cambridge, UK) and αSMA (dilution 
1:100, A2547, Sigma Aldrich, USA). Immunohistochemistry for F4/80 staining was 
done on 6 micron frozen sections that were fixed in acetone after removal from the 
freezer, followed by three wash steps in phosphate buffered saline (PBS) and 
incubation for 1 hour with a monoclonal F4/80 antibody (dilution 1:1000, MCA497R, 
ABD Serotec, USA). The sections were developed with 3,3’-diaminobenzidine 
chromogen (Dako, CA, USA) after incubation with the respective horseradish-
peroxidase (HRP) tagged secondary antibodies (Dako) and then counterstained with 
haematoxilin. The quantification was performed by capturing 10-12 non-overlapping 
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fields of renal cortex from stained sections at 200x magnification with a Leica 
microscope linked to a DFC 480 digital camera (Leica, Wetzlar, Germany). The 
percentage of stained area relative to the whole area in each field was assessed with 
image J software (Java-based software program, National Institutes of Health). 
 
 
6.2.7 Cross-linking assay 	  
Lyophilised kidney tissue was homogenised in PBS buffer and reduced with sodium 
borohydride for 30 min. The reaction was stopped with acetic acid.  The samples were 
washed with distilled water, hydrolysed with 6M hydrochloric acid (HCl) for 24 hours 
at 105°C and reconstituted with distilled water. Collagen crosslinks were extracted 
from the hydrolysate using an automated solid phase extraction system (GX-271 
ASPEC system, Gilson, Middleton, WI, USA) set up with GracePure solid phase 
extraction (SPE) C18-Aq columns and GracePure SPE Cation-X columns (Grace 
Discovery Sciences, Epping, VIC, Australia) as outlined in detail in Chapter 2.6.4. 
The quantitation of cross-links was done by ultra-high performance liquid 
chromatography-electrospray ionisation tandem mass spectrometry (UHPLC-ESI-
MS/MS) in a Thermo Dionex UHPLC and TSQ Endura triple quad mass spectrometer 
(ThermoFisher Scientific, North Ryde, NSW, Australia) as described in Chapter 
2.6.4.2.  	  
6.2.8 Statistical analysis 	  
Statistical analysis was performed as outlined in Chapter 2 using ANOVA with 
Bonferroni correction in Prism software V 6.0 (GraphPad, La Jolla, CA,USA) For 
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non-normally distributed data Mann-Whitney U test was used as indicated in the 
figure legends. Data are expressed as mean ± SEM with P-values less than 0.05 
considered to represent statistical significance.   
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6.3 Results 	  
6.3.1 Renal LOXL2 expression in diabetic and control mice 	  
In order to confirm the expression of LOXL2 upon disease induction, kidneys were 
stained with LOXL2 antibody. LOXL2 immunohistochemistry had a distinct staining 
pattern with a predominantly tubular localisation. There was strong staining along the 
corticomedullary junction, which did not differ between control and diabetic animals 
(Figure 6.1 C and D). However, diabetic mice had significantly increased staining in 
the renal cortex which was most pronounced in areas of tubular atrophy and damage 
(P<0.05 vs Ctrl, Figure 6.1 A and B). Most glomeruli of control mice did not stain for 
LOXL2 (Figure 6.1 E) whereas the diabetic mice had increased numbers of glomeruli 
with positive staining. Specifically mice with very high fasting blood glucose levels 
had glomeruli with very strong LOXL2 immunostaining even in areas where tubular 
staining was minimal (Figure 6.1 F).  
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Figure 6.1   LOXL2 expression in the different kidney compartments 
LOXL2 immunostaining was significantly increased in the renal cortices of diabetic 
animals (DM) (B) vs. control (Ctrl) (A). The medulla had a characteristic staining 
pattern along the corticomedullary junction without significant difference between 
Ctrl (C) and DM (D). Increased numbers of glomeruli stained positive for LOXL2 in 
DM (F) vs. Ctrl (E). Scale bar = 50µm. Mean ± SEM, *P<0.05 vs. Ctrl, n=5-7.  
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6.3.2 Clinical characteristics 	  
The clinical characteristics are summarised in table 6.2. STZ treated mice developed a 
significant elevation in fasting blood glucose levels (BGL) (P<0.01 vs. Ctrl) and had a 
significant reduction in body weight. HbA1c levels were significantly increased in all 
diabetic groups compared to control (P<0.01 vs. Ctrl), with no significant difference 
between the diabetic groups (DM, DM+LOXL2i, DM+Telmi, DM+LOXL2i+Telmi). 
Daily treatment with PXS-S2B over the 24-week period was well tolerated with no 
adverse clinical effects noted. At the conclusion of the experiment the liver, heart and 
lung were harvested and no histological abnormality was observed in animals treated 
with PXS-S2B (data not shown).  
 
 
Table 6.2   Weight and parameters of glycemic control 
n=5-8 Ctrl DM DM 
+LOXL2i 
DM 
+Telmi 
DM 
+LOXL2i 
+Telmi 
Body weight 
(g) 
 
25.0±0.31 21.5±0.90** 21.5±0.78** 23.1±0.62* 22.7±0.57** 
Average BGL 
(mmol/L) 
9.7±0.44 20.6±0.40** 23.88±0.72## 26.2±0.50## 24.7±0.65## 
HbA1c (%) 
 
4.3±0.05 8.1±0.18** 8.4±0.12** 8.7±0.23** 8.9±0.50** 	  
Body weight at the end of the experiment, blood glucose levels after a 6 hour daytime 
fast averaged over the course of the experiment and HbA1c in the final week of the 
experiment. Data are expressed as mean±SEM, **P<0.01 vs. control (Ctrl), 
##P<0.01 vs. diabetes (DM), n=5-8 using Mann Whitney test. 
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6.3.3 Effect of PXS-S2B on albuminuria in diabetic mice 
Albuminuria as a marker for glomerular damage was determined in the final week of 
the experiment. The urinary albumin to creatinine ratio was nearly fourfold increased 
in untreated diabetic mice to 813±194 µg/mg vs. 213±14 µg/mg in the control group 
(P<0.01 vs. Ctrl). Diabetic mice treated with PXS-S2B had a significant reduction of 
albuminuria (418±108 µg/mg, P<0.05 vs. DM). Treatment with telmisartan and the 
combination treatment (LOXL2i+Telmi) resulted in further reduction of albuminuria 
(168±19 µg/mg, P<0.01 vs. DM and 150±41 µg/mg, P<0.01 vs. DM respectively, 
Figure 6.2). 
 
                              
                  
Figure 6.2   Albuminuria in the diabetic model 
Urinary albumin/creatinine ratio in control, diabetic and diabetic mice treated with 
PXS-S2B and/or telmisartan. Data are expressed as mean±SEM, **P<0.01 vs. Ctrl, 
#P<0.05 vs. DM, ##P<0.01 vs. DM, n=5-8. 
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6.3.4 Effect of PXS-S2B treatment on glomerulosclerosis 
 
As diabetic nephropathy progresses excess ECM accumulates in the glomerular tuft 
leading to glomerulosclerosis. The untreated diabetic mice (Figure 6.3B) developed 
significant glomerulosclerosis compared to the control group (P<0.01 vs. Ctrl, Figure 
6.3A). Diabetic mice treated with PXS-S2B had a significant reduction in the 
glomerulosclerosis score (P<0.05 vs. DM, Figure 6.3C). The glomerulosclerosis index 
was further reduced when the treatment with PXS-S2B and telmisartan was combined 
(p<0.01 vs. DM, Figure 6.3E).  
 
6.3.5 Effect of PXS-S2B on tubulointerstital damage scores 	  
In contrast to glomerulosclerosis the diabetes-induced tubulointerstitial damage was 
less pronounced. In this model tubulointerstitial changes were mainly characterised by 
tubular thinning, atrophy and dilatation rather than an extensive ECM matrix 
deposition. Neither treatment with PXS-S2B nor telmisartan reduced tubulointerstital  
lesions in the diabetic mice (Figure 6.4).  
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Figure 6.3 Glomerulosclerosis  
Representative images of PAS stained kidney sections for (A) Ctrl, (B) DM, (C) 
DM+LOXL2i, (D) DM+Telmi, (E) DM+LOXL2i+Telmi, (magnification=original x 
400, scale bar = 50µm). (F) Glomerulosclerosis index score of 20 glomeruli, mean ± 
SEM, **P<0.01 vs. Ctrl, #P<0.05 vs. DM, ##P<0.01 vs. DM, n=5-8.  
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Figure 6.4   Tubulointerstitial damage  
Representative photographs of Masson Trichrome stained kidney sections for (A) 
Ctrl, (B) DM, (C) DM+LOXL2i, (D) DM+Telmi, (E) DM+LOXL2i+Telmi, (scale bar 
= 200µm). (F) Mean ± SEM of ubulointersitial damage score of 10 visual fields of 
renal cortex per group, n=5-8.  	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6.3.6 Effect of PXS-S2B treatment on extracellular matrix proteins 	  
Fibronectin, an adhesive glycoprotein activates integrins, functions as fibroblast 
chemoattractant and forms a scaffold for the deposition of fibrillar collagens. It is one 
of the first ECM proteins deposited in renal fibrosis. Immunohistochemical staining 
for cortical fibronectin was increased in diabetic mice (P<0.01 vs. Ctrl) and was 
deposited in sclerosed glomeruli and to a lesser extent in the tubulointerstitial space. 
Diabetic mice treated with either PXS-S2B or telmisartan had significant reduction in 
fibronectin mRNA (P<0.01 vs. DM and P<0.01 vs. DM respectively) and significant 
reduction in fibronectin immunostaining (P<0.05 and P<0.01 vs. DM respectively, 
Figure 6.5).  
 
Collagen I is minimally expressed in healthy kidneys but is known to increase in renal 
fibrosis. Similar to fibronectin, it appears in early stages of renal fibrosis (89). 
Collagen I immunostaining was significantly increased in diabetic mice and was 
predominantly localised in the tubulointersitital space (P<0.05 vs. Ctrl).  
Treatment with PXS-S2B resulted in significant reduction in COL1A1 mRNA 
expression and collagen I immunostaining (P<0.05 vs. DM). Telmisartan treatment 
similarly resulted in a significant reduction of collagen I immunuostaining (P<0.05 
vs. DM), which was not different from control values (Figure 6.6).  
 
Collagen IV protein, the most abundant collagen in healthy kidneys and integral 
component of tubular and glomerular basement membranes was slightly upregulated 
in diabetic kidneys although this did not reach statistical significance. There was a 
trend of reduction after treatment with PXS-S2B and a significant reduction in the 
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telmisartan and combined treatment group (P<0.05 vs. DM, P<0.01 vs DM 
respectively, Figure 6.7).  
 
 
 
Figure 6.5   Fibronectin expression 
Fibronectin was predominantly localised in the glomeruli. LOXL2 inhibition reduced 
fibronectin mRNA expression (F) and immunostaining (G). Representative 
photographs for (A) Ctrl, (B) DM, (C) DM+LOXL2i, (D) DM+Telmi, (E) 
DM+LOXL2i+Telmi, (magnification=original x 400, scale bar = 50µm), mean ± 
SEM, **P<0.01 vs. Ctrl, #P<0.05 vs. DM, ##P<0.01 vs. DM, n=5-8. 
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Figure 6.6   Collagen I expression 
Representative images of collagen I tubulointerstitial immunostaining for (A) Ctrl, (B) 
DM, (C) DM+LOXL2i, (D) DM+Telmi, (E) DM+LOXL2i+Telmi, scale bar-50µm, 
(F) Collagen I mRNA and (G) immunohistochemistry quantification.  Mean ± SEM, 
*P<0,05 vs. Ctrl, #P<0.05 vs. DM, ##P<0.01 vs. DM, n=5-8. 
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Figure 6.7   Collagen IV expression 
Representative images of Collagen IV immunostaining for (A) Ctrl, (B) DM, (C) 
DM+LOXL2i, (D) DM+Telmi, (E) DM+LOXL2i+Telmi, scale bar-50µm, (F) 
Collagen IV mRNA and (G) immunohistochemistry quantification. Mean ± SEM, 
#P<0.05 vs. DM by Mann-Whitney test, n=5-8 
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6.3.7 Effect of treatment with PXS-S2B on myofibroblast activation 	  
Activated myofibroblasts are the principle cells responsible for the excess ECM 
synthesis (135). De-novo expression of αSMA is a marker of myofibroblast activation 
and signals the transition to an ECM-producing phenotype. Immunostaining of αSMA 
was increased in diabetic mice (Figure 6.8) with a trend towards reduction after 
treatment with PXS-S2B, although this did not reach statistical significance. αSMA 
immunostaining was significantly reduced in the telmisartan group (P<0.05 vs. DM) 
but not in the combined treatment group.  
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Figure 6.8   αSMA expression 
Representative images of αSMA immunostaining for (A) Ctrl, (B) DM, (C) 
DM+LOXL2i, (D) DM+Telmi, (E) DM+LOXL2i+Telmi, scale bar-50µm, (F) αSMA  
immunohistochemistry quantification. Mean ± SEM, *P<0.05 vs. Ctrl, #P<0.05 vs. 
DM, n=5-8. 	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6.3.8 Effect of PXS-S2B on EMT 	  
Although there was a significant upregulation of the mesenchymal marker vimentin in 
diabetic kidneys in keeping with the increased presence of mesenchymal cells 
(P<0.05 vs. Ctrl), the epithelial marker E-Cadherin, which is typically downregulated 
in EMT showed only a trend of reduction in the diabetic group not reaching statistical 
significance. Treatment with PXS-S2B did not have an effect on the expression of 
these EMT markers (Figure 6.9). 
 
Figure 6.9   Expression of epithelial and mesenchymal EMT markers 
mRNA expression of E-Cadherin (A) and Vimentin (B). mean ± SEM, *P<0.05 vs. 
Ctrl, n=5-7.  
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6.3.9 Effect of PXS-S2B on inflammatory markers 	  
Diabetic kidneys in this model had a significant increase in the macrophage cell 
surface marker F4/80 consistent with reports that macrophages are key players in the 
pathogenesis of diabetic nephropathy (71).  Monocyte chemoattractant protein 1 
(MCP-1) which promotes transformation of monocytes into macrophages was also 
significantly increased in the diabetic group. Treatment with PXS-S2B had no effect 
on these inflammatory markers. 
	  	  
Figure 6.10   Inflammatory marker 
Expression of macrophage surface protein F4/80 (A-F) and MCP-1 (G). Mean ± 
SEM, *P<0.05 vs. Ctrl. n=5-8  
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6.3.10 Collagen Cross-linking 	  
Hydroxyproline levels were significantly increased in the diabetic kidneys (P<0.05 vs. 
Ctrl. As collagen fibers contain 12.5% hydroxyproline residues per weight of collagen 
(75), this finding reflects an increase in total collagen content in the diabetic mice and 
is in keeping with the detected increase of mostly collagen I by 
immunohistochemistry. DHLNL levels and pyridinoline (PYD) levels were 
normalised to hydroxyproline content and were used as a marker for immature and 
mature cross-links respectively. Surprisingly, there was no difference between the 
diabetic and control groups and none of the treatments were able to reduce the 
immature or mature cross-links (Figure 6.11). 
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Figure 6.11   Renal collagen cross-links in the diabetic model 
(A) Hydroxyproline content per dry weight of kidney tissue as a marker of total 
collagen content, (B) ratio of dihydroxylysinonorleucine (DHLNL) content to 
hydroxyproline content as a marker for immature cross-links and (C) pyridinoline 
(PYD) content per hydroxyproline as a marker for mature cross-links. Data are mean 
± SEM, *p<0.05 vs. Ctrl by student t test, n=5-8. 
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6.4 Discussion  	  
Despite the known involvement of LOXL2 in a variety of intra- and extracellular 
processes that affect ECM deposition and enhance fibrosis, its role as a potential 
treatment target in renal fibrosis is not well studied. As opposed to the early renal 
fibrosis model by unilateral ureteral obstruction described in Chapter 4, a chronic 
diabetic nephropathy model was used to investigate whether PXS-S2B, a selective, 
small molecule LOXL2 inhibitor, ameliorates renal fibrosis. In contrast to the UUO 
model, diabetic nephropathy is characterised by both tubulointerstitial and glomerular 
pathology, thus enabling us to investigate the potential antifibrotic effect of PXS-S2B 
in different renal compartments.  
 
We are the first to uniquely demonstrate increased levels of LOXL2 in renal cortices 
of diabetic mice. The expression pattern of LOXL2 in focal areas of overt tubular 
damage as well as in glomeruli characterised by glomerulosclerosis suggests its direct 
involvement in the renal fibrosis process. We then demonstrated a significant 
reduction in albuminuria and an attenuation of glomerulosclerosis in diabetic mice 
after 24-week treatment with the LOXL2 inhibitor PXS-S2B. This was associated 
with a reduction in the predominantly glomerular localised fibronectin as well as a 
decrease in tubulointerstitial collagen I along with a trend towards lower collagen IV 
and αSMA levels in the PXS-S2B treated diabetic group. These findings indicate that 
LOXL2 may be a potential therapeutic target in diabetic nephropathy. 
 
The induction of lysyl oxidases, in particular LOX and LOXL2 has been 
demonstrated in other models of renal fibrosis (66, 95, 110). In Sprague Dawley rats 
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with Adriamycin nephropathy, a model involving both glomerulosclerosis and 
tubulointerstitial fibrosis, LOX mRNA was upregulated in glomeruli, medulla and 
whole kidneys and this preceded the development of diffuse fibrotic lesions. 
Upregulation of LOXL2 has not only been observed in the UUO model but also in 
renal biopsies of patients with chronic kidney disease of various aetiologies. Higgins 
et al. found increased LOXL2 expression in the tubulointerstitial compartment of 
kidneys from patients with diabetic	  nephropathy, IgA nephropathy and hypertensive 
nephrosclerosis, underscoring the importance of LOXL2 in the development and 
progression of diabetic nephropathy and other aetiologies of renal fibrosis (110). 
 
Our studies show an attenuation of glomerulosclerosis and albuminuria as well as the 
reduction in glomerular fibronectin with the LOXL2 inhibitor treatment indicating a 
protective effect in the glomerulus. This finding is supported by a recent study, which 
highlighted the role of LOXL2 in the glomerulus. Anazco et al. demonstrated in 
microdissected mouse glomeruli that LOXL2 is the predominant lysyl oxidase and 
transcripts of the other lysyl oxidase family members were expressed at much lower 
levels. Further, it was demonstrated, that immunoreactivity in the glomerulus both 
localised to the extracellular and to the podocyte’s perinuclear compartment 
suggestive of local and endogenous production of LOXL2 by podocytes. In addition, 
they showed that LOXL2 cross-links the N-terminal 7S subunits in collagen IV, and 
may contribute to the accumulation of matrix proteins in glomerulosclerosis (5). 
High-throughput studies from microdissected glomeruli of patients with 
nephrosclerosis have also reported an increase of LOXL2 (187). Our data 
demonstrating that LOXL2 inhibition modifies glomerular ECM in diseased kidneys 
is in agreement with these studies.  
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In vitro microarray studies on glomerular podocytes exposed to hypoxic conditions 
revealed a more than two-fold upregulation of LOXL2 (47). Hypoxia has well been 
described as one of the pathogenetic factors in chronic kidney diseases due to both 
tubulointerstitial and glomerular capillary rarefaction (73).  LOXL2 is known to be 
induced by hypoxia via hypoxia-inducible factor-1 (HIF-1) (219). Hypoxia is a 
known fibrogenic stimulus (191) and LOXL2 may be the connecting link in 
perpetuating a vicious cycle of microvascular rarefaction, hypoxia and increased 
ECM synthesis in the glomerulus. The amelioration of glomerulosclerosis and 
proteinuria in this model by selective LOXL2 inhibition with PXS-S2B appears to be 
an indicator that this vicious cycle can be successfully interrupted.  
 
The effect of PXS-S2B was less obvious in the tubulointerstitial compartment than in 
the glomeruli. Although the treatment with the LOXL2 inhibitor decreased 
tubulointerstitial collagen I expression to the same extent as telmisartan, a reduction 
in the overall tubulointerstitial fibrosis score was not detected in any of the treatment 
groups. A previous study by Kosugi et al. detected, similar to our findings, partial 
benefits in the glomerulus but not in the tubulointerstitium of diabetic eNOS-/- mice 
with telmisartan treatment (141). A possible explanation for the lack of treatment 
benefits in the tubulointerstitial compartment in our study could be the fact that the 
tubulointerstitial damage was mainly characterised by flattened tubules, tubular 
dilatation and tubular atrophy but only minimal excess ECM deposition. Although the 
eNOS-/- mouse is to date one of the most acceptable rodent models for diabetic 
nephropathy, the severity of tubulointerstitial fibrosis did not fully resemble that of an 
advanced human diabetic nephropathy. It is well accepted that the mouse strain and 
genetic background may be important in determining the degree of tubulointerstitial 
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changes. The C57BL/6 strain which was the genetic background strain for eNOS-/- 
mice in our study is known to be relatively resistant to develop diabetic nephropathy 
whereas mice on a C57BLKS background are more nephropathy-sensitive and also 
demonstrate greater tubulointerstitial fibrosis (45). At the outset of our study there 
was no C57BLKS.eNOS-/- strain available. To date there are no published reports on 
STZ induced diabetic nephropathy in C57BLKS.eNOS-/- mice. However, 
tubulointerstitial fibrosis in eNOS-/- crossed with C57 BLKS db/db mice has been 
reported as minimal despite extensive glomerular changes. It is conceivable that the 
beneficial effect of PXS-S2B on ECM modification and tubulointerstitial matrix 
deposition was underestimated in our model and that the actual effect in advanced 
human disease, where tubulointerstitial fibrosis corresponds to decline in GFR is far 
greater than demonstrated. Further studies in chronic disease models with more 
pronounced tubulointerstitial fibrosis may be of value.  
 
As we did not determine tissue LOXL2 inhibitor activity, we cannot rule out potential 
underdosing. The dose was based on previous pharmacokinetic studies showing 
excellent tissue distribution of the compound in the kidney (unpublished data). We 
can only speculate whether an increase in the delivered drug, either by increasing the 
dose or frequency may have yielded an additional antifibrotic effect in the 
tubulointerstitial compartment and further studies are proposed. 
 
Myofibroblasts are the key effector cells that synthesise and secrete ECM proteins. 
The transient recruitment and activation of myofibroblasts represents a normal repair 
response to tissue injury. However, the persistence of myofibroblasts at sites of tissue 
injury is a hallmark of human fibrotic diseases (254). The diabetic mice in this model 
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had significantly increased numbers of activated myofibroblasts as evidenced by the 
elevated levels of renal αSMA. Following treatment with PXS-S2B there was a trend 
towards reduction in αSMA, although this did not reach statistical significance and is 
likely a consequence of the small sample size. EMT of injured tubular epithelial cells 
has been recognised to play a role in diabetic nephropathy and renal fibrosis in 
general. However, the extent by which it contributes to the pool of activated 
myofibroblasts in the kidney is still a topic of intense debate. Although studies in 
cancer biology have demonstrated that LOXL2 is able to regulate EMT via 
stabilisation of the EMT transcription factor Snail (199, 232), we found despite 
increased LOXL2 expression in the diseased renal cortices no significant reduction in 
E-Cadherin, which as a primary downstream target of Snail is generally repressed in 
EMT. This finding substantiates the notion that EMT did not play a significant role in 
this model.  It is in accordance with recent fate mapping studies that demonstrated 
only about 5% of myofibroblasts originate from a fully executed EMT, despite a 
significant number of tubular epithelial cells acquiring αSMA expression in fibrosis 
(149). 
 
This study did not demonstrate any difference in immature or mature collagen cross-
links between control and the diabetic groups. Consequently we were not able to 
demonstrate a reduction in collagen cross-links after treatment with PXS-S2B. It is 
likely that the lack of differential cross-link expression between control and diabetic 
animals in this model is due to the minimally increased ECM deposition in the 
tubulointerstitial department as discussed above. Subtle changes may have fallen 
under the detection threshold. Furthermore, DHLNL and pyridinoline are typical 
cross-links of fibrillar collagens such as collagen I and III. Collagen I expression was 
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only minimally upregulated in the diabetic group and was present predominantly in 
the tubulointerstitial compartment. On the other hand, collagen IV remained the most 
prominent collagen in the glomerulus, even in heavily sclerosed glomeruli. However, 
the lysyl oxidase-mediated cross-links in collagen IV differ from fibrillar collagen in 
that they contain much lower levels of DHLNL (14). In addition, a previous study of 
purified type IV collagen demonstrated an absence of the mature cross-link 
pyridinoline suggesting that a different type of mature cross-links is formed in 
collagen IV (14). Despite the structural difference, LOXL2 still plays a role in 
generating these cross-links. The study by Anzaco et al. demonstrated clearly that 
LOXL2 mediates the cross-link reaction in 7S subunits of collagen IV, although the 
exact chemical structure of these mature cross-links is yet to be determined (5). Thus, 
unless these collagen IV cross-links are further identified, the use of classical cross-
link detection techniques commonly used for fibrillar collagen may underestimate 
both the amount of LOXL2 induced cross-links and the effect of LOXL2 inhibition in 
the glomerular compartment where most of the benefits of PXS-S2B treatment were 
seen. 
 
The effect of lysyl oxidase activity goes beyond cross-linking of collagens. Lucero et 
al. demonstrated that LOX oxidises cell surface proteins including the PDGF 
receptor-β and inhibition of this process with BAPN reduced chemotactic responses 
in smooth muscle cells (167). While a similar effect with LOXL2 has not yet been 
demonstrated it is conceivable that the inhibition of LOXL2 with PXS-2B alters cell 
surface proteins leading to the beneficial effects seen in the glomeruli. Further studies 
are needed. 
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Despite recent advances, the number of studies investigating the role of lysyl oxidases 
in the kidney is scarce. More knowledge has been gained from observations in other 
fibrotic tissues.  LOXL2, in particular has been implicated to play a key role in the 
development of fibrosis in liver (27, 246) and lung (27, 58) as well as in cancer 
progression where a fibrotic microenvironment facilitates motility and invasion (51). 
Treatment with a monoclonal LOXL2 antibody (AB0024) in murine models of liver 
and lung fibrosis resulted in amelioration of histological fibrosis scores, substantial 
reduction in collagen levels and αSMA positive fibroblasts (27). Targeting 
specifically LOX instead of LOXL2 with a monoclonal antibody did not alter liver 
fibrosis scores (27), suggesting LOXL2 to be the superior target of antifibrotic 
therapy in these organs. Phase 2 clinical studies of the humanised monoclonal 
antibody Simtuzumab (formerly AB0024) in patients with liver fibrosis from non-
alcoholic steatohepatis (NASH) are underway (Clinical trials.gov identifier 
NCT01672866), however phase 2 studies in lung fibrosis were stopped, as the drug 
did not show evidence of a treatment benefit (207). In addition, administration of 
monoclonal antibodies carries the risk of various immune reactions that may result in 
unwanted side effects. Small molecule mechanism based inhibitors such as PXS-S2B 
may be better suited for drug development as they do not cause immune reactions and 
are unlikely to have the side effects of monoclonal antibodies.  
 
Taken together the findings obtained from this study indicate a beneficial effect of 
LOXL2 inhibition in diabetic mice protecting the glomerular structure and barrier 
function.  The multifaceted action of LOXL2 on ECM synthesis involving cross-
linking of collagens, myofibroblast activation and stimulation of increased matrix 
products makes it a promising target in diabetic kidney disease and possibly renal 
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fibrosis of other aetiologies. 	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Chapter 7  
 
Summary and future directions 
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7.1 Summary of thesis 	  
The thesis explored mechanisms underpinning fetal programming of renal disease and 
investigated a potential treatment strategy of renal fibrosis. These two aims were 
seemingly very different but as the incidence and prevalence of chronic kidney 
disease continues to rise, globally approaching epidemic proportions, we argue that 
both aspects, prevention and therapy, are equally important. 
 
The initial study linked maternal smoking to the offspring’s future risk of kidney 
disease through oxidative stress, mitochondrial perturbations and epigenetic 
modifications. Using a mouse model we found that exposure to cigarette smoke 
during gestation and lactation resulted in an increased susceptibility of the offspring 
to develop proteinuria in adulthood. In addition, immunostaining for 8-OHdG 
revealed oxidative DNA damage to the kidneys. These changes were seen throughout 
the offspring’s life and were associated with an increase in mitochondrial DNA copy 
number.  Dual staining with both a fluorogenic probe for total ROS and mitochondrial 
proteins confirmed that most of the oxidative stress had its origin in the mitochondria. 
In contrast to the sustained changes in oxidative stress markers, levels of the 
mitochondrial antioxidant enzyme MnSOD were reduced at birth and adulthood but 
not at weaning age. We detected mitochondrial structural changes as well as reduced 
levels of OXPHOS enzymes in a similar temporal distribution with alteration at birth 
and adulthood but not at weaning. The study is thus in support for the fetal 
programming of renal disease by maternal smoking through oxidative stress and 
mitochondrial perturbations. Moreover, the findings may suggest that the deleterious 
effects on mitochondria are mitigated at weaning possibly due to antioxidants in the 
breast milk but additional studies to confirm this hypothesis are needed. Further to the 
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documented mitochondrial perturbations, we found that global methylation was 
increased in the smoke exposed offspring kidneys at birth, supporting the notion that 
epigenetic modifications may add an additional layer of complexity to the fetal 
programming of disease. To further investigate whether the mitochondrial changes are 
linked to epigenetic modifications, gene-specific methylation profiles of the 
mitochondrial biogenesis regulator PGC-1α were examined.  The quantification of the 
methylation levels at the four tested CpG sites of the PGC-1α promotor did not reveal 
any changes between smoke exposed offspring and control. However, differential 
methylation at other CpG sites in the PGC-1α promotor cannot be excluded and 
requires future studies. The evidence supporting a role for epigenetic processes in the 
fetal programming of chronic disease susceptibility is constantly increasing (234, 260) 
and is worth exploring not only in specific genes but also on an epigenome-wide 
level. For future studies not only animal models should be considered but also the 
interrogation of human fetal cells and fetal tissue trough examination of placenta and 
amniotic fluid obtained at birth. 
 
While the proposed link of adverse in utero conditions to CKD susceptibility in later 
life via mitochondrial vulnerability and epigenetic processes highlights the need to 
design effective preventative strategies, the disease is often diagnosed when renal 
fibrosis is already established. Current treatments, which are limited to RAAS 
blocking agents, are at best only partially effective in delaying disease progression. 
Identification of new therapeutic targets remains an important step in combating the 
global burden of CKD. The second part of this thesis examined LOXL2, an amine 
oxidase with multifaceted action on ECM modulation as a potential treatment target. 
In Chapter 4 we demonstrated increased levels of LOXL2 transcripts in UUO 
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kidneys, which was consistent with a previous small biopsy study on patients with 
renal fibrosis of various aetiologies (110). Treatment with PXS-S2B, a selective, 
small molecule LOXL2 inhibitor in mice that had undergone UUO surgery did not 
reduce ECM matrix deposition, EMT markers, collagen cross-links or overall 
tubulointerstitial fibrosis scores. Notably, telmisartan did not have a renoprotective 
effect in this model either and only the combined blockade of the angiotensin receptor 
blocker and the LOXL2 inhibitor resulted in a significant reduction of collagen I 
protein and αSMA mRNA. It is possible that the absence of a treatment effect of 
LOXL2 inhibition in the UUO model is a result of the aggressive nature of the model 
with rapid development of tubulointerstitial fibrosis. In order to investigate 
mechanistically whether the lack of renoprotection after treatment with the selective 
LOXL2 inhibitor in the UUO model was indeed related to the experimental design or 
the compound itself, in vitro studies were proposed. In Chapter 5 we studied the 
regulation of LOXL2 in a human proximal tubule cell line and aimed to inhibit 
LOXL2 using both genetic knockdown and pharmacological blockade with PXS-
S2A, the biologically active form of PXS-S2B. The study demonstrated that hypoxia 
was a strong stimulus for LOXL2 up-regulation in HK-2 cells. However, blockade of 
LOXL2 by either small interfering RNA or treatment with the small molecule LOXL2 
inhibitor did not ameliorate the TGFβ-mediated fibrotic effects in either normoxic or 
hypoxic conditions. While we cannot rule out redundancy by other lysyl oxidase 
isoforms and propose future studies, another possible explanation for the absence of 
an anti-fibrotic effect lies in the inherent disadvantages of single-cell in vitro cultures. 
These systems lack the complexities of in vivo events, which are often influenced by 
multifaceted interactions of the environment, such as the ECM. Specifically, the 
extracellular action of LOXL2 and the effect on its inhibition may have been 
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underestimated in a tubular epithelial cell culture that has minimal secreted ECM 
products. In addition, we acknowledge that the effect of LOXL2 may differ in various 
parts of the nephron. A recent rodent study demonstrated specifically in glomeruli the 
predominance of LOXL2 above other lysyl oxidases and it’s involvement in collagen 
IV cross-linking (5). It was therefore decided to employ a different mouse model of 
renal fibrosis, which in contrast to the UUO model is characterised by additional 
glomerulosclerosis and a chronic disease process, thus more closely resembling the 
slowly progressive nature of most CKD aetiologies. Inhibition of LOXL2 by PXS-
S2B treatment in a diabetic model using STZ-treated eNOS-/- mice on C57 BL/6 
background resulted in reduction in proteinuria. This was associated with reduced 
glomerular fibronectin and amelioration of glomerulosclerosis scores. In addition, 
there was a reduction in tubulointerstitial collagen I deposition. However, 
tubulointerstitial fibrosis scores were not affected by the LOXL2 inhibitor treatment. 
We believe, this was largely a consequence of the mouse strain used, which 
demonstrated tubular atrophy and dilatation in diabetic mice but only minimal 
tubulointerstitial fibrosis. Further studies in different mouse strains are proposed as 
outlined in the next paragraph. Nevertheless, the renoprotective effect of PXS-S2B 
treatment on glomerular structure and function in the diabetic mouse model may 
indicate that LOXL2 is a potential therapeutic target in human diabetic nephropathy 
and renal fibrosis of other aetiologies. As glomerular damage is often seen in early 
stages of chronic kidney disease, LOXL2 inhibition may be an important treatment in 
delaying early progression of the disease, either on its own or in conjunction with 
other treatments such as RAAS blockade. 
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7.2 Future directions 	  
7.2.1 Analysis of placental tissue as a means to investigate the fetal adaptation 
to maternal smoking in humans 	  
While the thesis has demonstrated in an animal model the link between maternal 
smoking and the offspring’s susceptibility to renal oxidative stress, mitochondrial 
perturbations and adult onset proteinuria, there is need to extend and validate this 
research in human tissues. The placenta comprises the active interface between 
maternal and fetal blood circulation and maintains fetal homoeostasis by performing a 
wide range of physiological functions. These include the provision of an 
immunological barrier between fetus and mother, the transport of nutrients and the 
production of growth factors, hormones and signaling molecules that influence fetal 
and maternal metabolism. Increasing evidence suggests that the placenta also adapts 
to the maternal environment (185), thereby playing a key role in fetal programming. It 
is thus considered a footprint of the in utero environment and consists of fetal tissue 
that can be easily obtained at the time of delivery for fetal programming studies.  
 
7.2.2 Analysis of mitochondrial perturbations in the human placenta 	  
Whilst this thesis clearly demonstrated the offspring’s increased renal oxidative stress 
and mitochondrial perturbations in a mouse model of maternal smoking, future 
studies should be directed at examining human placentas of smoking mothers for 
evidence of oxidative stress and mitochondrial perturbations. This may shed light on 
the mechanisms underpinning fetal programming of disease. In addition, placental 
mitochondrial alterations, if demonstrated, may serve as an adjunct to clinical history 
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in identifying an at risk population that will require closer surveillance and future 
screening for CKD or other diseases  
 
7.2.3 Analysis of epigenetic modifications in the human placenta 	  
In Chapter 3 we also demonstrated altered global DNA methylation at birth in 
offspring kidneys of smoke-exposed dams. While we were unable to demonstrate 
differential methylation at four CpG sites of the PGC-1α promotor, we acknowledge 
that other CpG sites in the same promotor and in other genes require further 
examination. The placenta provides fetal tissue that is easily accessible postpartum to 
study epigenetic alterations in response to an adverse in utero environment. Indeed, 
epigenetic modifications have been demonstrated in the placental tissue of smoking 
mothers. Suter et al. analysed placental gene expression and DNA methylation 
associated with maternal smoking at an epigenome-wide level and concluded that 
maternal smoking is associated with differential DNA methylation at specific CpG 
sites, which deregulate a significant number of genes in the transcriptome (234). 
Interestingly further pathway analysis in their study revealed that some of the top 
canonical pathways include oxidative phosphorylation and mitochondrial function.  
Future studies in the placenta can also be directed at other epigenetic mechanisms 
such as histone acetylation. Nicotine exposed offspring in an animal model were 
found to have increased histone acetylation in the brain (235) but this may also be the 
case in other organs. Furthermore, the effect of valproate or hydralazine which are 
safely used in pregnancy and function as histone deacetylator as well as inhibitor of 
DNA methylation activity (61, 70) could be assessed for their ability to normalise the 
epigenetic change in the placenta and mitigate renal functional changes in adulthood. 
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7.2.4 Analysis of amniotic fluid of smoking mothers 	  
Hui et al. have shown that cell-free fetal RNA transcripts in amniotic fluid (AF) in the 
third trimester reflect real-time fetal physiology (119).  The authors provided 
evidence for a predominance of AF transcripts highly expressed in the lung, upper 
gastrointestinal tract and kidney, which is not surprising as these organs actively 
secrete or excrete into the amniotic fluid. Amniotic fluid can easily be obtained prior 
to caesarean section. To complement our data from the animal model we propose that 
AF-derived cell-free RNA of genes involved in mitochondrial homeostasis as well as 
kidney development and function from smoking mothers should be explored. These 
AF-derived transcripts may provide important information about abnormal renal 
development that may predispose to CKD susceptibility in later life.  
 
7.2.5 Data linkage and longitudinal studies of offspring of smoking mothers 	  
The prospective study of CKD development in offspring of smoking mothers who 
have participated in placental and AF analysis will be important to link the disease 
susceptibility to the in utero insult and mitochondrial alterations if present. Clearly 
this is a very long term project, but one that will provide important public health 
information. 
 
7.2.6 LOXL2 inhibition in a chronic model of tubulointerstitial fibrosis 	  
The findings in Chapter 6 demonstrated LOXL2 to be a suitable target for the 
treatment of renal fibrosis in diabetic nephropathy with protection of glomerular 
structure and function. The lack of tubulointerstitial fibrosis in the chosen diabetic 
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model raised the question whether a beneficial effect of LOXL2 inhibition in the 
tubulointerstitial compartment was underestimated. Given the known effects of 
LOXL2 on ECM modification, further studies using LOXL2 inhibition in different 
mouse strains with more pronounced tubulointerstitial fibrosis are proposed. STZ-
induced diabetes in CD1 mice for instance results in both glomerular pathology and 
severe tubulointerstitial fibrosis, thus resembling advanced human diabetic 
nephropathy (231). Alternatively, STZ-treated ZDF, WF and T2DN/Mewi rats have 
been shown to develop severe tubulointerstitial fibrosis and may be better suited to 
determine an antifibrotic effect of selective LOXL2 inhibition in the tubulointerstitial 
ECM (140). 
 
7.2.7 Redundancy of other lysyl oxidases  	  
This thesis focused on targeting selectively LOXL2, which was based on a previous 
study that targeted both LOX and LOXL2 with monoclonal antibodies in a liver 
fibrosis model and found LOXL2 to be the superior target in fibrogenesis (27). 
However, we acknowledge that the differential expression of LOX isoforms in liver 
fibrosis may differ from renal fibrosis. The study from Schietke et al., who 
demonstrated LOX but not LOXL2 to be constitutively expressed in healthy kidney 
samples (219) in addition to the investigations from Higgins et al. who demonstrated 
an upregulation of LOXL2 in a small series of biopsies in renal fibrosis patients 
suggest LOXL2 to be a suitable treatment target. Our study did not fully address the 
role that other lysyl oxidases may play in the pathogenesis of renal fibrosis. We found 
both LOXL2 and LOX mRNA upregulated in the UUO model. While we did not 
detect a compensatory increase of LOX mRNA in response to LOXL2 inhibition, we 
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cannot rule out that the actions of LOX are enough to perpetuate the fibrogenesis 
pathways even when LOXL2 is inhibited. Therefore, we propose that the expression 
and actions of lysyl oxidases other than LOXL2 need to be explored in renal fibrosis 
and dual or combined inhibition of different LOX isoforms need further elucidation. 
Haloallylamine-based small molecule inhibitors are easily amenable to structural 
modifications that alter potency and selectivity for the specific LOX isoforms. PXS-
S1A, a very powerful dual inhibitor of both LOX and LOXL2 has already been 
developed and could be explored in the above-mentioned models. Furthermore, the 
combination of lysyl oxidase inhibitors with other inhibitors of matrix cross-links 
could be investigated. As fibronectin was dominantly expressed in diabetic kidneys, 
both in the glomerular and tubulointerstitial compartment, tissue transglutaminase, 
which mediates enzymatic cross-linking of fibronectin may be considered as an 
additional target. 
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